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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
High-grade serous cancer (HGSC) is the most common form of epithelial ovarian cancer, 
characterized by its aggressive clinical course and poor overall survival. The high mortality 
rate of HGSC is caused by an asymptomatic early stage, due to which 70% of the patients 
present in stage III or IV, having extensive tumor burden and complaints (1). Patients with 
advanced-stage ovarian cancer have a 5-year survival rate of just 25% (2). 
Standard treatment for ovarian cancer consists of cytoreductive surgery, followed by six 
cycles of intravenous platinum-based chemotherapy (3). Alternatively, patients receive 
three cycles of neo-adjuvant chemotherapy before an interval cytoreductive surgery 
is performed. Intraperitoneal administration of chemotherapy increases the median 
overall survival of ovarian cancer patients by 16 months. However, patients experienced 
treatment-related toxicity and discomfort, making implementation into clinical practice 
difficult (4, 5). Recently, the effect of a single dose of intraperitoneal chemotherapy that 
was administered under hyperthermal conditions directly after cytoreductive surgery, 
was investigated in a multicenter, open-label, phase III trial. Hyperthermic intraperitoneal 
chemotherapy (HIPEC) increased overall survival by 11.8 months, from 33.9 to 45.7 months. 
Although HIPEC treatment required longer hospitalization of patients, no adverse events 
were detected compared to patients receiving cytoreductive surgery without HIPEC (6).
Despite the recent advances in ovarian cancer treatment, the majority of patients develop 
a recurrence and succumb to their disease. In order to improve survival rates, early 
diagnosis and new treatment options are needed. Therefore, more knowledge on the 
development and progression of HGSC is essential. So far, little is known about the early 
steps of HGSC development. First insights came with the identification of BRCA1 and 
BRCA2 as risk genes for the development of breast and ovarian cancer. BRCA mutation 
carriers nowadays undergo prophylactic salpingo-oophorectomy to prevent cancer 
development. HGSC precursor lesions in the removed fallopian tube were identified in the 
distal part or the fimbria (7-9). These precursor lesions shared morphological and biological 
features with HGSC, indicating that they might progress into cancer (10). 
The fallopian tube as site of HGSC development
HGSC precursor lesions are a morphologic continuum from mild to cancerous making 
it difficult to distinguish the different lesions. Since identification of a precursor lesion 
can have important clinical implications, reproducible diagnostic criteria are crucial. 
Therefore, the “Sectioning and Exentsively Examining the Fimbriated End” protocol 
was introduced for the thorough examination of fallopian tubes and to classify HGSC 
precursor lesions. The classification is based on morphological appearance as well as p53 
and Ki-67 expression (11, 12). 
The malignant transformation of the non-ciliated cells of the fallopian tube epithelium 
begins with a mutation in p53, termed p53-signature (Figure 1). As these cells have 
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a morphologically normal appearance, p53-signatures are identified based on the 
complete absence or overexpression of p53 by immunohistochemistry (13, 14). Over 
time, p53-signatures acquire more mutations, which results in cellular atypia, including 
nuclear enlargement and variable cell proliferation, as indicated by Ki-67 positivity, while 
cellular polarity is preserved. These lesions have been termed serous tubal intraepithelial 
lesions (STILs) and represent an intermediate between p53-signature and serous tubal 
intraepithelial carcinoma (STIC). In contrast to STILs, STICs have evident cellular atypia 
such as loss of cellular polarity and cilia, enlarged nuclei, prominent nucleoli, mitotic 
figures and apoptotic bodies (14). 
 
figure 1  Development of high-grade serous ovarian cancer. HGSC develops in the fimbriated 
end of the fallopian tube. A mutation in the tumor suppressor gene TP53 is the earliest 
detectable event of malignant transformation of the fallopian tube epithelium. P53-signatures 
gradually progress into serous tubal intraepithelial lesions (STILs) and further into serous tubal 
intraepithelial carcinomas (STICs). The epithelial cells acquire more mutations during this process 
and show increasing signs of cellular atypia. STICs finally give rise to HGSC that invades the basal 
membrane, colonizes the ovaries and forms metastases within the peritoneal cavity.
 
Although first identified in BRCA mutation carriers, precursor lesions have also been 
detected in patients without a genetic predisposition or familial history of ovarian cancer. 
P53-signatures are common in women with and without a germline mutation in BRCA1 or 
2 (15). In contrast, STICs are only occasionally detected in healthy women, whereas they 
are more frequently found in healthy women with a germline mutation in BRCA1/2 or in 
women having HGSC (15-17). This raises the question whether the process of malignant 
transformation of the fallopian tube epithelium is the same for women with and without a 
germline mutation in the BRCA genes. 
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Molecular analysis identified the same p53 mutation in ovarian cancer precursor lesions 
and the concurrent ovarian cancer (18-20). The group of Velculescu performed exome-
wide sequence and structural analyses of p53-signatures, STICs and HGSC in five patients 
without a genetic predisposition. Almost all alterations present in p53-signatures 
were present in the STIC and HGSC of the same patient. However, the STICs contained 
additional mutations that were not present in the p53-signatures, and HGSC contained 
de novo mutations that were not present in the STICs. These findings strengthen the 
hypothesis that p53-signatures gradually progress via STICs into HGSC. Mathematical 
modeling suggests that the malignant transformation takes about 7 years. Once HGSC 
is present, metastasis occurs quickly, within 2 years (21).  Nevertheless, the fact that STILs 
and STICs are barely found in healthy women without a germline mutation in the BRCA 
genes, questions the malignant transformation from p53-signature to STIL, STIC, and 
finally HGSC or the time required for the malignant transformation.
HGSC metastasis and relapse
HGSC spreads in a diffuse intra-abdominal fashion. Even though peripheral blood of 
cancer patients contains circulating tumor cells, metastases are generally found within 
the peritoneal cavity, highlighting that this is a privileged site for ovarian cancer cells (22). 
A prominent feature of ovarian cancer is the accumulation of fluid within the peritoneal 
cavity, called ascites. About one third of advanced-stage ovarian cancer patients develop 
ascites, which can cause symptoms such as anorexia, nausea, and abdominal swelling and 
pain. Ascites accumulates due to a disrupted balance of fluid production and reabsorption, 
possibly by impaired fluid drainage and increased net filtration. Currently, ascites is 
treated by treating the underlying disease (23). It remains unclear whether ascites is a sign 
of advanced-stage disease or whether it is already present when tumor cells disseminate 
and metastasize. Ascites circulates through the abdomen, serving as transport medium for 
disseminated tumor cells (Figure 2) (22). Furthermore, ascites is rich in cytokines and growth 
factors, creating a microenvironment that promotes ovarian cancer metastasis (24, 25). 
Even though ovarian cancer patients respond well to first-line therapy, consisting of surgery 
and chemotherapy, the majority gets disease recurrence within 18 months (26).  Cancer stem 
cells (CSCs) might be the cause for the high relapse frequency in ovarian cancer. CSCs are 
a rare population of cells with self-renewal capacity. They give rise to more differentiated, 
fast-proliferating tumor cells that fuel tumor growth. Their low proliferation rate in 
combination with genetic and epigenetic changes, renders CSCs resistant to classical anti-
tumor therapies (27, 28). Hence, CSCs that remain in the peritoneal cavity after surgery and 
chemotherapy may be responsible for tumor recurrence. Eliminating CSCs is therefore 
important to improve overall survival in advanced-stage HGSC patients (29). 
14
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figure 2  Intra-peritoneal metastasis of high-grade serous ovarian cancer. The fimbriated end 
of the fallopian tube is the primary site for HGSC development. Ascites transports single cells 
that detach from the primary tumor through the peritoneal cavity and serves as growth medium, 
thereby promoting the dissemination of tumor cells. Ovarian cancer cells can bind to distant sites, 
forming metastases in different organs such as colon, liver, omentum or peritoneum. 
The immune system in ovarian cancer
The immune system is a complex network of cells and signaling molecules that work in 
concert to protect our body from invading pathogens and cancerous cells. If this delicate 
balance is disturbed, auto-immune diseases or cancer can arise (30, 31). Ovarian cancer has 
long been neglected as an immunogenic tumor. Today we know that the immune system 
plays an important role in HGSC development and progression.
Infiltrating immune cells were detected in STICs and ascites of HGSC patients, although 
their function and correlation with survival remains to be elucidated (25, 32). So far, most 
research has focused on the immune environment in primary tumor tissue. In advanced-
stage HGSC, tumor infiltrating CD8+ cytotoxic T cells were associated with improved 
survival (33), opening new avenues for therapy. Boosting the anti-tumor immune response 
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by immunotherapy could be a potential new treatment option. However, the effector 
functions of CD8+ T cells are often inhibited in the tumor microenvironment. For example, 
tumor infiltration by immunosuppressive regulatory T cells that inhibit the functions of 
CD8+ T cells, are correlated with worse clinical outcome (34). 
For effective immunotherapy, a whole array of immunosuppressive mechanisms in ovarian 
cancer need to be overcome (35). Therefore, more knowledge on the immune response in 
HGSC is needed.
Outline of the thesis
This thesis aims to investigate the role of the immune system in ovarian cancer 
development, progression and metastasis. Chapter 2 reviews the role of the different 
tumor-infiltrating immune cells in ovarian cancer and immunotherapeutic strategies. In 
chapter 3, we propose to use DC vaccination against NANOG, a protein expressed by 
cancer stem cells, to prevent disease recurrence. This strategy could provide effective 
long-term control of cancer stem cells that might be the source of ovarian cancer relapse. 
The role of the immune system in the early steps of HGSC development is investigated 
in chapter 4. We used immunofluorescent multiplexing to analyze the T cell infiltrate in 
ovarian cancer precursor lesions and ovarian cancer. A compromised immune system in 
the peritoneal cavity could be the reason for the high seeding efficiency of ovarian cancer 
cells. In chapter 5, we assessed the functionality of ascites-derived lymphocytes. Previous 
studies showed that tumor-infiltrating lymphocytes were associated with improved 
patient outcome in advanced stage ovarian cancer. In chapter 6, we tested whether this 
also holds true for ovarian cancer ascites. Since ovarian cancer is an immunogenic tumor, 
immunotherapy could be a promising treatment strategy to boost the body’s immune 
system to fight cancer. Chapter 7 describes the spontaneous regression of ovarian cancer 
after septic peritonitis, demonstrating the power of the immune system. Chapter 8 
summarizes the findings of this thesis and places them into context of current knowledge 
on the role of the immune system in ovarian cancer. 
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Abstract
Ovarian cancer is a devastating disease with a high relapse rate. Due to a mostly 
asymptomatic early stage and lack of early diagnostic tools, the disease is usually diagnosed 
in a late stage. Surgery and chemotherapy with taxanes and platinum compounds are very 
effective in reducing tumor burden. However, relapses occur frequently and there is a lack 
of credible second-line options. Therefore, new treatment modalities are eagerly awaited. 
The presence and influx of immune cells in the ovarian cancer tumor microenvironment 
are correlated with survival. High numbers of infiltrating T cells correlate with improved 
progression free and overall survival, while the presence of regulatory T cells and 
expression of T cell inhibitory molecules is correlated with a poor prognosis. These data 
indicate that immunotherapy, especially cell-based immunotherapy, could be a promising 
novel addition to the treatment of ovarian cancer. Here, we review the available data on 
the immune contexture of ovarian cancer and discuss novel strategies and targets for 
immunotherapy in ovarian cancer. In the end, the addition of immunotherapy to existing 
therapeutic options could lead to a great improvement in the outcome of ovarian cancer, 
especially when targeting cancer stem cells. 
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Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Approximately 
22,000 new cases of ovarian cancer were diagnosed in 2014 in the US alone. Annually, 
ovarian cancer results in over 14,000 deaths (1). Over the last 20 years only a small decrease 
in those figures was seen. The median age at the time of diagnosis is 63 years (2), although 
women with a high risk genetic predisposition typically develop ovarian cancer 10 years 
earlier (3). Due to a lack of reliable screening tools in the early phase of the disease, which 
is usually asymptomatic, more than 75% of patients are diagnosed in an advanced stage 
International Federation of Gynecology and Obstetrics (FIGO) stages III–IV (4).
The current standard for first-line therapy of ovarian cancer consists of cytoreductive 
surgery and adjuvant chemotherapy based on platinum drugs in combination with 
Taxanes. Unfortunately, a large proportion of patients (20-40%) do not respond to first-
line chemotherapy (2). Furthermore, recurrence rates are 25% in early stage patients 
and higher than 80% in advanced stage patients (4). The median survival time of patients 
with advanced stage disease is 65 months. Current second-line therapies are generally 
not curative, resulting in short-term progression-free survival for most patients (2). The 
route of administration of adjuvant chemotherapy also has an effect on therapy outcome. 
Intraperitoneal chemotherapy leads to a longer progression free and overall survival 
compared to intravenous chemotherapy. However, it is not widely adopted due to toxic 
side effects, intraperitoneal delivery problems and other complications (5). Intensification 
of the treatment by addition of a third chemotherapeutic or extended duration of platinum 
or Taxane chemotherapy showed no further improvements in clinical outcome in phase 
3 trials. The sequence of treatment modalities was also studied. Initial treatment with 
chemotherapy (neoadjuvant therapy) followed by surgical cytoreduction had no clinical 
benefit over surgical cytoreduction followed by chemotherapy (2).
Looking back at the last 30 years, no substantial decrease in death rates has been achieved. 
Thus, there is a desperate need for novel treatment strategies for ovarian cancer. One such 
strategy involves activating the patient’s own immune system for therapeutic benefit in 
cancer, referred to as immunotherapy (6). Immunotherapy has shown considerable clinical 
promise in recent years and has the potential for a life-long cure of cancer. In this review, 
we examine the immunological contexture in ovarian cancer, evaluate the clinical promise 
of immunotherapeutic approaches and discuss innovative combination modalities.
Rationale for immunotherapy
Although not considered as an ‘immunogenic’ tumor such as melanoma, clinical evidence 
hints at a role for the immune system in EOC. Infiltration of CD3+ immune cells in ovarian 
tumors correlates with improved progression free survival (7), suggesting that ovarian 
cancer is vulnerable to immunological attack. The presence and activation state of other 
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immune effector cells, such as Natural Killer (NK) cells and γδ-T cells, also correlate with 
improved clinical outcomes. There is accumulating evidence suggesting that surgery 
and chemotherapy also modulate the immune system. Surgery can significantly reduce 
the numbers of suppressive regulatory T cells (TRegs) in EOC patients leading to an 
improvement in the ratio of CD8/TRegs. Additionally, peripheral CD8+ T cells in these 
patients produce higher levels of IFNγ after surgery (8). Recent studies demonstrate that 
chemotherapeutic compounds trigger the immune system (9, 10). These chemotherapeutic 
compounds, including the platinum-based compounds, can induce tumor cell stress and 
death that leads to the induction of an antitumor immune response. Platinum compounds 
were also shown to enhance the recognition and killing of tumor cells by immune cells 
as well as enhancing dendritic cell (DC) function (11-13). Additionally, patients that have 
CD3+ T cells present in the tumor have improved responses to chemotherapy and are more 
frequently optimally debulked (7).
Natural killer cells
NK cells are the cytotoxic cells of the innate immune system, which are involved in the 
killing of tumor cells. NK cells can be divided in two subsets, based on expression of the 
surface molecule CD56 (14). CD56bright CD16− NK cells produce high amounts of cytokines 
upon activation, but exhibit low cytotoxicity. CD56dim CD16+ NK cells produce low amounts 
of cytokines, but exhibit high cytotoxicity and the ability to mediate antibody-dependent 
cellular cytotoxicity (ADDC) through CD16. NK cells recognize and eliminate allogeneic 
or stressed cells, such as infected or tumor cells (14). EOC exploits various mechanisms 
to limit NK cell-mediated tumor killing. Firstly, low numbers of NK cells infiltrate primary 
EOC (7). Secondly, infiltrating NK cells are enriched for the less cytotoxic CD56bright cells 
compared to autologous peripheral blood (32% versus 10%) (15). Furthermore, EOC also 
suppresses NK cells through the expression of surface molecules or secretion of soluble 
factors like CA-125, which shields tumor cells from cytotoxicity (16, 17). Surprisingly, the 
presence of CD16+ NK cells was significantly correlated with decreased overall survival of 
ovarian cancer patients (18). In summary, although it is still unclear whether the presence 
of NK cells has a beneficial effect on the outcome of EOC, there are several mechanisms in 
the tumor microenvironment that abolish NK cell anti-tumor immunity.
CD8+ T cells
CD8+ T cells are the cytotoxic effector cells of the adaptive immune system responsible for 
killing of tumor cells. A seminal study by Zhang and colleagues showed that the presence 
of tumor-infiltrating lymphocytes (TILs) correlates with favorable clinical outcome (7). The 
median progression-free survival of these patients was 22.4 months and median overall 
survival 50.3 months. In contrast, patients without TILs had a median progression-free 
survival of 5.8 months and a median overall survival of 18 months. Only a small percentage 
(4.5%) of these survived up to 5 years, whereas this percentage was significantly higher 
(38%) in patients with TILs. This demonstrates that infiltrating T cells in EOC is a strong 
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prognostic factor for favorable clinical outcome. Later, the CD3+ T cell population was 
further refined to CD3+ CD8+ cytotoxic T cells (19). Since then, other studies and meta-
analyses have confirmed that the presence of TILs are a predictor of favorable clinical 
outcome in EOC (20, 21). This was further corroborated by an immunohistological study 
of post-surgical ovarian carcinoma biopsies (stages I–IV), which demonstrated that 
intraepithelial CD8+ T lymphocyte count is a positive prognostic factor (22).
CD4+ Th17 cells
Recently, a number of studies looked at the role of Th17 cells in ovarian cancer. Th17 cells 
are a subset of CD4+ T cells that secrete a special set of cytokines, including IL-17A, IL-
17F, and IL-23. The pro-inflammatory function of Th17 cells in autoimmune diseases has 
been well established, but their role in cancer is less clear (23). Th17 cells can be found in 
both, EOC tumors and malignant ascites (24-26). Furthermore, Th17 cells are enriched in 
the tumor compared to tumor-draining lymph nodes, cancer patient peripheral blood and 
healthy donor peripheral blood (24-26). IFN-γ and IL-17 produced by Th17 cells attract CD8+ 
T cells to the tumor microenvironment in a dose-dependent manner. Thus, Th17 cells might 
have beneficial effects on anti-tumor responses. Indeed, IL-17 production was shown to be 
a significant predictor for overall ovarian cancer survival, 78 vs. 27 months overall survival 
for patients with high vs. low levels of IL-17 (25).
Ovarian cancer generates an immunosuppressive 
microenvironment
As highlighted above, the immune system is able to target EOC tumors and influence 
overall survival. However, EOC cells can exploit several mechanisms to evade 
immunological elimination. These include the expression of T cell inhibitory receptors 
on tumor cells and immune cells, and the recruitment of immunosuppressive cells, such 
as TRegs and tumor-associated macrophages. This immunosuppressive environment is 
further augmented in ovarian cancer. Below we will discuss some of the most important 
suppressive mechanisms in place. 
Expression of inhibitory receptors on tumor cells
The presence of TILs is invariantly correlated with improved survival and, interestingly, 
CD8+ T cell count was inversely correlated with the level of expression of programmed 
cell death ligand 1 (PD-L1 or B7-H1) in ovarian carcinoma tissues. PD-L1 is expressed 
on a wide range of peripheral tissues and suppresses T cell responses (27). PD-L2 is 
expressed on macrophages and dendritic cells (28). Both ligands induce T cell anergy or 
apoptosis through binding to PD-1 on the T cells. In patients with high expression of PD-
L1, the overall 5-year survival rate was lower than in patients with low PD-L1 (22). PD-L2 
expression was not significantly correlated with overall patient survival. Thus, intratumoral 
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T cell infiltration and PD-L1 expression are two independent, opposing prognostic factors 
for clinical outcome. PD-L1 likely limits CD8+ T cell invasion in the tumorigenic tissues. 
Currently, the blockade of PD-L1 by monoclonal antibodies is being explored in a clinical 
trial (NCT01772004).
Regulatory T cells
Classical TRegs are defined by the expression of CD4, CD25 and Foxp3. Under steady 
state conditions, TRegs limit autoimmune responses through modulation of DC and CD8+ 
T cell activation (29). Recently, a novel, Foxp3− regulatory T cell was described that 
expresses high levels of PD-L1. This subset was induced by IFN-β, a cytokine secreted in 
huge amounts by plasmacytoid DCs. It remains to be seen if those TRegs are also found in 
EOC, but plasmacytoid DCs are abundantly present. Classical TRegs are recruited to and 
infiltrate solid ovarian tumors and metastatic lesions in ascites (30, 31). A study by Woo and 
colleagues found that 30% of CD4+ T cells co-expressed CD25 in ovarian tumor samples 
(30), whereas TRegs represented 23 ± 11% (mean ± s.e.m.) of the tumor-infiltrating CD4+ 
T cell population (31). CD4+CD25+ T cells expressing Foxp3 were able to suppress the 
proliferation of CD3+CD25− T cells in vitro, indicating that the TRegs were fully functional 
and mature. Furthermore, the presence of TRegs was negatively correlated with overall 
survival of ovarian cancer patients (31). Follow-up studies reported conflicting results 
for TReg influx and overall survival (19, 32, 33). In two studies, positive ratios of CD8+/ TReg 
correlated with better overall survival (19, 32), whereas no correlation was found in a third 
study (33). The basis for the difference in clinical outcome between these studies is unclear 
but the discrepancy might be explained by recent data indicating that Foxp3 is also 
expressed by a number of epithelial tumor cells (34) and by in vitro activated T cells (35).
In the section above, positive correlation between a higher frequency of Th17 cells and 
improved survival was highlighted. However, the frequency of these cells in EOC tumors 
decreases with cancer progression, with stage I tumors having the highest and advanced 
stages having the lowest infiltration of Th17 cells. In contrast, TRegs increase with disease 
progression and are inversely correlated to Th17 cell numbers (25, 26). This observation 
might be explained by the presence of high quantities of TGF-β. Whereas low TGF-β 
concentrations promote expansion of Th17 cells, high concentrations actually induce 
differentiation to Foxp3+ TRegs. Additionally, TRegs directly suppress production of IL-17 (25).
Dendritic cells
Despite their potential to elicit strong anti-tumor immunity, the beneficial effects 
of DC antigen-presentation are rarely engaged in EOC. Rather, the ovarian tumor 
microenvironment suppresses DC maturation and function. CD11c+ myeloid DCs 
(mDCs) isolated from ovarian tumor draining lymph nodes express higher levels of PD-
L1 compared to non-tumor lymph nodes and blood monocytes. These PD-L1high mDCs 
were impaired in their ability to stimulate T cell responses. Blocking PD-L1 restored T cell 
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proliferation and reduced tumor growth in a murine EOC model (36). In support of these 
findings, human ovarian cancer CD11b+CD11c+ DCs were found to co-express PD-L1 and 
PD-1 and suppressed T cell proliferation through the PD-L1/PD-1 pathway in a contact-
dependent manner (37). Plasmacytoid DCs (pDCs) were also reported to contribute to 
immunosuppression in the tumor microenvironment and promote tumor growth, either 
through promotion of neoangiogenesis or by promoting TReg expansion (38, 39). Conversely, 
the presence of pDCs in the tumor correlates with poor progression free survival (40).
Tumor-associated macrophages
Macrophages are the phagocytic cells of innate immunity and, similar to DCs, they 
can induce T cell activation, although they are a lot weaker than DCs in that respect. 
Macrophages can be broadly divided in two phenotypes: classically activated (M1-
polarized) and alternatively activated (M2-polarized) macrophages (41). M1 macrophages 
are involved in Th1 immune responses, while M2 macrophages are involved in Th2 
responses, which are associated with tumor progression. Tumor-associated macrophages 
(TAMs) closely resemble M2 macrophages and are thought to be gradually polarized 
towards immunosuppressive macrophages during tumor progression (42, 43). TAMs are 
abundantly present in the ovarian tumor and malignant ascites (43-45). The number of 
TAMs significantly correlates with malignancy in serous and mucinous ovarian carcinomas 
(45). In the tumor microenvironment, TAMs recruit TRegs through the secretion of CCL22 
(31, 43). In turn, TRegs also potentiate the suppressive activity of TAMs by the production 
of IL-10, which induces high expression of the surface molecule B7-H4 on TAMs (46). Like 
its family members, PD-L1 and PD-L2, B7-H4 negatively regulates T cell responses. The 
expression level of B7-H4 in ovarian cancer is quite heterogeneous and high expression 
levels correlate with decreased overall survival of patients (47).
Immunotherapy
As outlined above, there is ample evidence for a natural pre-existing anti-tumor immune 
responses in ovarian cancer, which is manipulated and suppressed by the tumor 
microenvironment. The goal of cancer immunotherapy is to initiate an anti-tumor immune 
response or to re-activate and boost a pre-existing one. Effective rejection of the tumor 
by the host immune system depends on sufficient numbers of effector cells that infiltrate 
the tumor and exhibit cytotoxicity towards tumor cells. Cellular immunotherapies have 
the potential to generate large numbers of effector cells that are directed towards tumor 
cells. Besides raising large numbers of effector cells, their functional time window has to 
be expanded. This can be achieved by inhibiting suppressive factors like the inhibitory 
receptors or suppressive cells.
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Tumor-associated antigens as target for cellular 
immunotherapy
T cell activation involves the presentation of tumor-derived antigens on major-
histocompatibility complex (MHC) molecules by DCs. The balance between co-
stimulatory and co-inhibitory molecules on the surface of antigen presenting cells (APCs) 
determines an activating or tolerogenic T cell response. During malignant transformation, 
tumor cells often start to express tumor-associated antigens (TAA). These are antigens, 
which are exclusively or preferentially expressed on tumor cells and can elicit a specific 
host immune response. A number of bonafide ovarian TAAs have been identified, such 
as HER-2/neu, MAGE-A1, mfolate binding protein (FBP), p53, NY-ESO-1, EpCAM and CA-
125. These antigens have been explored as single agent or combination vaccines in phase 
I/II trials. The peptide vaccines were generally well tolerated, toxicity was limited to local 
grade 1 and 2 inflammatory reactions. Although the vaccines led to induction of specific 
T cells in a significant number of patients, clinical efficacy was lacking (48-52). However, it 
should be noted that most of these were very small phase I/II trials, set up to test toxicity 
and immunological responses. Some of these trials could benefit from larger, placebo-
controlled phase III trials. One such promising example is an NY-ESO-1 vaccine containing 
recombinant vaccinia and fowlpox vectors to further boost an immune response. In the 
phase II trial involving 22 recurrent ovarian cancer patients, 3 were seropositive for NY-
ESO-1 at the start of the trial, and 8 other patients seroconverted during vaccination. 
Median overall survival was 48 months, which is much longer than the 15 months for 
patients that lacked immune activation (53).
Cellular immunotherapies
Adoptive cell transfer (ACT) therapy
Early studies established the feasibility of ex vivo expansion of TILs using recombinant 
IL-2 and confirmed the persistence and survival of TILs after re-infusion in patients (54, 55). 
Inclusion of autologous antigen-pulsed DCs to the ex vivo expansion phase was shown to 
promote the expansion of tumor-specific effector CD8+ T cells (56, 57). A pilot trial involving 
13 recurrent ovarian cancer patients (stages II–IV) tested ACT of TILs after optimal 
debulking surgery and cisplatin chemotherapy (58). The control group was not treated with 
TILs after primary surgery and chemotherapy. Progression-free survival was significantly 
higher in the TIL-treated group compared to the control group. Even though patients were 
not randomly assigned to both arms, this trial nonetheless illustrates the potency of ACT 
TIL therapies for ovarian cancer. 
However, ACT can have considerable drawbacks. Some ovarian tumors do not yield 
sufficient tumor-specific lymphocytes for ex vivo expansion. Additionally, cellular 
immunotherapy has to overcome tolerance to self-antigens. A strategy to overcome 
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these drawbacks is to genetically engineer T cells to express either tumor-specific T cell 
receptors (TCRs) or chimeric antigen receptors (CARs) (Figure 1) (59). The first approach 
uses high-affinity TCRs isolated from patients, which are then retrovirally transfected into 
non-specific T cells. These T cells, expressing high affinity tumor-specific TCRs, can then 
be infused in patients. For the second approach, variable regions of antibodies are fused 
to TCR intracellular activating domains to create a receptor that is capable of activating T 
cells upon antigen recognition. These CARs can be transfected into T cells and infused in 
autologous patients. 
figure 1  Cellular immunotherapy approaches. There are several ways to employ the immune 
system in the fight against cancer. (A) For dendritic cell (DC) vaccination, monocytes are isolated 
from the patient’s blood and ex vivo differentiated into immature monocyte-derived DCs. 
Alternatively, naturally-occurring DCs can be isolated from the blood. The DCs are subsequently 
matured and loaded with tumor-associated antigens (TAA). Both procedures generate tumor-
specific DCs, which are re-infused into the patient and migrate to the lymph nodes. In the 
lymph nodes, these DCs will then activate tumor-specific T cells and thus induce a potent anti-
tumor immune response. (B) In the case of adoptive cellular transfer (ACT), tumor-infiltrating 
lymphocytes (TILs) are isolated from the patients. These TILs are expanded ex vivo and re-infused 
into the patients. If not enough tumor-specific T cells can be isolated, nonspecific T cells are 
modified prior to expansion and re-injection. They are either engineered to express a tumor-
specific T cell receptor (TCR), isolated from tumor-specific T cells from the same patient, or an 
artificially constructed chimeric antigen receptor (CAR). Tumor-specific T cells migrate to the 
tumor were they recognize and kill the cancer cells.
 
A number of CAR strategies have been tested in vitro and in vivo settings, although much 
work still needs to be done in clinical studies (see Supplementary Table 1 for an overview 
of all clinical trials discussed in this review). T cells from 5 ovarian cancer patients were 
transduced with Mov-γ, a CAR for FBP and stably retained in vitro FBP-specificity after 
large expansion (60). Presently, ACT of CAR-modified T cells has been tested in a single 
phase I trial. CARs were designed by fusion of an anti-folate receptor (FR) antibody to 
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the signaling domain of FcRγ. One cohort of 8 recurrent ovarian cancer patients was 
treated with 3 cycles of high dose IL-2 administration and allogeneic FR-modified T cell 
re-infusion. The other cohort of 6 recurrent patients was treated with dual-specific FR-
modified T cells that responded to both FR antigen and allogeneic antigens, followed by 
immunization with allogeneic peripheral blood mononuclear cells (PBMCs) to stimulate 
T cell proliferation in the patient. Five patients in the first cohort showed grade 3 and 4 
toxicities, which were likely caused by high doses of IL-2, the remainder of the patients 
showed only grade 1 and 2 toxicities (61). The number of transferred T cells rapidly declined 
and T cell inhibitory factors accumulated in 3 patients, further limiting an effective immune 
response. No tumor regression was observed in any patient during the trial indicating that 
the procedure has to be further optimized. A new phase I trial, based on a refined FRα CAR 
was initiated to test efficacy and maximum dosage in ovarian cancer patients (stages II–
IV) (62). The trial has not been completed.
Dendritic cell-based vaccines
DCs are highly efficient activators of the adaptive immune response and play a key role in 
activating naïve T cells by presenting antigens on MHC I molecules (27). Two main subsets 
of DCs in circulation can be distinguished by the expression of cell surface markers: CD11c+ 
mDCs and BDCA2+ pDCs. The mDCs can be further subdivided into BDCA1+ (CD1c+), 
BDCA3+, and CD16+ mDCs (63). DC vaccination involves the isolation of autologous DCs 
followed by ex vivo loading with TAAs, induction of DC maturation and re-infusion into 
the patients to initiate a tumor-specific CD8+ T cell response (Figure 1) (27). An advantage 
of this strategy is that it may boost the immunogenicity of otherwise weak TAAs and will 
induce long-lasting immunologic memory. 
Several methods of generating TAA-presenting DCs have been explored as immunotherapy 
for ovarian cancer. Evidently, the choice of the TAA is one of the most important 
parameters. Nonetheless, a response against a TAA, even one present on the majority 
of tumor cells, will probably not lead to complete eradication of the tumor. The tumor 
cells outnumber the generated CD8+ T cells by far. Therefore, immunotherapy can only be 
successful when the bulk of the tumor has been removed by other means. Surgery and/or 
chemotherapy could be used to this end and then followed up by immunotherapy. Such 
combination treatments are presently being explored in trials where the bulk of the tumor 
is removed and then tumor lysate-loaded DCs are infused. The tumor lysate contains TAAs 
present in the tumor but only the most immunodominant will end up in MHC class I. The 
disadvantage of using tumor lysate is that the TAA remains unknown. 
A number of clinical studies on DC vaccination in ovarian cancer have been performed. 
Firstly, in a phase I trial involving 3 advanced stage ovarian cancer patients, DCs were 
pulsed with either HER-2/neu or MUC-1 peptides and re-infused in the patient (64). After 
3 cycles of DC vaccination, tumor-specific CD8+ T cells were detectable in 2 patients. In a 
second phase I trial, involving 6 patients with ovarian cancer, DCs were pulsed with keyhole 
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limpet hemocyanin (KLH) and whole tumor lysates before re-infusion in the patient (65). 
The treatment was well tolerated and 3 patients showed stable disease between 25 to 45 
weeks during the study. T cell proliferation in response to KLH and to whole tumor lysate 
was observed in 6 patients and in 2 patients, respectively. In a fourth phase I trial, involving 
4 ovarian cancer patients, the HER-2/neu-based DC therapy Lapuleucel-T (Neuvenge, 
Dendreon) was evaluated for toxicity and disease progression (66). Administration 
of Lapuleucel-T was well tolerated. Short-term stable disease was reported for 2 of the 
4 ovarian cancer patients in response to DC vaccination (time to progression 18.3 and 
15.7 weeks). In a randomized phase I/II trial that involved 11 ovarian cancer patients 
(stages Ic–IV), DC therapy was explored as maintenance therapy (67). DCs were pulsed 
with HER-2/neu, hTERT, and PADRE peptides, without intravenous cyclophosphamide 
(arm 1) or with cyclophosphamide (arm 2) as adjuvant to deplete TRegs. The patients were 
also immunized with pneumococcal vaccine to additionally boost immune responses. The 
treatment was well tolerated; no grade 3 or 4 toxicities were reported. A single dose of 
intravenous cyclophosphamide (300 mg/m2) did not reduce the number of circulating 
TRegs in arm 2. Immune responses to DC vaccination were modest; induction of antigen-
specific T cell responses was detected in a subset of patients. The estimated 3-year 
progression-free and overall survival was not significantly different between treatment 
arms (p = 0.17 respectively p = 1.00). In another clinical study, involving 6 recurrent ovarian 
cancer patients, the combination of DC therapy with the VEGF-inhibitor bevacizumab was 
investigated (68). DCs were isolated from patients who subsequently received 2 cycles of 
bevacizumab, followed by seven daily doses of cyclophosphamide. DCs were pulsed with 
whole tumor lysates and infused in the patient during 3 cycles. Three patients underwent 
a second trial, consisting of higher doses of cyclophosphamide and fludarabine plus re-
infusion of CD3/CD28 stimulated T cells and ex vivo matured DCs. Both treatments 
were well tolerated. TReg depletion was not observed in response to cyclophosphamide 
treatments. Four patients responded to the initial treatment with partial responses or 
stable disease. Two of the three patients who enrolled in the second trial, demonstrated a 
complete response or stable disease. 
Another opportunity for DC vaccination in ovarian cancer, which is yet to be explored, 
is the targeting of cancer stem cells (CSCs). CSCs are cancer cells that have properties 
similar to normal stem cells, in particular the ability to give rise to all cell types found 
in a particular cancer type. These cells are generally resistant to chemotherapy and are 
believed to be the source of tumor relapse. As highlighted in a recent meeting (69) the 
exclusive property of a stem cell or cancer stem cell is self-renewal. As a consequence 
of this innate ability, CSCs express stem cell markers like OCT4A, SOX2 and NANOG. 
Maintaining the expression of these markers is the result of several derailed 
signaling networks. Without the maintenance of these stem cell proteins, the cell will 
differentiate and ultimately die. Spheroid cell cultures, which have an enriched CSC 
population, are far less sensitive to chemotherapy due to several mechanisms. Just as 
“normal” stem cells, they are mostly quiescent and thus resistant to chemotherapeutic 
drugs that target DNA replication. Additionally, they also express protein pumps that 
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expel chemotherapeutic drugs (70). These features ensure that chemotherapy will kill 
the majority of the normal tumor cells, whereas the CSCs remain and eventually lead to 
recurrence. 
Unfortunately, eradicating CSCs is not simple. The initial paradigm was that eradicating 
CSCs would cure cancer as tumor cells would eventually die and not be replenished (71). 
Now, it is apparent that more complex factors also play a role. Eradicated CSCs are replaced 
by more mature ‘stem cells’ that gain access to the vacated CSC niche and acquire self-
renewal properties (72). Thus it seems that even if CSCs were susceptible to chemotherapy, 
this would not be enough to prevent the tumor from coming back. Immunotherapy is a 
prime candidate to keep these CSCs in check. After inducing an anti-CSC response, the 
immune system will further react with a memory response. This means that, as soon as 
the antigen re-surfaces, due to the cells that occupy the stem cell niche acquire stem cell 
features, these memory cells will become effector cells and eliminate the CSC. This is the 
same memory mechanism that is active against pathogenic microorganisms and forms the 
basis of therapeutic and prophylactic vaccination against pathogens. In ovarian cancer, 
OCT4A expression was found in a rare cancer cell population, akin to CSCs (73). Moreover, 
T cell reactivity towards OCT4 was demonstrated, making OCKT4A an attractive and 
feasible target for vaccination strategies (74) Taken together, DC therapy is feasible and 
well tolerated for a number of tumor antigens. Preliminary clinical results in phase I/II 
trials are encouraging, but larger randomized trials are needed to further improve DC 
immunotherapies. Finally, there is still the intriguing yet unexplored strategy of targeting 
CSCs with DC vaccination.
Summarizing conclusions
Ovarian cancer is an immunogenic cancer, but…
Here we reviewed the involvement of the immune system in ovarian cancer, and have 
demonstrated that although ovarian cancer has historically not been regarded as 
‘immunogenic cancer’, accumulating evidence indicates that the immune system 
plays an important role in the outcome of intervention strategies whether it is surgery, 
chemotherapy, or other modalities. Multiple studies have shown that T cells infiltrate 
ovarian tumors and that this is associated with a favorable clinical outcome. Specifically, 
the presence of CD8+ cytotoxic T cells delays disease progression and extends overall 
survival of cancer patients. In contrast, the presence of TRegs, recruited through secretion 
of chemokines by tumor cells, is associated with poorer clinical outcome. On the other 
hand, the CD4+ Th17 T cell subset has beneficial effects on tumor rejection by the host 
immune response and is also associated with improved survival of ovarian cancer 
patients. 
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…There are many immunosuppressive mechanisms at work
Despite the presence of infiltrating lymphocytes in many patients, the tumor is thought to 
ultimately escape immunosurveillance by fostering an immunosuppressive environment. 
NK cells are inactivated by contact-dependent interactions with tumor cells, resulting in 
downregulation of activating receptors, and by the secretion of soluble factors, which 
limit NK cell infiltration. Tumor-associated macrophages are polarized towards an 
immunosuppressive M2 phenotype and are recruited to promote neoangiogenesis, tumor 
invasion and inhibition of other immune cells. Furthermore, the cytotoxic activity of 
tumor-infiltrating CD8+ T cells is thwarted through expression of co-inhibitory molecules 
on tumor cells that render these effector cells anergic. Finally, DCs are recruited in an 
immature state and are unable to efficiently present antigens to elicit adaptive immune 
responses. Instead, immature DCs suppress the activity of other immune cells and 
promote tumor growth e.g., through neoangiogenesis.
Cellular immunotherapy
The fact that the immune system plays an important role in the outcome of ovarian cancer 
intervention and the fact that immune evasion seems to be a requirement for disease 
progression indicate that ovarian cancer might be susceptible to immunotherapy. DC 
vaccination against TAAs is a promising strategy to activate the immune system in ovarian 
cancer patients. While phase I/II trials indicate that vaccination is well tolerated and 
capable of inducing tumor-specific T cell responses, further testing in larger phase III trials 
is required to truly evaluate clinical outcome. Adoptive transfer of TILs has improved in the 
last decades and novel implementation strategies for ACT are being tested in the clinic.
Future challenges
The main challenge facing immunotherapy in ovarian cancer is overcoming the 
immunosuppressive tumor microenvironment (e.g., PD-L1/2 expression, anergic NK 
and T cells, TRegs, TAMs, and immature DCs). These form considerable barriers that 
the host’s immune system must overcome in order to mount an effective anti-tumor 
response. Fortunately, many novel strategies to break immunosuppression are currently 
being developed in clinical setting. Blocking of the immune checkpoint receptor PD-
1, the receptor for PD-L1 and PD-L2, is showing impressive effects in an ongoing trial in 
melanoma patients (NCT01295827). Phase I/II trials for other cancers have also been 
initiated and it is only a matter of time before these will also include ovarian cancer 
(NCT01772004). Another immune checkpoint, CTLA-4, has also been targeted for clinical 
intervention. The anti-CTLA-4 monoclonal antibody, Ipilimumab, showed promising 
results in advanced melanoma patients and gained FDA approval in 2011. A phase II trial in 
recurrent ovarian cancer patients was recently initiated and the results are eagerly awaited 
(NCT01611558). Another very important issue, which is still to be addressed, is that of 
ovarian cancer heterogeneity. Recent studies show that EOC encompasses a number of 
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histologically, clinically and molecularly diverse subtypes. Gene expression profiling has 
identified 5 distinct subtypes, including one that has been described as ‘immunoreactive’ 
and another as ‘chemo-sensitive’ (75, 76). These studies clearly demonstrate that these 
subtypes have very different prognoses. The clinical studies described in this review did 
not select the patients on these molecular subtypes, but it would be very interesting to 
see whether the patients that respond to immunotherapy have tumors belonging to the 
immunoreactive subtype. Molecular subtyping of the tumors of patients included in new 
and ongoing trials would provide very valuable data in order to address this question. In 
the end, this could result in novel criteria for the selection of patients for immunotherapy 
based on the tumor molecular subtype. 
figure 2  Ovarian cancer treatment strategy. Tumors are very heterogeneous and consist of many 
different cell types. They are not only composed of rapidly dividing tumor cells, but also contain 
slowly dividing cells with stem cell-like properties, called cancer stem cells (CSCs). CSCs form a 
rare cell population, which is self-renewing and gives rise to new cancer cells. First line therapy in 
ovarian cancer is debulking surgery, aiming at removal of the main tumor mass. This is followed 
by chemotherapy to destroy tumor cells that were not removed during surgery. Chemotherapy 
targets cells with a high proliferation rate and, therefore, CSCs survive. These CSCs can give rise 
to a new tumor and have been proposed to be the reason for disease relapse. DC vaccination 
could be used to specifically target CSCs. The tumor burden of a patient is drastically reduced 
after surgery and chemotherapy, rendering DC vaccination more effective. Injection of autologous 
DCs pulsed with CSC-specific peptides into lymph nodes might induce a potent immune response 
against CSC. CSC-specific T cells could migrate to the tumor where they kill CSCs. DC vaccination 
furthermore generates a long-lasting memory response, which would be activated if new cancer 
cells are arise, thus preventing disease recurrence.
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Realistically, the short-term application of immunotherapy in ovarian cancer might 
be adjuvant therapy rather than first-line monotherapy (Figure 2). Most patients are 
diagnosed with ovarian cancer in advanced stages with considerable tumor burden and 
a long evolution of tumor immune evasion. Mounting a durable anti-tumor immune 
response might simply be a too formidable task for the host immune system in late 
stages of disease progression, even in those patients that have an immunoreactive tumor 
subtype. Cytoreductive surgery and chemotherapy offer very efficient tumor debulking, 
severely lowering the tumor burden. Adjuvant immunotherapy would then be a method to 
eradicate remaining (micro)metastases leading to cure. An additional advantage of such 
a sequential treatment modality is that patients can also benefit from the immunological 
effects of the surgery and especially the chemotherapy. A number of chemotherapeutic 
compounds, including the platinum compounds used in ovarian cancer, are known 
to have immunostimulatory effects that could be exploited following therapy (9, 11, 
12). The induction of immunogenic cell death by these drugs can lead to DC activation 
and initiation of immune responses against TAAs. Furthermore, they may also disrupt 
immunosuppressive networks by downregulation of PD-L1 and 2 and sensitization of 
tumor cells to T cell killing. It will be important to address how to synergize chemotherapy 
with immunotherapy in order to achieve disruption of immunosuppression and subsequent 
activation of the immune system. In terms of preferred immunotherapeutic modality, DC 
vaccination might be the best option as it synergizes with platinum chemotherapy (12) 
and can be targeted to cancer stem cells, which are resistant to chemotherapy and are 
responsible for relapse. In conclusion, although more research is needed and is ongoing, 
immunotherapy is a viable addition and can have a (much needed) positive contribution to 
existing intervention strategies to ovarian cancer.
Conflict of interest statement
The authors declare no conflict of (financial) interests.
Acknowledgements
We would like to thank all researchers whose work contributed to advancing our 
knowledge of the immune contexture of ovarian cancer but could not be cited due to 
space constraints. S. V. Hato is supported by a grant from the Dutch Cancer Society and 
Alpe deHuZes foundation (KUN2013-5958). RT was supported by a grant from the Dutch 
government to the Netherlands Institute for Regenerative Medicine (NIRM, grant No. 
FES0908).
All authors declare no financial disclosures. 
CHAPTER 2
34
References
1 Siegel, R., et al., Cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 2014. 64(1): p. 
9-29.
2 Jayson, G.C., et al., Ovarian cancer. The Lancet, 2014.
3 Mavaddat, N., et al., Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From 
Prospective Analysis of EMBRACE. Journal of the National Cancer Institute, 2013. 105(11): p. 
812-822.
4. Salani, R., et al., Posttreatment surveillance and diagnosis of recurrence in women with 
gynecologic malignancies: Society of Gynecologic Oncologists recommendations. American 
Journal of Obstetrics & Gynecology, 2011. 204(6): p. 466-478.
5. Markman, M. and J.L. Walker, Intraperitoneal chemotherapy of ovarian cancer: a review, with a 
focus on practical aspects of treatment. Journal of Clinical Oncology, 2006. 24(6): p. 988-994.
6. Mellman, I., G. Coukos, and G. Dranoff, Cancer immunotherapy comes of age. Nature, 2011. 
480(7378): p. 480-489.
7 Zhang, L., et al., Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. New 
England Journal of Medicine, 2003. 348(3): p. 203-213.
8 Napoletano, C., et al., Ovarian cancer cytoreduction induces changes in T cell population subsets 
reducing immunosuppression. Journal of Cellular and Molecular Medicine, 2010. 14(12): p. 
2748-59.
9 Hato, S.V., et al., Molecular pathways: the immunogenic effects of platinum-based 
chemotherapeutics. Clinical Cancer Research, 2014. 20(11): p. 2831-7.
10 Kroemer, G., et al., Immunogenic cell death in cancer therapy. Annual Review of Immunology, 
2013. 31: p. 51-72.
11 Hato, S.V., I.J. de Vries, and W.J. Lesterhuis, STATing the importance of immune modulation by 
platinum chemotherapeutics. Oncoimmunology, 2012. 1(2): p. 234-236.
12 Lesterhuis, W.J., et al., Platinum-based drugs disrupt STAT6-mediated suppression of immune 
responses against cancer in humans and mice. The Journal of Clinical Investigation, 2011. 
121(8): p. 3100-8.
13 Ramakrishnan, R., et al., Chemotherapy enhances tumor cell susceptibility to CTL-mediated 
killing during cancer immunotherapy in mice. The Journal of Clinical Investigation, 2010. 
120(4): p. 1111-1124.
14 Vivier, E., et al., Targeting natural killer cells and natural killer T cells in cancer. Nature Reviews 
Immunology, 2012. 12(4): p. 239-252.
15 Carlsten, M., et al., Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by 
Down-Regulating DNAM-1 on NK Cells. The Journal of Immunology, 2009. 183(8): p. 4921-
4930.
16 Belisle, J.A., et al., Peritoneal natural killer cells from epithelial ovarian cancer patients show an 
altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology, 2007. 122(3): 
p. 418-429.
17 Patankar, M.S., et al., Potent suppression of natural killer cell response mediated by the ovarian 
tumor marker CA125. Gynecologic Oncology, 2005. 99(3): p. 704-713.
18 Dong, H.P., et al., NK- and B-Cell Infiltration Correlates With Worse Outcome in Metastatic 
Ovarian Carcinoma. American Journal of Clinical Pathology, 2006. 125(3): p. 451-458.
19 Sato, E., et al., Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T 
cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National 
Academy of Sciences of the United States of America, 2005. 102(51): p. 18538-18543.
20 Gooden, M.J.M., et al., The prognostic influence of tumour-infiltrating lymphocytes in cancer: a 
systematic review with meta-analysis. British Journal of Cancer, 2011. 105(1): p. 93-103.
CELLULAR IMMUNOTHERAPY IN OVARIAN CANCER
35
21 Hwang, W.-T., et al., Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-
analysis. Gynecologic Oncology, 2012. 124(2): p. 192-198.
22 Hamanishi, J., et al., Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T 
lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National 
Academy of Sciences, 2007. 104(9): p. 3360-3365.
23 Zou, W. and N.P. Restifo, TH17 cells in tumour immunity and immunotherapy. Nature Reviews 
Immunology, 2010. 10(4): p. 248-256.
24 Miyahara, Y., et al., Generation and regulation of human CD4+ IL-17-producing T cells in ovarian 
cancer. Proceedings of the National Academy of Sciences, 2008. 105(40): p. 15505-15510.
25 Kryczek, I., et al., Phenotype, distribution, generation, and functional and clinical relevance of 
Th17 cells in the human tumor environments. Blood, 2009. 114(6): p. 1141-1149.
26 Fialová, A., et al., Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual 
shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. 
International Journal of Cancer, 2013. 132(5): p. 1070-1079.
27 Vasaturo, A., et al., Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor 
Microenvironment for DC Vaccination: A Game of Stop and Go. Frontiers in Immunology, 2013. 
4: p. 417.
28 Rozali, E.N., et al., Programmed death ligand 2 in cancer-induced immune suppression. Clinical & 
Developmental Immunology, 2012. 2012: p. 656340.
29 Ito, T., et al., Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and 
Periphery. Immunity, 2008. 28(6): p. 870-880.
30 Woo, E.Y., et al., Regulatory CD4+CD25+ T Cells in Tumors from Patients with Early-Stage Non-
Small Cell Lung Cancer and Late-Stage Ovarian Cancer. Cancer Research, 2001. 61(12): p. 4766-
4772.
31 Curiel, T.J., et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune 
privilege and predicts reduced survival. Nature Medicine, 2004. 10(9): p. 942-949.
32 Adams, S.F., et al., Intraepithelial T cells and tumor proliferation. Cancer, 2009. 115(13): p. 
2891-2902.
33 Barnett, J.C., et al., Ovarian cancer tumor infiltrating T-regulatory cells are associated with a 
metastatic phenotype. Gynecologic Oncology, 2010. 116(3): p. 556-562.
34 Karanikas, V., et al., Foxp3 expression in human cancer cells. Journal of Translational Medicine, 
2008. 6(1): p. 19.
35 Roncarolo, M.-G. and S. Gregori, Is FOXP3 a bona fide marker for human regulatory T cells? 
European Journal of Immunology, 2008. 38(4): p. 925-927.
36 Curiel, T.J., et al., Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor 
immunity. Nature Medicine, 2003. 9(5): p. 562-567.
37 Krempski, J., et al., Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate 
Immune Suppression in Ovarian Cancer. The Journal of Immunology, 2011. 186(12): p. 6905-
6913.
38 Conrad, C., et al., Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer 
via ICOS Costimulation of Foxp3+ T-Regulatory Cells. Cancer Research, 2012. 72(20): p. 5240-
5249.
39 Curiel, T.J., et al., Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian 
Cancer. Cancer Research, 2004. 64(16): p. 5535-5538.
40 Labidi-Galy, S.I., et al., Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells 
Contribute to Immune Tolerance in Ovarian Cancer. Cancer Research, 2011. 71(16): p. 5423-
5434.
41 Colvin, E.K., Tumor associated macrophages contribute to tumor progression in ovarian cancer. 
Frontiers in Oncology, 2014. 4.
CHAPTER 2
36
42 Mantovani, A. and A. Sica, Macrophages, innate immunity and cancer: balance, tolerance, and 
diversity. Current Opinion in Immunology, 2010. 22(2): p. 231-237.
43 Hagemann, T., et al., Ovarian cancer cells polarize macrophages toward a tumor-associated 
phenotype. The Journal of Immunology, 2006. 176(8): p. 5023-5032.
44 Takaishi, K., et al., Involvement of M2-polarized macrophages in the ascites from advanced 
epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Science, 2010. 
101(10): p. 2128-2136.
45 Kawamura, K., et al., Detection of M2 macrophages and colony-stimulating factor 1 expression 
in serous and mucinous ovarian epithelial tumors. Pathology International, 2009. 59(5): p. 300-
305.
46 Kryczek, I., et al., Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive 
Mode for Regulatory T Cells. The Journal of Immunology, 2006. 177(1): p. 40-44.
47 Kryczek, I., et al., B7-H4 expression identifies a novel suppressive macrophage population in 
human ovarian carcinoma. The Journal of Experimental Medicine, 2006. 203(4): p. 871-881.
48 Disis, M.L., et al., Humoral epitope-spreading following immunization with a HER-2/neu peptide 
based vaccine in cancer patients. Journal of Clinical Immunology, 2004. 24(5): p. 571-578.
49 Leffers, N., et al., Immunization with a P53 synthetic long peptide vaccine induces P53-specific 
immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer, 
2009. 125(9): p. 2104-2113.
50 Rahma, O., et al., A gynecologic oncology group phase II trial of two p53 peptide vaccine 
approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk 
ovarian cancer patients. Cancer immunology, immunotherapy, 2012. 61(3): p. 373-384.
51 Diefenbach, C.S.M., et al., Safety and Immunogenicity Study of NY-ESO-1b Peptide and 
Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First 
Remission. Clinical Cancer Research, 2008. 14(9): p. 2740-2748.
52 Sabbatini, P., et al., Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and 
Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients. 
Clinical Cancer Research, 2012. 18(23): p. 6497-6508.
53 Odunsi, K., et al., Efficacy of vaccination with recombinant vaccinia and fowlpox vectors 
expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proceedings of the 
National Academy of Sciences, 2012. 109(15): p. 5797-5802.
54 Freedman, R.S., et al., Intraperitoneal adoptive immunotherapy of ovarian carcinoma with 
tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. Journal of 
Immunotherapy, 1994. 16(3): p. 198-210.
55 Aoki, Y., et al., Use of Adoptive Transfer of Tumor-infiltrating Lymphocytes Alone or in 
Combination with Cisplatin-containing Chemotherapy in Patients with Epithelial Ovarian 
Cancer. Cancer Research, 1991. 51(7): p. 1934-1939.
56 Santin, A.D., et al., Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-
eluted peptide-pulsed autologous dendritic cells. Obstetrics and Gynecology, 2000. 96(3): p. 
422-30.
57 Santin, A.D., et al., Restoration of tumor specific human leukocyte antigens class I-restricted 
cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with 
advanced ovarian cancer. International Journal of Gynecological Cancer, 2004. 14(1): p. 64-75.
58 Fujita, K., et al., Prolonged disease-free period in patients with advanced epithelial ovarian cancer 
after adoptive transfer of tumor-infiltrating lymphocytes. Clinical Cancer Research, 1995. 1(5): 
p. 501-507.
59 Restifo, N.P., M.E. Dudley, and S.A. Rosenberg, Adoptive immunotherapy for cancer: harnessing 
the T cell response. Nature Reviews Immunology, 2012. 12(4): p. 269-281.
60 Parker, L.L., et al., Expansion and characterization of T cells transduced with a chimeric receptor 
against ovarian cancer. Human Gene Therapy, 2000. 11(17): p. 2377-2387.
CELLULAR IMMUNOTHERAPY IN OVARIAN CANCER
37
61 Kershaw, M.H., et al., A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells 
for Ovarian Cancer. Clinical Cancer Research, 2006. 12(20): p. 6106-6115.
62 Kandalaft, L.E., D.J. Powell, Jr., and G. Coukos, A phase I clinical trial of adoptive transfer of folate 
receptor-alpha redirected autologous T cells for recurrent ovarian cancer. Journal of Translational 
Medicine, 2012. 10: p. 157.
63 Merad, M., et al., The dendritic cell lineage: ontogeny and function of dendritic cells and their 
subsets in the steady state and the inflamed setting. Annual Review of Immunology, 2013. 31.
64 Brossart, P., et al., Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with 
peptide-pulsed dendritic cells. Blood, 2000. 96(9): p. 3102-3108.
65 Hernando, J., et al., Vaccination with autologous tumour antigen-pulsed dendritic cells in 
advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. 
Cancer immunology, immunotherapy, 2002. 51(1): p. 45-52.
66 Peethambaram, P.P., et al., A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in 
Patients with Refractory Metastatic Tumors that Express HER-2/neu. Clinical Cancer Research, 
2009. 15(18): p. 5937-5944.
67 Chu, C.S., et al., Phase I/II randomized trial of dendritic cell vaccination with or without 
cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second 
remission. Cancer immunology, immunotherapy, 2012. 61(5): p. 629-641.
68 Kandalaft, L.E., et al., Autologous lysate-pulsed dendritic cell vaccination followed by 
adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. 
Oncoimmunology, 2013. 2(1).
69 Adorno-Cruz, V., et al., Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and 
sources of therapy resistance. Cancer Research, 2015. 75(6): p. 924-9.
70 Liao, J., et al., Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor 
Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism. 
PloS One, 2014. 9(1): p. e84941.
71 Jones, R.J. and W. Matsui, Cancer Stem Cells: From Bench to Bedside. Journal of the American 
Society for Blood and Marrow Transplantation, 2007. 13(1): p. 47-52.
72 Kaiser, J., The cancer stem cell gamble. Science, 2015. 347(6219): p. 226.
73 Di, J., et al., The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and 
tumor tissue of ovarian cancer patients. Cellular Oncology, 2013. 36(5): p. 363-74.
74 Di, J., et al., Functional OCT4-specific CD4 and CD8 T cells in healthy controls and ovarian cancer 
patients. Oncoimmunology, 2013. 2(5): p. e24271.
75 Tothill, R.W., et al., Novel molecular subtypes of serous and endometrioid ovarian cancer linked to 
clinical outcome. Clinical Cancer Research, 2008. 14(16): p. 5198-208.
76 Research, C.G.A., Integrated genomic analyses of ovarian carcinoma. Nature, 2011. 474(7353): 
p. 609-15. 
CHAPTER 2
38
Supplementary material
su
pp
le
m
en
ta
ry
 t
ab
le
 1 
 S
um
m
ar
y 
of
 im
m
un
ot
he
ra
py
 c
lin
ic
al
 tr
ia
ls
 in
vo
lv
in
g 
ov
ar
ia
n 
ca
nc
er
 p
at
ie
nt
s.
 T
hi
s 
ta
bl
e 
su
m
m
ar
iz
es
 a
ll 
th
e 
cl
in
ic
al
 tr
ia
ls
 d
is
cu
ss
ed
 in
  
th
e 
te
xt
 a
nd
 p
ro
vi
de
s 
in
fo
rm
at
io
n 
on
 n
um
be
r 
of
 p
at
ie
nt
s 
in
cl
ud
ed
, 
tu
m
or
 c
la
ss
ifi
ca
ti
on
 a
nd
 s
ta
gi
ng
, 
th
e 
im
m
un
ot
he
ra
pe
ut
ic
 i
nt
er
ve
nt
io
n,
 a
s 
w
el
l 
as
 t
he
  
an
ti
ge
n 
ta
rg
et
ed
, i
m
m
un
ol
og
ic
al
 re
sp
on
se
s a
nd
 c
lin
ic
al
 re
sp
on
se
. 
 
Tr
ia
l
C
la
ss
ifi
ca
ti
on
 
Ph
as
e
Ta
rg
et
 a
nt
ig
en
 /
 
Tr
ea
tm
en
t
Im
m
un
ol
og
ic
al
 re
sp
on
se
C
lin
ic
al
 re
sp
on
se
R
ef
Pa
ti
en
ts
 w
it
h 
st
ag
es
 II
I-
IV
 
br
ea
st
 (3
1)
, o
va
ri
an
 (5
),
 o
r 
no
n 
sm
al
l c
el
l l
un
g 
ca
nc
er
 
(2
).
-
I
H
ER
-2
/n
eu
Pe
pt
id
e 
va
cc
in
e
H
ER
-2
/n
eu
 Ig
G
 s
pe
ci
fic
 a
nt
ib
od
y 
re
-
sp
on
se
 (6
0%
). 
H
um
or
al
 in
tr
am
ol
ec
u-
la
r e
pi
to
pe
-s
pr
ea
di
ng
 w
ith
in
 H
ER
-2
/
ne
u 
(4
9%
). 
In
te
rm
ol
ec
ul
ar
 
ep
ito
pe
-s
pr
ea
di
ng
 to
 p
53
 (2
0%
).
N
.d
.
[4
8]
O
va
ri
an
 c
an
ce
r w
it
h 
el
e-
va
te
d 
C
A
-1
25
 (2
0)
.
-
II
P5
3 
/ 
Pe
pt
id
e 
va
cc
in
e
IF
N
-γ
 p
ro
du
ci
ng
 p
53
-s
pe
ci
fic
 C
D
4+
 
T-
ce
ll 
re
sp
on
se
s 
(1
00
%
). 
 P
53
-s
pe
ci
f-
ic
 T
-c
el
ls
 p
re
se
nt
 in
 a
 b
io
ps
y 
of
 th
e 
la
st
 im
m
un
iz
at
io
n 
si
te
 (5
3%
).
St
ab
le
 d
is
ea
se
 (1
0%
). 
Pr
og
re
ss
iv
e 
di
se
as
e 
(9
0%
). 
G
ra
de
 1
/2
 to
xi
ci
ty
.
[4
9]
St
ag
e 
II
I, 
IV
, o
r r
ec
ur
re
nt
 
ov
ar
ia
n 
ca
nc
er
 w
it
h 
N
ED
 
(2
1)
.
A
rm
 1
: P
53
 p
ep
ti
de
, G
M
-
C
SF
, M
on
ta
ni
de
 IS
A
-5
1,
 
IL
-2
. 
A
rm
 2
: P
53
 D
C
 v
ac
ci
ne
, 
IL
-2
.
-
II
P5
3 
/ 
Pe
pt
id
e 
va
c-
ci
ne
/ 
D
C
 v
ac
ci
ne
Po
si
tiv
e 
im
m
un
e 
re
sp
on
se
s 
by
 
EL
IS
PO
T 
or
 te
tr
am
er
 a
ss
ay
s 
in
 a
rm
 A
 
(6
9%
) o
r a
rm
 B
 (8
3%
). 
IL
-2
 in
du
ce
d 
Tr
eg
 c
el
l e
xp
an
si
on
.
M
ed
ia
n 
O
S 
(4
0.
8 
m
o 
vs
. 2
9.
6 
m
o,
 P
 
= 
0.
26
), 
m
ed
ia
n 
PF
S 
(4
.2
 m
o 
vs
. 8
.7
 
m
o,
 P
 =
 0
.8
1)
. G
ra
de
 3
/4
 to
xi
ci
ty
 
du
e 
to
 IL
-2
 tr
ea
tm
en
t.
[5
0]
St
ag
e 
II
IC
-I
V
 (9
).
Pa
pi
lla
ry
 s
er
ou
s 
(8
) 
or
 p
rim
ar
y 
M
ul
le
ria
n 
ad
en
oc
ar
ci
no
m
a 
(1
).
I
N
Y-
ES
O
-1
b 
/ 
 P
ep
-
tid
e 
va
cc
in
e
Po
si
tiv
e 
im
m
un
e 
re
sp
on
se
s 
by
 E
LI
S-
PO
T 
or
 te
tr
am
er
 a
ss
ay
s 
(8
9%
).
M
ed
ia
n 
PF
S 
13
 m
o.
 C
om
pl
et
e 
cl
in
ic
al
 re
m
is
si
on
 (3
3%
), 
re
cu
rr
en
t 
di
se
as
e 
(6
7%
). 
G
ra
de
 1
/2
 to
xi
ci
ty
.
[5
1]
St
ag
e 
II
-I
V
 o
va
ri
an
, f
al
lo
pi
-
an
 tu
be
 o
r p
er
it
on
ea
l 
ep
it
he
lia
l c
ar
ci
no
m
a 
(2
8)
. 
A
rm
 1
: N
Y-
ES
O
-1
b.
 
A
rm
 2
: N
Y-
ES
O
-1
b,
 M
on
-
ta
ni
de
-I
SA
-5
1 
V
G
. 
A
rm
 3
: N
Y-
ES
O
-1
b,
 
M
on
ta
ni
de
-I
SA
-5
1 
V
G
, 
Po
ly
-I
C
LC
.
Se
ro
us
 c
ar
ci
no
m
a 
(2
4)
, e
nd
om
et
ro
id
 
ca
rc
in
om
a 
(2
), 
or
 
ca
rc
in
om
a 
no
t s
pe
ci
-
fie
d 
(2
).
I
N
Y-
ES
O
-1
b 
/ 
Pe
pt
id
e 
va
cc
in
e
N
Y-
ES
O
-1
–s
pe
ci
fic
 a
nt
ib
od
ie
s 
in
 a
rm
 
1 
(0
%
), 
ar
m
 2
 (4
6%
) a
nd
 a
rm
 3
 (9
1%
). 
C
D
8+
 T
 c
el
ls
 in
 a
rm
 1
 (0
%
), 
ar
m
 2
 
(6
2%
) a
nd
 a
rm
 3
 (9
1)
.
A
rm
 1
: P
ro
gr
es
si
ve
 d
is
ea
se
 (7
5%
), 
no
 e
vi
de
nc
e 
of
 d
is
ea
se
 (2
5%
). 
A
rm
 
2:
 P
ro
gr
es
si
ve
 d
is
ea
se
 (7
7%
), 
no
 
ev
id
en
ce
 o
f d
is
ea
se
 (2
3%
). 
A
rm
 3
: 
Pr
og
re
ss
iv
e 
di
se
as
e 
(8
2%
), 
st
ab
le
 
di
se
as
e 
(1
8%
). 
G
ra
de
 1
/2
 to
xi
ci
ty
.
[5
2]
St
ag
e 
II
I-
IV
 m
el
an
om
a 
(2
5)
 o
r e
pi
th
el
ia
l o
va
ri
an
 
ca
nc
er
 (2
2)
.
Se
ro
us
 c
ar
ci
no
m
a 
(1
8)
 o
r c
ar
ci
no
m
a 
no
t 
sp
ec
ifi
ed
 (4
).
II
N
Y-
ES
O
-1
b 
/ 
Pe
pt
id
e 
va
cc
in
e
N
Y-
ES
O
-1
 s
er
op
os
iti
ve
 a
t t
he
 s
ta
rt
 
(1
4%
), 
N
Y-
ES
O
-1
 s
er
oc
on
ve
rs
io
n 
(3
6%
). 
Pr
ee
xi
st
in
g 
C
D
4+
 (6
8%
) 
an
d 
C
D
8+
 (1
4%
) T
 c
el
l r
es
po
ns
es
. 
Po
st
-v
ac
ci
na
tio
n 
C
D
4+
 (9
1%
) a
nd
 
C
D
8+
 (4
5%
) T
 c
el
l r
es
po
ns
es
.
M
ed
ia
n 
O
S 
re
sp
on
de
rs
 4
8 
m
o 
vs
 
no
n-
re
sp
on
de
rs
 1
5 
m
o.
 M
ed
ia
n 
PF
S 
re
sp
on
de
rs
 2
1 
m
 (9
5%
 C
I, 
16
–2
9 
m
o)
. G
ra
de
 1
/2
 to
xi
ci
ty
.
[5
3]
A
dv
an
ce
d 
pl
at
in
um
-r
e-
si
st
an
t e
pi
th
el
ia
l o
va
ri
an
 
ca
rc
in
om
a 
(1
1)
. P
at
ie
nt
s 
re
ce
iv
ed
 rI
L-
2 
al
on
e 
(3
) o
r 
rI
L-
2 
an
d 
ex
 v
iv
o 
ex
pa
nd
ed
 
TI
Ls
.
-
I
N
.a
. /
A
C
T
N
.d
.
A
sc
ite
s 
re
gr
es
si
on
 (1
8%
), 
tu
m
or
 a
nd
 
C
A
-1
25
 re
du
ct
io
n 
(9
%
) a
nd
 s
ta
bl
e 
tu
m
or
 a
nd
 C
A
-1
25
 (9
%
). 
G
ra
de
 3
 
to
xi
ci
ty
 in
 c
yc
le
s 
of
 rI
L-
2 
ad
m
in
is
-
tr
at
io
n.
[5
4]
A
dv
an
ce
d 
or
 re
cu
rr
en
t 
ep
it
he
lia
l o
va
ri
an
 c
an
ce
r 
(1
7)
.
A
rm
 1
: C
yc
lo
ph
os
ph
a-
m
id
e,
 e
x 
vi
vo
 e
xp
an
de
d 
TI
Ls
. 
A
rm
 2
: C
is
pl
at
in
-b
as
ed
 
ch
em
ot
he
ra
py
, e
x 
vi
vo
 
ex
pa
nd
ed
 T
IL
s.
Se
ro
us
 a
de
no
ca
rc
i-
no
m
a 
(1
1)
, p
ap
ill
ar
y 
se
ro
us
 (3
), 
en
do
m
e-
tr
io
id
 (2
), 
or
 c
le
ar
 c
el
l 
ca
rc
in
om
a 
(1
). 
I
N
.a
. /
 
A
C
T
N
.d
.
C
om
bi
ne
d 
ar
m
s:
 c
om
pl
et
e 
re
gr
es
-
si
on
 (4
1%
), 
pa
rt
ia
l r
eg
re
ss
io
n 
(1
2%
). 
N
o 
re
cu
rr
en
ce
 a
t f
ol
lo
w
-u
p 
of
 1
5 
m
o 
(2
4%
).
[5
5]
St
ag
e 
II
, I
II
, I
V
 re
cu
rr
en
t 
ep
it
he
lia
l o
va
ri
an
 c
an
ce
r 
(2
4)
. O
pt
im
al
ly
 d
eb
ul
ke
d 
+ 
ci
sp
la
ti
n 
ch
em
ot
he
ra
py
. 
A
rm
 1
:  
Ex
 v
iv
o 
ex
pa
nd
ed
 
TI
Ls
 (1
1)
. 
A
rm
 2
: N
o 
tr
ea
tm
en
t (
13
).
Se
ro
us
 (1
4)
, m
uc
i-
no
us
 (3
), 
en
do
m
e-
tr
io
id
 c
ar
ci
no
m
a 
(4
), 
or
 u
nd
iff
er
en
tia
te
d 
ad
en
oc
ar
ci
no
m
a 
(3
).
-
N
.a
. /
 
A
C
T
N
.d
.
O
S 
3-
ye
ar
 in
 T
IL
 v
s.
 c
on
tr
ol
 (1
00
%
 
vs
. 6
7.
5%
, p
<0
.0
1)
. P
FS
 3
-y
ea
r i
n 
TI
L 
vs
. c
on
tr
ol
 (8
2.
1%
 v
s.
 5
4.
5%
, 
p<
0.
05
).
[5
8]
R
ec
ur
re
nt
 o
va
ri
an
 c
an
ce
r 
(1
4)
. 
A
rm
 1
: F
R-
m
od
ifi
ed
 T
IL
s,
 
rI
L-
2.
A
rm
 2
: D
ua
l-
sp
ec
ifi
c 
FR
-m
od
ifi
ed
 T
IL
s.
-
I
FR
 /
 
C
A
R
Ra
pi
dl
y 
de
cl
in
in
g 
nu
m
be
rs
 o
f 
ge
ne
-m
od
ifi
ed
 T
 c
el
ls
 in
 c
irc
ul
at
io
n 
in
 a
ll 
pa
tie
nt
s.
 L
ac
k 
of
 s
pe
ci
fic
 T
 c
el
l 
lo
ca
liz
at
io
n 
to
 th
e 
tu
m
or
.
N
o 
re
du
ct
io
n 
in
 tu
m
or
 b
ur
de
n.
 
G
ra
de
 3
/4
 to
xi
ci
ty
 d
ue
 to
 IL
-2
.
[6
1]
CELLULAR IMMUNOTHERAPY IN OVARIAN CANCER
39
su
pp
le
m
en
ta
ry
 t
ab
le
 1 
 S
um
m
ar
y 
of
 im
m
un
ot
he
ra
py
 c
lin
ic
al
 tr
ia
ls
 in
vo
lv
in
g 
ov
ar
ia
n 
ca
nc
er
 p
at
ie
nt
s.
 T
hi
s 
ta
bl
e 
su
m
m
ar
iz
es
 a
ll 
th
e 
cl
in
ic
al
 tr
ia
ls
 d
is
cu
ss
ed
 in
  
th
e 
te
xt
 a
nd
 p
ro
vi
de
s 
in
fo
rm
at
io
n 
on
 n
um
be
r 
of
 p
at
ie
nt
s 
in
cl
ud
ed
, 
tu
m
or
 c
la
ss
ifi
ca
ti
on
 a
nd
 s
ta
gi
ng
, 
th
e 
im
m
un
ot
he
ra
pe
ut
ic
 i
nt
er
ve
nt
io
n,
 a
s 
w
el
l 
as
 t
he
  
an
ti
ge
n 
ta
rg
et
ed
, i
m
m
un
ol
og
ic
al
 re
sp
on
se
s a
nd
 c
lin
ic
al
 re
sp
on
se
. 
 
Tr
ia
l
C
la
ss
ifi
ca
ti
on
 
Ph
as
e
Ta
rg
et
 a
nt
ig
en
 /
 
Tr
ea
tm
en
t
Im
m
un
ol
og
ic
al
 re
sp
on
se
C
lin
ic
al
 re
sp
on
se
R
ef
Pa
ti
en
ts
 w
it
h 
st
ag
es
 II
I-
IV
 
br
ea
st
 (3
1)
, o
va
ri
an
 (5
),
 o
r 
no
n 
sm
al
l c
el
l l
un
g 
ca
nc
er
 
(2
).
-
I
H
ER
-2
/n
eu
Pe
pt
id
e 
va
cc
in
e
H
ER
-2
/n
eu
 Ig
G
 s
pe
ci
fic
 a
nt
ib
od
y 
re
-
sp
on
se
 (6
0%
). 
H
um
or
al
 in
tr
am
ol
ec
u-
la
r e
pi
to
pe
-s
pr
ea
di
ng
 w
ith
in
 H
ER
-2
/
ne
u 
(4
9%
). 
In
te
rm
ol
ec
ul
ar
 
ep
ito
pe
-s
pr
ea
di
ng
 to
 p
53
 (2
0%
).
N
.d
.
[4
8]
O
va
ri
an
 c
an
ce
r w
it
h 
el
e-
va
te
d 
C
A
-1
25
 (2
0)
.
-
II
P5
3 
/ 
Pe
pt
id
e 
va
cc
in
e
IF
N
-γ
 p
ro
du
ci
ng
 p
53
-s
pe
ci
fic
 C
D
4+
 
T-
ce
ll 
re
sp
on
se
s 
(1
00
%
). 
 P
53
-s
pe
ci
f-
ic
 T
-c
el
ls
 p
re
se
nt
 in
 a
 b
io
ps
y 
of
 th
e 
la
st
 im
m
un
iz
at
io
n 
si
te
 (5
3%
).
St
ab
le
 d
is
ea
se
 (1
0%
). 
Pr
og
re
ss
iv
e 
di
se
as
e 
(9
0%
). 
G
ra
de
 1
/2
 to
xi
ci
ty
.
[4
9]
St
ag
e 
II
I, 
IV
, o
r r
ec
ur
re
nt
 
ov
ar
ia
n 
ca
nc
er
 w
it
h 
N
ED
 
(2
1)
.
A
rm
 1
: P
53
 p
ep
ti
de
, G
M
-
C
SF
, M
on
ta
ni
de
 IS
A
-5
1,
 
IL
-2
. 
A
rm
 2
: P
53
 D
C
 v
ac
ci
ne
, 
IL
-2
.
-
II
P5
3 
/ 
Pe
pt
id
e 
va
c-
ci
ne
/ 
D
C
 v
ac
ci
ne
Po
si
tiv
e 
im
m
un
e 
re
sp
on
se
s 
by
 
EL
IS
PO
T 
or
 te
tr
am
er
 a
ss
ay
s 
in
 a
rm
 A
 
(6
9%
) o
r a
rm
 B
 (8
3%
). 
IL
-2
 in
du
ce
d 
Tr
eg
 c
el
l e
xp
an
si
on
.
M
ed
ia
n 
O
S 
(4
0.
8 
m
o 
vs
. 2
9.
6 
m
o,
 P
 
= 
0.
26
), 
m
ed
ia
n 
PF
S 
(4
.2
 m
o 
vs
. 8
.7
 
m
o,
 P
 =
 0
.8
1)
. G
ra
de
 3
/4
 to
xi
ci
ty
 
du
e 
to
 IL
-2
 tr
ea
tm
en
t.
[5
0]
St
ag
e 
II
IC
-I
V
 (9
).
Pa
pi
lla
ry
 s
er
ou
s 
(8
) 
or
 p
rim
ar
y 
M
ul
le
ria
n 
ad
en
oc
ar
ci
no
m
a 
(1
).
I
N
Y-
ES
O
-1
b 
/ 
 P
ep
-
tid
e 
va
cc
in
e
Po
si
tiv
e 
im
m
un
e 
re
sp
on
se
s 
by
 E
LI
S-
PO
T 
or
 te
tr
am
er
 a
ss
ay
s 
(8
9%
).
M
ed
ia
n 
PF
S 
13
 m
o.
 C
om
pl
et
e 
cl
in
ic
al
 re
m
is
si
on
 (3
3%
), 
re
cu
rr
en
t 
di
se
as
e 
(6
7%
). 
G
ra
de
 1
/2
 to
xi
ci
ty
.
[5
1]
St
ag
e 
II
-I
V
 o
va
ri
an
, f
al
lo
pi
-
an
 tu
be
 o
r p
er
it
on
ea
l 
ep
it
he
lia
l c
ar
ci
no
m
a 
(2
8)
. 
A
rm
 1
: N
Y-
ES
O
-1
b.
 
A
rm
 2
: N
Y-
ES
O
-1
b,
 M
on
-
ta
ni
de
-I
SA
-5
1 
V
G
. 
A
rm
 3
: N
Y-
ES
O
-1
b,
 
M
on
ta
ni
de
-I
SA
-5
1 
V
G
, 
Po
ly
-I
C
LC
.
Se
ro
us
 c
ar
ci
no
m
a 
(2
4)
, e
nd
om
et
ro
id
 
ca
rc
in
om
a 
(2
), 
or
 
ca
rc
in
om
a 
no
t s
pe
ci
-
fie
d 
(2
).
I
N
Y-
ES
O
-1
b 
/ 
Pe
pt
id
e 
va
cc
in
e
N
Y-
ES
O
-1
–s
pe
ci
fic
 a
nt
ib
od
ie
s 
in
 a
rm
 
1 
(0
%
), 
ar
m
 2
 (4
6%
) a
nd
 a
rm
 3
 (9
1%
). 
C
D
8+
 T
 c
el
ls
 in
 a
rm
 1
 (0
%
), 
ar
m
 2
 
(6
2%
) a
nd
 a
rm
 3
 (9
1)
.
A
rm
 1
: P
ro
gr
es
si
ve
 d
is
ea
se
 (7
5%
), 
no
 e
vi
de
nc
e 
of
 d
is
ea
se
 (2
5%
). 
A
rm
 
2:
 P
ro
gr
es
si
ve
 d
is
ea
se
 (7
7%
), 
no
 
ev
id
en
ce
 o
f d
is
ea
se
 (2
3%
). 
A
rm
 3
: 
Pr
og
re
ss
iv
e 
di
se
as
e 
(8
2%
), 
st
ab
le
 
di
se
as
e 
(1
8%
). 
G
ra
de
 1
/2
 to
xi
ci
ty
.
[5
2]
St
ag
e 
II
I-
IV
 m
el
an
om
a 
(2
5)
 o
r e
pi
th
el
ia
l o
va
ri
an
 
ca
nc
er
 (2
2)
.
Se
ro
us
 c
ar
ci
no
m
a 
(1
8)
 o
r c
ar
ci
no
m
a 
no
t 
sp
ec
ifi
ed
 (4
).
II
N
Y-
ES
O
-1
b 
/ 
Pe
pt
id
e 
va
cc
in
e
N
Y-
ES
O
-1
 s
er
op
os
iti
ve
 a
t t
he
 s
ta
rt
 
(1
4%
), 
N
Y-
ES
O
-1
 s
er
oc
on
ve
rs
io
n 
(3
6%
). 
Pr
ee
xi
st
in
g 
C
D
4+
 (6
8%
) 
an
d 
C
D
8+
 (1
4%
) T
 c
el
l r
es
po
ns
es
. 
Po
st
-v
ac
ci
na
tio
n 
C
D
4+
 (9
1%
) a
nd
 
C
D
8+
 (4
5%
) T
 c
el
l r
es
po
ns
es
.
M
ed
ia
n 
O
S 
re
sp
on
de
rs
 4
8 
m
o 
vs
 
no
n-
re
sp
on
de
rs
 1
5 
m
o.
 M
ed
ia
n 
PF
S 
re
sp
on
de
rs
 2
1 
m
 (9
5%
 C
I, 
16
–2
9 
m
o)
. G
ra
de
 1
/2
 to
xi
ci
ty
.
[5
3]
A
dv
an
ce
d 
pl
at
in
um
-r
e-
si
st
an
t e
pi
th
el
ia
l o
va
ri
an
 
ca
rc
in
om
a 
(1
1)
. P
at
ie
nt
s 
re
ce
iv
ed
 rI
L-
2 
al
on
e 
(3
) o
r 
rI
L-
2 
an
d 
ex
 v
iv
o 
ex
pa
nd
ed
 
TI
Ls
.
-
I
N
.a
. /
A
C
T
N
.d
.
A
sc
ite
s 
re
gr
es
si
on
 (1
8%
), 
tu
m
or
 a
nd
 
C
A
-1
25
 re
du
ct
io
n 
(9
%
) a
nd
 s
ta
bl
e 
tu
m
or
 a
nd
 C
A
-1
25
 (9
%
). 
G
ra
de
 3
 
to
xi
ci
ty
 in
 c
yc
le
s 
of
 rI
L-
2 
ad
m
in
is
-
tr
at
io
n.
[5
4]
A
dv
an
ce
d 
or
 re
cu
rr
en
t 
ep
it
he
lia
l o
va
ri
an
 c
an
ce
r 
(1
7)
.
A
rm
 1
: C
yc
lo
ph
os
ph
a-
m
id
e,
 e
x 
vi
vo
 e
xp
an
de
d 
TI
Ls
. 
A
rm
 2
: C
is
pl
at
in
-b
as
ed
 
ch
em
ot
he
ra
py
, e
x 
vi
vo
 
ex
pa
nd
ed
 T
IL
s.
Se
ro
us
 a
de
no
ca
rc
i-
no
m
a 
(1
1)
, p
ap
ill
ar
y 
se
ro
us
 (3
), 
en
do
m
e-
tr
io
id
 (2
), 
or
 c
le
ar
 c
el
l 
ca
rc
in
om
a 
(1
). 
I
N
.a
. /
 
A
C
T
N
.d
.
C
om
bi
ne
d 
ar
m
s:
 c
om
pl
et
e 
re
gr
es
-
si
on
 (4
1%
), 
pa
rt
ia
l r
eg
re
ss
io
n 
(1
2%
). 
N
o 
re
cu
rr
en
ce
 a
t f
ol
lo
w
-u
p 
of
 1
5 
m
o 
(2
4%
).
[5
5]
St
ag
e 
II
, I
II
, I
V
 re
cu
rr
en
t 
ep
it
he
lia
l o
va
ri
an
 c
an
ce
r 
(2
4)
. O
pt
im
al
ly
 d
eb
ul
ke
d 
+ 
ci
sp
la
ti
n 
ch
em
ot
he
ra
py
. 
A
rm
 1
:  
Ex
 v
iv
o 
ex
pa
nd
ed
 
TI
Ls
 (1
1)
. 
A
rm
 2
: N
o 
tr
ea
tm
en
t (
13
).
Se
ro
us
 (1
4)
, m
uc
i-
no
us
 (3
), 
en
do
m
e-
tr
io
id
 c
ar
ci
no
m
a 
(4
), 
or
 u
nd
iff
er
en
tia
te
d 
ad
en
oc
ar
ci
no
m
a 
(3
).
-
N
.a
. /
 
A
C
T
N
.d
.
O
S 
3-
ye
ar
 in
 T
IL
 v
s.
 c
on
tr
ol
 (1
00
%
 
vs
. 6
7.
5%
, p
<0
.0
1)
. P
FS
 3
-y
ea
r i
n 
TI
L 
vs
. c
on
tr
ol
 (8
2.
1%
 v
s.
 5
4.
5%
, 
p<
0.
05
).
[5
8]
R
ec
ur
re
nt
 o
va
ri
an
 c
an
ce
r 
(1
4)
. 
A
rm
 1
: F
R-
m
od
ifi
ed
 T
IL
s,
 
rI
L-
2.
A
rm
 2
: D
ua
l-
sp
ec
ifi
c 
FR
-m
od
ifi
ed
 T
IL
s.
-
I
FR
 /
 
C
A
R
Ra
pi
dl
y 
de
cl
in
in
g 
nu
m
be
rs
 o
f 
ge
ne
-m
od
ifi
ed
 T
 c
el
ls
 in
 c
irc
ul
at
io
n 
in
 a
ll 
pa
tie
nt
s.
 L
ac
k 
of
 s
pe
ci
fic
 T
 c
el
l 
lo
ca
liz
at
io
n 
to
 th
e 
tu
m
or
.
N
o 
re
du
ct
io
n 
in
 tu
m
or
 b
ur
de
n.
 
G
ra
de
 3
/4
 to
xi
ci
ty
 d
ue
 to
 IL
-2
.
[6
1]
CHAPTER 2
40
Tr
ia
l
C
la
ss
ifi
ca
ti
on
 
Ph
as
e
Ta
rg
et
 a
nt
ig
en
 /
 
Tr
ea
tm
en
t
Im
m
un
ol
og
ic
al
 re
sp
on
se
C
lin
ic
al
 re
sp
on
se
R
ef
R
ec
ur
re
nt
 b
re
as
t (
7)
 a
nd
 
ov
ar
ia
n 
ca
nc
er
 (3
).
-
I
H
ER
-2
/n
eu
, M
U
C
1 
/
D
C
 v
ac
ci
na
tio
n
Pe
pt
id
e-
sp
ec
ifi
c 
C
TL
s 
de
te
ct
ab
le
 
(5
0%
). 
In
te
rm
ol
ec
ul
ar
 e
pi
-
to
pe
-s
pr
ea
di
ng
 to
 C
EA
, M
A
G
E-
3 
an
d 
M
U
C
1 
(2
0%
).
N
.d
.
[6
4]
R
ec
ur
re
nt
 o
va
ri
an
 c
an
ce
r 
(6
) o
r u
te
ri
ne
 s
ar
co
m
a 
(2
).
-
I
KL
H
, w
ho
le
 tu
m
or
 
an
tig
en
s 
/
D
C
 v
ac
ci
na
tio
n
D
el
ay
ed
-t
yp
e 
hy
pe
rs
en
si
tiv
ity
 
re
ac
tiv
ity
 to
w
ar
ds
 K
LH
 (7
5%
), 
tu
m
or
 
ly
sa
te
-s
pe
ci
fic
 im
m
un
e 
re
sp
on
se
 
(1
3%
)
St
ab
le
 d
is
ea
se
 b
et
w
ee
n 
25
 a
nd
 4
5 
w
ee
ks
 (3
8%
), 
pr
og
re
ss
iv
e 
di
se
as
e 
(6
2%
). 
G
ra
de
 1
 to
xi
ci
ty
.
[6
5]
H
ER
-2
/n
eu
-p
os
it
iv
e 
br
ea
st
 
(1
1)
, c
ol
or
ec
ta
l (
3)
 o
r r
e-
cu
rr
en
t o
va
ri
an
 c
an
ce
r (
4)
.
-
I
H
ER
-2
/n
eu
 (L
ap
ul
eu
-
ce
l-T
) /
 
D
C
 v
ac
ci
na
tio
n
Im
m
un
e 
re
sp
on
se
s 
to
 im
m
un
iz
in
g 
an
tig
en
s 
(B
A
70
72
 a
nd
 H
ER
50
0)
 a
ft
er
 
tw
o 
m
o.
St
ab
le
 d
is
ea
se
 in
 b
re
as
t c
an
ce
r 
pa
tie
nt
s 
(1
8%
), 
sh
or
t-
te
rm
 s
ta
bl
e 
di
se
as
e 
in
 o
va
ria
n 
ca
nc
er
 p
at
ie
nt
s 
(1
1%
). 
G
ra
de
 1
/2
 to
xi
ci
ty
, n
o 
au
to
-
im
m
un
e 
co
m
pl
ic
at
io
ns
.
[6
6]
R
ec
ur
re
nt
 o
va
ri
an
 c
an
ce
r, 
st
ag
es
 Ic
-I
V.
A
ll 
ar
m
s:
 P
ne
um
oc
oc
ca
l 
va
cc
in
e.
 
A
rm
 1
: D
C
 v
ac
ci
na
ti
on
. 
A
rm
 2
: D
C
 v
ac
ci
na
ti
on
, 
cy
cl
op
ho
sp
ha
m
id
e.
Se
ro
us
 c
ar
ci
no
m
a 
(6
), 
en
do
m
et
ro
id
 
ca
rc
in
om
a 
(1
), 
cl
ea
r 
ce
ll 
ca
rc
in
om
a 
(1
), 
m
ix
ed
 c
ar
ci
no
m
a 
(1
), 
or
 u
nd
iff
er
en
tia
te
d 
ca
rc
in
om
a 
(1
)
I/
II
H
ER
-2
/n
eu
, h
TE
RT
, 
PA
D
RE
 /
 
D
C
 v
ac
ci
na
tio
n
M
od
es
t T
-c
el
l r
es
po
ns
es
 to
 H
ER
-2
/
ne
u 
an
d 
hT
ER
T 
po
st
-v
ac
ci
ne
 b
y 
EL
IS
PO
T.
 A
rm
 2
: T
ra
ns
ie
nt
 re
du
ct
io
n 
in
 n
eu
tr
op
hi
ls
, n
o 
ch
an
ge
 in
 to
ta
l 
ly
m
ph
oc
yt
es
 o
r r
eg
ul
at
or
y 
T 
ce
lls
.
N
o 
ev
id
en
ce
 o
f d
is
ea
se
 a
t 3
6 
m
o 
(5
5%
), 
pr
og
re
ss
iv
e 
di
se
as
e 
(4
5%
). 
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
s 
in
 O
S 
an
d 
PF
S 
be
tw
ee
n 
ar
m
s.
 G
ra
de
 1
/2
 
to
xi
ci
ty
.
[6
7]
St
ag
e 
II
c-
IV
 re
cu
rr
en
t o
va
ri
-
an
 c
an
ce
r (
6)
. 
Fi
rs
t t
ri
al
: B
ev
ac
iz
um
ab
 a
nd
 
m
et
ro
no
m
ic
 c
yc
lo
ph
os
ph
a-
m
id
e 
(6
).
Se
co
nd
 tr
ia
l: 
Cy
cl
op
ho
sp
ha
-
m
id
e,
 fl
ud
ar
ab
in
e,
 A
C
T 
of
 T
 
ce
lls
, D
C
 v
ac
ci
na
ti
on
 (3
).
-
I
N
.a
. /
A
C
T/
D
C
 v
ac
ci
na
tio
n
Tu
m
or
-r
ea
ct
iv
e 
T 
ce
lls
 in
 fi
rs
t t
ria
l 
(6
7%
). 
Tu
m
or
-r
ea
ct
iv
e 
T 
ce
lls
 (6
7%
) 
in
 s
ec
on
d 
tr
ia
l. 
N
o 
de
cr
ea
se
 in
 re
gu
-
la
to
ry
 T
 c
el
ls
 o
bs
er
ve
d.
Pa
rt
ia
l r
es
po
ns
es
 (3
3%
), 
st
ab
le
 
di
se
as
e 
(3
3%
), 
pr
og
re
ss
iv
e 
di
se
as
e 
(3
3%
) a
ft
er
 fi
rs
t t
ria
l. 
C
om
pl
et
e 
re
-
sp
on
se
 (3
3%
), 
st
ab
le
 d
is
ea
se
 (3
3%
) 
an
d 
pr
og
re
ss
iv
e 
di
se
as
e 
(3
3%
) a
ft
er
 
se
co
nd
 tr
ia
l. 
G
ra
de
 1
/2
 to
xi
ci
ty
.
[6
8]
N
ot
 d
et
er
m
in
ed
 (N
.d
), 
no
t a
pp
lic
ab
le
 (N
.a
.).


Chapter 3
Immune Curbing of Cancer 
Stem Cells by CTLs Directed  
to NANOG
 
Christina Wefers, Gerty Schreibelt, Leon F.A.G. Massuger,  
I. Jolanda M. de Vries, Ruurd Torensma
Frontiers in Immunology, 2018. 9
44
CHAPTER 3
Abstract
Cancer stem cells (CSCs) have been identified as the source of tumor growth and disease 
recurrence. Eradication of CSCs is thus essential to achieve durable responses, but CSCs are 
resistant to current anti-tumor therapies. Novel therapeutic approaches that specifically 
target CSCs will, therefore, be crucial to improve patient outcome. Immunotherapies, 
which boost the body’s own immune system to eliminate cancerous cells, could be an 
alternative approach to target CSCs. Vaccines of dendritic cells (DCs) loaded with tumor 
antigens can evoke highly specific anti-tumor T cell responses. Importantly, DC vaccination 
also promotes immunological memory formation, paving the way for long-term cancer 
control. Here, we propose a DC vaccination that specifically targets CSCs. DCs loaded with 
NANOG peptides, a protein required for maintaining stem cell properties, could evoke 
a potent anti-tumor immune response against CSCs. We hypothesize that the resulting 
immunological memory will also control newly formed CSCs, thereby preventing disease 
recurrence. 
45
IMMUNE CURBING OF CANCER STEM CELLS BY CTLs DIRECTED TO NANOG
Current approaches to target cancer stem cells (CSCs)
CSCs form a rare population of tumor cells with a unique ability to self-renew. Although 
CSCs proliferate slowly, they give rise to more differentiated, fast-growing tumor cells 
that sustain and fuel tumor growth. Their low proliferation rate, combined with the 
expression of drug transporters, enables CSCs to survive classical anti-tumor treatments. 
Furthermore, continuous genomic and epigenomic changes allow CSCs to develop new 
resistance mechanisms that can be passed on to their progeny (1). Current anti-tumor 
therapies targeting the tumor bulk thus often fail to eliminate CSCs.
The realization that eradicating CSCs is essential to prevent disease relapse has greatly 
stimulated CSC research. The search term “cancer stem cells” yields over 75,000 hits in 
PUBMED, and numerous papers describe CSC proteins and their pathways. This has led to 
different treatment strategies that target CSC, either by inducing CSC killing, by forcing 
their differentiation, or by inhibiting key signaling pathways.
Initially, large libraries of small molecules were screened for candidates that kill CSCs 
(for a recent review see Ref. (2, 3)). These molecules target different key signaling 
pathways of CSCs. Salinomycin was one of the first compounds discovered (3). Another 
example is the small molecule IGC-001, which affects the Wnt pathway by interfering 
with β-catenin (4). NOTCH signaling could be inhibited through γ-secretase inhibition 
of MK-0752 (5). The two FDA approved drugs Vismodegib and Erismodegib block the 
Hedgehog signaling pathway and are tested in clinical trials for the treatment of basal-
cell carcinoma (6-8).
Aside from synthetic molecules, also naturally occurring small molecules and food 
components can interfere with CSC signaling. A vast number of papers describe the 
signaling targets of these natural compounds and the mechanisms of CSCs killing 
(for review see Ref. (9)). Several compounds showed inhibiting functions in vitro (10, 11). 
Statistical analyses even demonstrated that eating cruciferous vegetables (12, 13) can 
prolong survival of cancer patients. Curcumin is effective in several tumors. However, 
curcumin only works at high dosage (8 g/day), probably because its low solubility limits 
availability. A modified, more soluble form of curcumin is, therefore, being tested in several 
trials (14). Although food components killed tumor cells in vitro, they could not prevent 
cancer development in vivo (15-17). A likely reason for this discrepancy is that food mostly 
contains inactive precursors of active compounds. For example, only a minority of people 
has an intestinal flora that promotes the conversion of the precursor glucoraphanin into 
the CSCs inhibitor sulforaphane (18, 19). 
Just like their synthetic counterparts, natural small molecules from food components 
affect the Hedgehog-, the Wnt-, and the Notch-Jagged signaling pathways. However, this 
approach can result in severe side effects, as these signaling pathways are also essential 
for normal stem cells. Stem cells in the colon crypts - which are crucial for regenerating and 
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sustaining colon tissue - depend on the Wnt pathway. Targeting Wnt signaling, therefore, 
comes with a risk of collateral damage (20-22). 
To prevent these side effects, antibody-drug conjugates (ADCs) can be used to specifically 
target and kill CSCs via cell surface markers, such as LGR5, CD133, or DLL3 (23-25). Even 
though these ADCs showed promising results in murine experimental models of colon 
and lung cancer, their success should be interpreted with caution. CSC markers are 
heterogeneously expressed on the stem cell population, and to date, none of the identified 
surface markers is specific for CSCs (26). Aspecific ADCs may also eradicate normal stem 
cells that share surface markers with CSCs. Furthermore, the instability of current ADCs in 
the circulation may lead to premature drug release and off-target toxicity (27). 
Another approach induces terminal differentiation of CSCs through epigenetic 
targeting. The best-known example is all-trans retinoic acid, which is used to treat acute 
promyelocytic leukemia. This compound induces histone modifications that force CSCs 
to differentiate (28). Similarly, histone deacetylases (HDAC) are promising targets in CSCs, 
as several clinically available HDAC inhibitors can preferentially target CSCs in vitro (29). 
However, little is known about the epigenetic regulation of CSCs and treatment with 
HDAC inhibitors could cause toxicity by disrupting gene regulation in normal tissue stem 
cells. 
Even though current approaches to target CSCs in solid tumors are promising, they do face 
major challenges. First, reliable CSC-specific markers and signaling pathways need to be 
identified to prevent off-target effects. Second, none of these strategies can cope with CSC 
plasticity, the interconversion of CSCs and more differentiated tumor cells. Eradication of 
CSCs can only be achieved if these problems are adequately addressed.
Stem cell transcription factors are ideal targets to inhibit 
CSCs
The best way to kill CSCs is to target their unique proteins, not or low expressed by 
somatic cells (30). Candidates are the transcription factors OKT4A, SOX2, c-MYC, and 
KLF4, which also transform somatic cells into stem cells (iPS) (31). Most types of cancers 
express several of these transcription factors in a low percentage of cells (32-35), although 
some cancer types express only one or two of these transcription factors (36-38). Another 
candidate is the transcription factor NANOG, which regulates several cellular functions 
(Figure 1) (39). NANOG is required for maintaining stem cell properties and is re-expressed 
in a wide array of cancers (40-44). It furthermore promotes cell proliferation, migration, and 
metastasis, likely by downregulation of cell-cell interactions via E-cadherin (45) and control 
of cell cycle-related proteins (46). NANOG also renderers CSCs resistant to chemotherapy, 
for example, by inhibition of p53-mediated apoptosis (47). Expression of NANOG and its 
pseudo genes is low or absent in normal cells, making it an ideal therapeutic target (48-51). 
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figure 1  Cellular functions of NANOG in cancer stem cells (CSCs). The transcription factor 
NANOG is expressed by CSCs and has a variety of functions. NANOG is essential to maintain 
the self-renewal properties of CSCs. Furthermore, NANOG regulates cell proliferation via the 
interaction with cell cycle proteins, such as cyclin D. It also downregulates the expression of 
E-cadherin, enabling cells to detach and migrate to form distant metastasis. Finally, NANOG 
promotes cell survival and resistance to therapy. NANOG interferes with tumor suppressor p53, 
protecting cells from apoptosis. 
 
Expression of stem cell factor NANOG in CSCs
Expression of NANOG in CSCs is detected in a variety of cancer types, including glioma 
(34), breast cancer (52), ovarian cancer (53), and lung cancer (54). The realization that the 
resistant cancer cells that drive tumor recurrence after classical treatment express 
NANOG (34, 51, 55-60) have prompted the development of NANOG inhibitors. These 
inhibitors were remarkably successful in experimental models (42, 51, 55, 61-63). For example, 
activator-like effector nuclease (TALEN) was able to disrupt NANOG function in Hela 
cells in vitro, increasing chemosensitivity and reversing the epithelial-to-mesenchymal 
transition (64). In breast cancer cells, shRNA against NANOG reduced cell proliferation 
and migration (46). However, in vivo targeting of these compounds to CSCs will be a major 
challenge. Furthermore, wiping out NANOG by TALEN or shRNA (46, 64-66) will not suffice 
to eradicate cancer. Through a process known as plasticity, differentiated cancer cells 
become CSCs by re-expressing NANOG (67-71), which also occurs in non-pathogenic cells 
(72). NANOG inhibiting compounds like RNAi or small inhibitors, therefore, have to be 
given lifelong to keep the tumor encaged. Thus, although NANOG may be suitable to 
specifically target CSCs, there is a need for novel strategies that can also control new CSCs 
arising through plasticity.
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The immune system as CSC killer
Our body has developed a unique strategy to provide long-term protection from pathogens 
and cancerous cells: the immune system. Tumor infiltration by CD8+ immune cells is 
associated with prolonged patient survival (73). However, these CD8+ T cells are often 
unable to eradicate the tumor because of inhibition by other, immunosuppressive cells in 
the tumor microenvironment, such as regulatory T cells (TRegs). To reflect the strength of this 
immunosuppression, an “immunoscore” of a tumor can be computed as the ratio between 
immune stimulating and immune inhibiting cells (74). Immunotherapies aim to tip this 
balance toward immune activation. For example, immune checkpoint antibodies alleviate 
immunosuppression and increase patient survival, proving that the immune system can 
combat cancer. However, can the immune system also prevent further cancer growth by 
attacking stem cell antigens? The first indication comes from a study where the immune 
system was activated by vaccinating with glioblastoma lysate of either normal cancer cells 
or CSCs (75). The quantity of stem cell antigens is much higher in the CSC lysate, which 
evokes a better immune response against the cancer. Other studies have shown that cancer 
patients as well as healthy subjects can have immunological memory against OCT4, a CSC 
transcription factor (76, 77). However, this memory response could not cure or prevent 
cancer. Full responses appear to require rejuvenation of the immune system by means of 
DCs loaded with tumor antigens (78). Nevertheless, the existence of immunological memory 
against CSC transcription factors is promising, as it suggests that it should be possible to 
generate long-lasting immune responses that control the CSCs that drive tumor growth.
The tumor uses several ways to stop immune-mediated killing
An important reason why existing anti-tumor immune cells fail to eradicate the tumor 
is active immunosuppression by the tumor microenvironment. Surviving tumors have 
escaped immunological clearance by paralyzing the immune system, exploiting several 
natural mechanisms by which the body can dampen immune reactions. These mechanisms 
include the attraction of immunosuppressive cells (TRegs, myeloid-derived suppressor cells), 
induction of inhibitory cytokines (IL-10, TGF-β), reduction of MHC class I expression, 
expression of metabolic enzymes, such as indoleamine 2,3-dioxygenase and arginase (which 
breakdown either tryptophan or arginine, respectively) (79), and the PD-1/PD-L1 axis (80, 
81). Furthermore, mesenchymal stem cells (MSCs) are part of the tumor microenvironment 
and able to inhibit the immune system. In vitro-cultured MSCs express NANOG and the 
expression of immune-modulatory molecules is dependent on NANOG. Destroying 
NANOG in activated MSCs in the tumor bed by the immune system will limit the immune 
inhibitors and is an added advantage (82). Yet another way to prevent immune attack is 
modification of the lipid pathways, resulting in a block of T cell proliferation (83). Checkpoint 
antibodies relieve part of this inhibition and thereby prolong overall survival (84). However, 
as tumors use multiple immunosuppressive strategies, a single antagonist will be unable to 
fully abrogate immunosuppression and eradicate the tumor. It is, therefore, crucial to also 
look at other methods to tip the balance back in favor of anti-cancer immunity.
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Cytotoxic T cells need target molecules to kill tumor cells
Another factor that may hamper T cell responses against CSCs is insufficient expression 
of MHC class I. Before cytotoxic T lymphocytes (CTLs) can kill a tumor cell, they must 
first recognize tumor antigens presented on MHC class I. Whereas several studies 
reported reduced expression of MHC class I on CSCs, other studies nevertheless found a 
cytotoxic CD8+ T cell response against CSCs (reviewed in Ref. (85)). CSCs lacking MHC 
class I should be recognized by NK cells. In ovarian cancer, NK cells obtained from CD34 
hematopoietic stem cells destroy cancer cells in a sphere assay, a classical way to culture 
CSCs (86). MHC class I expression in stem cell marker positive cells can be analyzed 
using single cell m-RNA sequencing. The Broad Institute performed single cell mRNA 
sequencing in oligodendroglioma CSCs and their differentiated offspring (Figure 2) (87). A 
stem cell score and a lineage score were computed for each cell, enabling classification as 
stem cell, astrocyte, or oligodendrocyte. These data are available online (https://portals.
broadinstitute.org/single_cell) and allowed us to investigate MHC class I expression on 
CSCs. Analysis showed that CSCs express HLA-A and B (Figure 3). Only a minority of CSCs 
and mature cancer cells did not express MHC class I. Although these results suggest that it is 
feasible to evoke a CTL response against CSCs, MHC class I negative CSCs and mature cancer 
cells will escape elimination, forming a phenotype invincible by CD8+ T cells (88). These cells 
regain MHC class I during this dedifferentiation (89). This “soft” MHC class I loss can be 
resolved by administering IFN-γ or reverting epigenetic modifications via HDAC inhibitors 
(90). Importantly, we detected MHC class I on NANOG positive cells in ascites of ovarian 
cancer patients (Figure 4), whereas NANOG negative tumor cells were partially MHC class 
I negative. Apparently, the conversion of more mature cancer cells into CSCs (plasticity) 
requires epigenetic changes that allow re-expression of MHC class I. These findings suggest 
that NANOG expressing CSCs should be vulnerable to attack by CD8+ T cells.
figure 2  Differentiation hierarchy in oligodendrogliomas. Differentiation hierarchy based 
on differentiation scores (X) and stem cell scores (Y). Three distinct expression programs: 
oligodendrocyte (positive X, negative Y), astrocyte (negative X, negative Y), and stem cells 
(positive Y). Each dot represents a single cell. Reprinted by permission from Tirosh et al. (87).
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figure 3  HLA expression in oligodendroglioma. Expression pattern of HLA-A (A) and HLA-B 
(B) in oligodendrocytes, astrocytes, and cancer stem cells. Every dot represents a single cell. 
Oligodendrocyte lineage (positive X, negative Y), astrocyte lineage (negative X, negative Y), and 
stem cells (positive Y). Expression level indicated by colors from gray (low expression) to red (high 
expression).
 
 
figure 4  Cancer stem cells in high-grade serous ovarian cancer ascites. (A) Isolated mononuclear 
cells from ascites of ovarian cancer patients (n=13) were stained for CD45, NANOG, and HLA-ABC. 
NANOG positivity was assessed in the CD45- population to exclude immune cells. NANOG- and 
NANOG+ cells were gated and HLA-ABC expression was analyzed in both populations. Gray line = 
isotype control; black line = sample. (B) Percentage of NANOG+ cells in ascites. (C) Percentage of 
HLA-ABC+ cells in the NANOG- and NANOG+ population. Red line indicates mean. 
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DC vaccination against NANOG: CTL memory as guard 
against CSCs
DC vaccination could evoke cytotoxic T cells directed to CSCs and might induce 
immunological memory. Thus, this approach could not only eradicate existing CSCs but 
also provide the long-term ability to remove new CSCs arising through plasticity. While 
over 100 trials have tried to boost the immune system by injecting autologous DCs 
loaded with aberrantly expressed or mutated proteins (neoantigens) (91, 92), only a few 
DC vaccination trials try to target CSCs. Several problems currently hamper the efficacy 
of these DC vaccination approaches against CSCs. First, they generally rely on isolation 
of autologous CSCs and loading of DCs with CSC lysates (75, 93, 94), a personal approach 
that is labor intensive and is hindered by the current lack of surface makers that can 
reliably isolate CSCs. Second, it remains unknown which neoantigens in the lysate elicit 
an immune response, and the number of these immunogenic neoantigens depends 
on the tumor. For example, colon cancer has five times more mutations than breast 
cancer (95). A high mutation rate increases the chance that neoantigens are presented 
to the immune system. But, neoantigens also need to bind with strong affinity to MHC 
molecules, as this determines the strength of the immune response (96). Current DC 
vaccination strategies against CSCs, therefore, have limited control over the initiated 
immune response and might not be suitable for every tumor type. A more elegant way to 
eradicate CSCs is to load autologous DCs with specific peptides rather than tumor lysate, 
as this approach would provide better control over the immune response generated. 
Specifically, we propose loading DCs with NANOG peptides. Because cancer cells re-
express NANOG when they regain stem cell properties, generation of immunological 
memory after DC vaccination against NANOG would help the immune system to cope 
with CSC plasticity. Therefore, we used the NetMHCpan algorithm to determine which 
peptides from the NANOG protein can bind to MHC class I (97). Several HLA types are 
able to bind multiple NANOG peptides that could be presented to T cells (Table 1). In 
patients with HLA types that lack strong binders (e.g. HLA-A2), peptides from other CSC 
transcription factors, such as SOX2 or OKT4a, could be used (Table 2). As individuals 
generally have 4 to 6 different HLA class I molecules, cocktails of NANOG peptides that 
bind to the different HLA molecules should induce a potent immune response against 
CSCs. These results suggest that it is feasible to create DC vaccines tuned to the needs 
of individual patients.
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table 1  Predicted peptides from NANOG that bind to the most common HLA-A types.
Pos HLA Peptide Score %Rank BindLevel
128
288
170
275
233
285
27
131
266
124
297
147
288
78
160
79
143
129
282
135
173
205
285
240
276
292
218
213
235
157
275
288
50
285
170
233
49
268
128
173
246
276
166
169
HLA-A*01:01
HLA-A*01:01
HLA-A*01:01
HLA-A*01:01
HLA-A*01:01
HLA-A*01:01
HLA-A*01:01
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
HLA-A*03:01
HLA-A*03:01
HLA-A*03:01
HLA-A*03:01
HLA-A*03:01
HLA-A*03:01
HLA-A*03:01
HLA-A*24:02
HLA-A*24:02
HLA-A*24:02
HLA-A*24:02
HLA-A*24:02
HLA-A*24:02
HLA-A*24:02
HLA-A*24:02
HLA-A*24:02
HLA-A*24:02
HLA-A*24:02
HLA-A*24:02
HLA-A*26:01
HLA-A*26:01
HLA-A*26:01
HLA-A*26:01
HLA-A*26:01
HLA-A*26:01
HLA-A*26:01
HLA-A*26:01
HLA-A*26:01
HLA-A*26:01
HLA-A*26:01
HLA-A*26:01
HLA-A*26:01
HLA-A*26:01
LSNILNLSY
QTMDLFLNY
SAPTYPSLY
NVIQQTTRY
NQAWNSPFY
STPQTMDLF
VICGPEENY
ILNLSYKQV
ALEAAGEGL
QMQELSNIL
SMNMQPEDV
RMKSKRWQK
QTMDLFLNY
TSAEKSVAK
KNSNGVTQK
SAEKSVAKK
FQNQRMKSK
SNILNLSYK
RYFSTPQTM
SYKQVKTWF
TYPSLYSSY
TWSNQTQNI
STPQTMDLF
FYNCGEESL
VIQQTTRYF
LFLNYSMNM
NHSWNTQTW
IQSWSNHSW
AWNSPFYNC
NWPKNSNGV
NVIQQTTRY
QTMDLFLNY
TVSPLPSSM
STPQTMDLF
SAPTYPSLY
NQAWNSPFY
ETVSPLPSS
EAAGEGLNV
LSNILNLSY
TYPSLYSSY
ESLQSCMQF
VIQQTTRYF
TQKASAPTY
ASAPTYPSL
0.9255780
0.8760120
0.5532640
0.4023770
0.2635820
0.2121550
0.1250780
0.2368040
0.1952110
0.1879200
0.1508660
0.7268520
0.5218220
0.4538630
0.2295020
0.1701430
0.1509210
0.1032670
0.9442420
0.8083160
0.7459470
0.5638980
0.4523060
0.3568780
0.2610950
0.2471650
0.2330860
0.1941240
0.1533600
0.1298940
0.9459840
0.9259880
0.4361040
0.4204560
0.3277070
0.1351790
0.1209600
0.1149430
0.1003280
0.1000530
0.0944910
0.0780350
0.0711170
0.0591680
0.0772
0.1220
0.4238
0.6690
1.0330
1.2491
1.9183
1.2900
1.5189
1.5702
1.8894
0.1333
0.3469
0.4542
1.0894
1.3846
1.5158
1.9548
0.0464
0.1963
0.2532
0.4686
0.6464
0.8489
1.1693
1.2256
1.2872
1.4867
1.7525
1.9590
0.0055
0.0076
0.2259
0.2396
0.3584
0.9734
1.0868
1.1405
1.2837
1.2865
1.3466
1.5685
1.6778
1.9468
<= SB
<= SB
<= SB
<= WB
<= WB
<= WB
<= WB
<= WB
<= WB
<= WB
<= WB
<= SB
<= SB
<= SB
<= WB
<= WB
<= WB
<= WB
<= SB
<= SB
<= SB
<= SB
<= WB
<= WB
<= WB
<= WB
<= WB
<= WB
<= WB
<= WB
<= SB
<= SB
<= SB
<= SB
<= SB
<= WB
<= WB
<= WB
<= WB
<= WB
<= WB
<= WB
<= WB
<= WB
Peptide length 9; Rank Threshold for strong binding peptide 0.500; Rank Threshold for weak binding peptide 
2.000; SB = strong binding; WB = weak binding; predicted peptides were generated using NetMHCpan Ver-
sion 4.0 (http://www.cbs.dtu.dk/services/NetMHCpan/
53
IMMUNE CURBING OF CANCER STEM CELLS BY CTLs DIRECTED TO NANOG
table 2  Predicted SOX2 and OCT4A peptides that bind to HLA-A.
 
 
Why do we not have memory T cells?
Apparently, no immunity against NANOG exists under normal conditions or cancer would 
never develop. This suggests that while antigen-presenting cells may present NANOG, 
this presentation fails to trigger cytotoxic T cells. Several factors may account for this 
discrepancy. The strength of the immune response depends on the duration of antigen 
presentation, the affinity of peptides for HLA, and the abundance of peptides. The latter 
is evident from melanoma, where a normal protein (gp100) becomes immunogenic upon 
upregulation in malignant cells (98, 99). The peptides presented on the cell’s surface are 
continuously refreshed to reflect the internal intracellular pool of peptides. Peptides of less 
expressed proteins will typically be presented on HLA molecules in very low quantities that 
will be rapidly replaced for more abundant peptides. Moreover, both CSCs and DCs, the 
main presenters of antigenic peptides, are extremely rare. The chance that a DC encounters 
a CSC presenting NANOG peptides is, therefore, very low. Thus, immunity against NANOG 
requires a boost by either vaccination or by administration of DCs loaded with NANOG 
peptides. This approach would increase the number of DCs presenting CSC antigens, and 
also allows for the selection of suitable peptides based on the patient’s HLA-type.
Do in vitro raised CTLs kill CSCs?
To assess the potential of vaccination with NANOG-loaded DCs, it is crucial to investigate 
whether CTLs raised against NANOG in vitro are capable of killing CSCs. Current 
Pos HLA Peptide Score %Rank BindLevel
SOX2
275
131
58
125
236
216
OCT4A
268
249
72
203
163
332
93
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
HLA-A*02:01
SMYLPGAEV
LLAPGGNSM
KMAQENPKM
YTLPGGLLA
ALGSMGSVV
YMNGSPTYS
GLEKDVVRV
FLQCPKPTL
GMAYCGPQV
LLQKWVEEA
TQADVGLTL
ALYSSVPFP
SQPEGEAGV
0.669833
0.429050
0.375814
0.257884
0.203653
0.146827
0.719995
0.645456
0.492133
0.419854
0.372758
0.166148
0.164799
0.2687
0.6673
0.7882
1.1925
1.4680
1.9276
0.2203
0.2944
0.5388
0.6892
0.7950
1.7452
1.7569
<= SB
<= WB
<= WB
<= WB
<= WB
<= WB
<= SB
<= SB
<= WB
<= WB
<= WB
<= WB
<= WB
Peptide length 9; Rank Threshold for strong binding peptide 0.500; Rank Threshold for weak binding peptide 
2.000; SB = strong binding; WB = weak binding; predicted peptides were generated using NetMHCpan Ver-
sion 4.0 (http://www.cbs.dtu.dk/services/NetMHCpan/).
54
CHAPTER 3
approaches come with limitations that make it difficult to assess the killing capacity of 
CTLs directed to CSCs. For example, recent data indicate that adherent cells only harbor 
a minute number of CSCs, but it is hard to generate a cell line from tumor tissue. To 
circumvent this problem, it is possible to grow spheroids from tumor tissue using low 
adhesive culture plates and special, serum-free media supplemented with the growth 
factors EGF and FGF (100-105). As these cultures go into apoptosis when the CSC is 
destroyed, as shown for the food supplements and NK cells (86), T cell killing of CSCs can be 
investigated by analyzing the shrinkage of spheroids co-cultured with in vitro raised T cells. 
However, spheroids are rather simple structures that do not capture the complexity of an 
organ and are thus unsuitable to assess side effects. So far, we do not know if immunity 
to NANOG is detrimental for the patient. For melanoma patients, we sometimes observe 
vitiligo around a reactive mole, indicating that CTLs also attack normal melanocytes.
Although in vivo experiments in xenotransplanted mice with siRNA against NANOG did 
not show adverse effects on normal mouse tissues, these results should be interpreted 
with caution as it is unknown whether siRNA also inhibits murine Nanog. Moreover, mice 
have a different MHC class I and thus present other peptides from murine Nanog.
Organoids as a method to explore the safety of vaccination with NANOG-
loaded DCs
Organoids from CSCs and normal stem cells would be a better approach to test both the 
efficacy and safety of CTLs raised against NANOG (106-109). Organoids are 3D structures 
grown from stem cells that are able to recapitulate organ structure and organ-specific cell 
types. They can be grown from embryonic or induced pluripotent stem cells, from organ-
restricted adult stem cells, or from isolated CSCs. Organoid models currently exist for 
many different tissues, including brain, lung, small intestine, and kidney (110, 111). Living 
NANOG-expressing stem cells can be obtained by labeling cells with NANOG nanoflares 
and sorting the positive cells (112, 113). This enables to test DC vaccination against NANOG 
in a more natural 3D environment, solving the limitations of current in vitro and in vivo 
approaches.
Conclusion
Reduction of the tumor mass, by either surgery or radiotherapy, is typically the first 
treatment for solid tumors. However, complete removal of the tumor mass is impossible 
in some cancer types, leading to disease recurrence when chemotherapy fails to eradicate 
remaining CSCs. DC vaccination against NANOG could solve this problem by specifically 
removing CSCs that fuel cancer growth. Importantly, these vaccines can be tuned to the 
patient’s HLA type to maximize response rates. If NANOG peptides cannot be presented 
by a patient’s MHC class I molecules, peptides against the stem cell transcription factors 
SOX2 or OKT4 may be used.
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Despite the promise of this CSC targeting approach, durable immune responses will 
likely require a combination of DC vaccination with other therapies. Chemotherapy is not 
suitable in combination with DC vaccination, as it attacks hematopoietic cells in the bone 
marrow, making it difficult to recover enough autologous DCs for vaccination. To ensure 
an optimal immune response, inhibiting cells and soluble inhibitors should be removed as 
much as possible. Combining DC vaccination against NANOG with immune checkpoint 
inhibitors might help to overcome immunosuppressive mechanisms and, thereby, 
potentiate the immune response directed against NANOG.
Material and methods
Patient material
Ascites was obtained from stage III and IV high-grade serous ovarian cancer patients 
before start of the treatment. The study was carried out in accordance with the guidelines 
and regulation of the Radboudumc. The protocol was approved by the “Commissie 
Mensgebonden Onderzoek” (CMO Arnhem- Nijmegen). All subjects gave informed 
consent in accordance with the Declaration of Helsinki. Some samples were obtained 
before written consent was needed. Ascites was considered as waste material and only oral 
informed consent was necessary. All patients gave this oral informed consent to help future 
patients and were aware that it was not for their own benefit but for research purpose.
Flow cytometry staining
Mononuclear cells from ascites were isolated using Ficoll-gradient centrifugation (Axis 
Shield) (114). Cells were washed with PBA (PBS/0.5% BSA/0.01% NaN3) and blocked for 
10 min in PBA with 2% FcR blocking reagent (Miltenyi). Afterwards, cells were incubated 
for 30 min with a-CD45-V450 (1:50, BS Biosciences) and a-HLA-ABC-APC (1:4, Miltenyi). 
Subsequently, cells were fixed in 4% PFA and permeabilized with PBA containing 0.5% 
saponin (Sigma). Next, cells were incubated for 30 min with a-NANOG-PE (R&D Systems). 
Samples were measured on a BD FACS Verse and analyzed using FlowJo Version 10.
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Abstract
The anti-tumor immune response comprises a complex and dynamic interplay between 
various immune factors, and may either negatively or positively affect high-grade serous 
ovarian cancer progression. Until now, it is unknown whether the immune response is 
involved in the pre-invasive stage during carcinogenesis. In this study, we assessed the 
T cell infiltrate in serous tubal intraepithelial carcinoma (STIC), the precursor lesion of 
pelvic high-grade serous carcinoma (HGSC) and investigated associations with several 
clinicopathological parameters. We applied a novel and powerful technique of multiplex 
immunohistochemistry, followed by quantitative and automated whole-slide analysis 
using an optimized pathology imaging system on a large cohort of STICs, associated 
carcinomas and normal fallopian tubes as control (N = 59). Compared to normal fallopian 
tubes, STICs were observed to have a significantly increased density of CD3+ T cells, 
including increased densities of helper, cytotoxic, and regulatory T cell subsets. Within 
subjects, an additional increase of infiltrating cytotoxic and regulatory T cells was observed 
in invasive HGSC compared to the paired STIC. The increase of CD3+ T cells in STIC and 
HGSC was more significant in the stromal compartment rather than intraepithelial. Finally, 
CD3+ T cell densities in STIC were not associated with the presence or absence of paired 
invasive HGSC. We conclude that the host immune response occurs in a pre-invasive 
stage of pelvic HGSC. These findings may serve as a starting point in our understanding of 
cancer immunity in STIC and the potential effect on malignant progression. 
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Introduction
High-grade serous carcinoma (HGSC) is the most common subtype of epithelial ovarian 
cancer, characterized by clinically aggressive behavior and a poor overall survival (1). In 
recent years, major advances in the molecular understanding of ovarian cancer as a 
heterogeneous disease have emerged new prospects for improved screening, prevention, 
and therapy. 
Pelvic HGSCs are marked by high genetic instability with a TP53 mutation being present 
in more than 95% of tumors (2-4). There is compelling evidence from clinical and molecular 
studies that most pelvic HGSCs arise from the serous fallopian tube epithelium. The 
serous tubal intraepithelial carcinoma (STIC), a focal non-invasive cytological appearance 
of HGSC typically located in the distal fallopian tube, has been identified as putative 
precursor lesion of pelvic HGSC (5). STICs are composed of ‘secretory cells’, the non-
ciliated population of the fallopian tube epithelium, and exhibit features such as variable 
stratification, increased proliferation and loss of nuclear polarity (6). Genetic analysis 
detected identical TP53 mutations in STIC and associated invasive carcinoma, supporting 
the fallopian tube as site of origin for pelvic HGSC (7, 8).
The immune system plays an important role in cancer and is considered to have a 
significant influence on its clinical outcome (9). In ovarian cancer, high numbers of tumor 
infiltrating cytotoxic T cells (Tc) (CD8+, CD8+CD103+, CD103+PD-1+) are associated 
with prolonged patient survival (10-15). In contrast, infiltration of regulatory T cells 
(TReg) (CD4+CD25+Foxp3+) and lower ratios of CD8+/TRegs have an unfavorable effect on 
prognosis, as Tregs are able to suppress the ovarian cancer immune response (10, 16, 17). 
It has been suggested that in advanced-stage ovarian cancer, an immune suppressive 
microenvironment dominates within the abdominal cavity, which may enable the tumor 
to escape the immune system (18, 19). Based on the current knowledge, several promising 
anti-cancer immunotherapeutic strategies have nowadays been developed in order to 
boost the anti-tumor immune response (20, 21). 
Information about the immunological response in the early steps of HGSC development is 
limited and may be helpful to determine its role in the progression of pre-invasive STICs into 
a full blown HGSC. We hypothesize that differences in the immunogenicity of STICs might 
reflect its potency of progressing into an invasive carcinoma. STICs may be recognized by 
the immune system as pathogenic and may be cleared or at least controlled, thus preventing 
tumor development. On the other hand, precursor lesions might escape immune 
surveillance or attract cells that suppress the local immune system, thereby creating a 
microenvironment that promotes tumor development. In a substantial subset of STICs, the 
presence of an immune infiltrate has been observed (22). In addition, George et al. analyzed 
immune cells in a small cohort of STICs and detected increased numbers of macrophages 
(CD68+) while numbers of lymphocytes (CD3+) were found to be comparable to healthy 
controls (23). Still, information on the role of different immune cells within STICs is lacking. 
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In order to characterize the immune microenvironment in precursor lesions of HGSC, we 
analyzed the presence of T cells in STICs. These precursor lesions are frequently found in 
healthy BRCA-1 and -2 mutation carriers and non-mutation carriers diagnosed with HGSC, 
whereas they are barely identified in removed fallopian tubes of healthy women. In patients 
that present with HGSC, STICs are found adjacent to or isolated from the primary tumor. 
This allowed us to investigate the immune cell infiltrate in paired STIC and HGSC from 
individual patients. A recently developed method of multiplex immunofluorescent staining 
was used, followed by high-resolution whole-slide imaging, and quantification of cells 
by an automated image analysis software, providing us with the opportunity to perform 
an automated and objective measurement of different T cell subsets within tissues. This 
technology was applied to a large cohort of STIC, paired HGSC, and normal fallopian tubes. 
Results
Clinicopathological characteristics
Using the validated STIC algorithm, STICs were identified in 59 patients and included 96 
focal STIC lesions in total. The median patient age was 63 years (range 34-82) (Table 1). 
Most patients (N = 52, 88%) were diagnosed with STIC and associated invasive HGSC and 
seven patients (12%) had STIC only. Twenty-five patients (42%) received neoadjuvant 
chemotherapy prior to surgery while 34 (56%) did not. Multifocal STIC was detected in 19 
cases (32%). One of the patients diagnosed with STIC only, had developed pelvic HGSC 
two years after initial diagnosis. 
table 1  Clinicopathological characteristics of the patient cohort (N = 59).
N %
Median age (range) 63 (34-82)
Germline BRCA mutation
   BRCA1 mutation
   BRCA2 mutation   
   No BRCA mutation
   Unknown
8
6
8
37
13.6
10.2
13.6
62.7
Associated invasive carcinoma
   Yes
   No
52
7
88.1
11.9
Neoadjuvant chemotherapy 
   Yes
   No
25
34
42.4
57.6
P53 immunohistochemistry
   Overexpression
   No expression 
45
14
76.3
23.7
Multifocal STIC
   Yes
   No
19
40
32.2
67.8
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figure 1  Multiplex fluorescent staining and phenotyping of T cells in normal fallopian tubes, 
STIC and invasive HGSC. (A) Examples of multiplex opal 6-color immunofluorescent staining of 
normal fallopian tube epithelium (FTE), STIC, and invasive HGSC (20x zoom). (B) InForm software 
was applied for automatic segmentation of stroma and tumor tissue. (C) Afterwards, a trained 
algorithm was used to segment and phenotype cells. (D) Results of quantitative analysis were 
presented in a computer-generated overview. Please note that a region of interest (marked by the 
light red area) indicates STIC. 
 
Automated image analysis and T cell quantification 
Tissue sections were stained for CD3, CD8, Foxp3, CK8.18, and DAPI using multiplex 
fluorescent immunohistochemistry with tyramide signal amplification. DAPI visualizes the 
nucleus, whereas CK8.18  was used to stain epithelial cells in both, healthy and cancerous 
tissues. T cell subsets were identified by expression of CD3, CD8, and Foxp3. T helper (Th) 
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cells were characterized as CD3+CD8-Foxp3-, cytotoxic T (Tc) cells as CD3+CD8+Foxp3-, and 
T regulatory (TReg) cells as CD3+CD8-Foxp3+. Quantitative and whole-slide image analysis 
using an optimized pathology imaging system was performed to measure the presence of 
T cell subsets within tissues. First, tissue segmentation based on expression of CK8.18 was 
applied to multispectral images to differentiate between stroma and epithelium (Figure 
1A, B). Afterwards, cells were segmented and phenotyped (Figure 1C). Finally, analyzed 
images were stitched to generate whole-slide overviews (Figure 1D). 
Increased T cell infiltration in STIC and HGSC
In order to explore the presence of T cells in STIC, we first focused on the presence of 
the entire CD3+ T cell population. The total T cell density (cells/mm2) was calculated and 
included both, the stromal and epithelial compartment. The T cell density in STIC and 
HGSC was significantly increased compared to the density in normal fallopian tubes (mean 
difference 340 cells/mm2 and 540 cells/mm2, respectively) (Figure 2A). Overall, there was a 
gradual increase in the T cell density from normal fallopian tube tissue to STIC and HGSC.
  
figure 2  Density (cells/mm2) of T cells associated with STIC. (A) T cell density of normal controls, 
STIC and HGSC. (B) Density of T helper (Th) cells, (C) cytotoxic T (Tc) cells, and (D) regulatory T 
(TReg) cells in normal fallopian tubes, STIC and HGSC. (E) T cell density in multifocal STIC derived 
from individual patients. Red horizontal line represents mean.
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figure 3  Examples of fluorescent staining of T cell subsets in normal fallopian tube, STIC, 
and invasive HGSC (zoom 20x). (A) Normal fallopian tube epithelium. (B) STIC (case without 
associated HGSC). (C) STIC (case with associated HGSC). (D) The paired HGSC of STIC C. (E) 
Overview of STIC (marked by the dotted line).
 
We evaluated the immunological response in STIC more precisely by analyzing the different 
T cell subsets, including CD3+CD8-Foxp3- Th cells, CD3+CD8+Foxp3- Tc cells, and CD3+CD8-
Foxp3+ TRegs (Figure 3). In STIC, the density of Th and Tc cells was significantly higher than 
the density in normal fallopian tubes (mean difference 137 cells/mm2, p < 0.001 and mean 
difference 160 cells/mm2, p = 0.047, respectively) (Figure 2B, C). Similarly, HGSC contained 
significantly more Th and Tc cells than normal fallopian tubes (mean difference 150 cells/mm2, 
p < 0.001 and mean difference 309 cells/mm2, p = 0.004). However, the density of Th and 
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Tc between STIC and HGSC was comparable. In contrast, the density of TRegs was not only 
increased in STIC and HGSC compared to normal fallopian tubes (mean difference 43 
cells/mm2, p < 0.001 and mean difference 84 cells/mm2, p < 0.001, respectively), there was 
also a significant increase in HGSC compared to STIC (mean difference 41 cells/mm2, p 
< 0.045) (Figure 2D). In general, the density of Tc cells was higher than the density of Th 
cells, and the density of Th cells was higher than the density of TRegs (Tc > Th > TReg) in normal 
fallopian tube, STIC, and HGSC. 
Comparable T cell infiltration in multifocal STIC
Within a single patient, multiple focal lesions of STIC can be detected. Our unique 
collection of multiple STIC per patient made it possible to investigate whether there are 
differences between these focal lesions. A total number of 19 patients with a median of 
2 STICs per patient were analyzed, mostly including unilaterally located STIC, except for 
patient 45 and 51 with bilaterally located STIC. The density of the total T cell population 
was assessed for up to 10 focal lesions derived from single patients (Figure 2E). The 
density of T cells was comparable in paired multifocal lesions in the majority of patients 
(e.g. patient 4, 11, 23, 38, 51, and 58), while a few cases showed large differences in T cell 
densities between focal lesions (e.g. patient 49 and 54). 
Shift in T cell location during malignant transformation
By applying epithelial/stromal tissue segmentation, we compared T cell densities between 
these compartments. In normal fallopian tubes, the intraepithelial T cell density was 
significantly higher compared to the density in the stromal compartment (mean difference 
161 cells/mm2, p < 0.001). In STIC, there was no difference in the T cell density between the 
epithelial and stromal compartment (mean difference 80 cells/mm2, p = 0.710) (Figure 4A), 
whereas the T cell density in HGSC was significantly higher in the stroma (mean difference 
319 cells/mm2, p=0.006). 
The same pattern was seen for Tc cells (Figure 4C). The density of Tc in normal fallopian 
tubes was increased in the epithelial compartment compared to the stromal compartment 
(mean difference 158 cells/mm2, p < 0.001), whereas it was comparable in STIC, and 
significantly increased in the stroma in HGSC (mean difference 187 cells/mm2, p = 0.007). 
In contrast, there was no difference in the density of Th cells and TRegs in the stromal 
and epithelial compartment of normal fallopian tubes (Figure 4B, D). TRegs were equally 
distributed between the stromal and epithelial compartment in STIC, whereas Th cells 
were more abundant in the stroma (mean difference 104 cells/mm2, p = 0.008). In HGSC, 
the density of both Th cells and TRegs was significantly higher in the stromal compartment 
(mean difference 108 cells/mm2, p < 0.001 and mean difference 47 cells/mm2, p = 0.056, 
respectively). 
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figure 4  Location of T cells in normal fallopian tubes, STIC and HGSC. (A) Density (cells/mm2) 
of T cells in the stromal and epithelial compartment of normal fallopian tubes, STIC and HGSC. 
(B) Density of helper T (Th) cells, (C) cytotoxic T (Tc) cells, and (D) regulatory T (TReg) cells in the 
stromal and epithelial compartment of normal fallopian tubes, STIC and HGSC. Red horizontal 
lines indicate mean.
 
Presence of T cells within paired STIC and HGSC of individual patients
The immunological response in the (pre)cancer microenvironment may substantially 
vary between and within subjects. By analyzing the presence and localization of T cells 
in STIC and the paired invasive HGSC, we might get insight into the intrinsic patient-
related variation. Due to our unique collection of paired STIC and HGSC, we were able to 
analyze intralesional variation in 51 cases. One paired carcinoma was not assessed for T 
cell presence due to its absence in additional stainings. Overall, the density of T cells in 
STIC was significantly lower than the density of T cells in paired invasive HGSC (mean 
difference 239 cells/mm2, p = 0.035) (Supplementary data, Table S1). 
Next, we focused on the density of T cell subsets in STIC and paired invasive HGSC within 
individual patients. The density of Th cells was comparable in STIC and paired HGSC (mean 
difference 33 cells/mm2, p = 0.79) while numbers of Tc cells and TRegs were significantly 
lower in STIC compared to associated HGSC (mean difference 163 cells/mm2, p = 0.031 
and mean difference 43 cells/mm2, p < 0.001; respectively) (Table 2). 
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table 2  Mean T cell densities (cells/mm2) of subsets of helper, cytotoxic, and regulatory T cells 
in normal fallopian tubes, STIC, and paired invasive HGSC (data included T cells located in the 
stromal and epithelial compartment).
 
Additionally, we compared T cell densities for each compartment (i.e. epithelial or stromal) 
between the paired lesions. The intraepithelial density of T cells was not different between 
STIC and paired HGSC (mean difference 31 cells/mm2, p = 0.91), while the density of T 
cells in the stromal compartment in STIC was significantly lower than the density in paired 
HGSC (mean difference 314 cells/mm2, p = 0.012) (data not shown).  
 
figure 5  Density (cells/mm2) of T cells in STIC associated with clinicopathological parameters. 
(A) T cell density in STIC cases without and with associated invasive HGSC. (B) Subsets of helper 
(Th), cytotoxic (Tc), and regulatory (TReg) T cells in STIC cases without and with associated invasive 
HGSC. (C) T cell density in STIC before and after the use of platinum-based chemotherapy. (D) 
Subsets of helper T (Th) cells, cytotoxic (Tc) T cells, and regulatory T (TReg) cells in STIC before and 
after of platinum-based chemotherapy. Red horizontal line represents mean.  
Mean density (cells/mm2) Normal vs. STIC STIC vs. paired HGSC
T-cells Normal STIC Paired 
HGSC
Fold change P-value Fold change P-value
Th 3.6 140.9 173.6 39.1 < 0.001 1.2 0.79
Tc 84.9 244.9 408.1 2.9 0.01 1.7 0.031
TReg 1.4 44.2 87.5 31.6 < 0.001 2 < 0.001
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T cell infiltration in STICs is independent of clinicopathological 
characteristics
To gain more insight into the presence of T cells in STIC without the existence of invasive 
HGSC, we compared the T-cell density in patients diagnosed with STIC only and patients 
diagnosed with STIC and associated HGSC (Figure 5A). There was no difference in the 
total T cell density between these two groups (mean difference 281 cells/mm2, p = 0.21). 
Regarding the different T cell subsets, there was a trend towards increased density of Th 
and Tc cells in STIC only compared to STIC with associated HGSC (mean difference 136 
cells/mm2, p = 0.052 and mean difference 137 cells/mm2, p = 0.407, respectively), while 
numbers of TRegs were comparable (mean difference 7 cells/mm2, p = 0.98) (Figure 5B). 
Furthermore, treatment might have an influence on the presence of T cells in STIC and 
HGSC. We therefore compared T cell densities in patients that were and were not treated 
with chemotherapy before tissue collection. No significant difference in the density of 
T cells in STIC of patients that did or did not receive platinum-based chemotherapy was 
observed (mean difference 101 cells/mm2, p = 0.27). Similarly, there was no difference in 
the distribution of T cell subsets (i.e. helper, cytotoxic, and regulatory T-cell) (Figure 5C, D). 
Discussion
The presence of tumor-infiltrating lymphocytes within the (pre-)cancer microenvironment 
is considered to reflect the immunological response against cancer antigens. In the present 
study, we evaluate the presence of T cells in serous tubal intraepithelial carcinoma (STIC), 
the precursor lesion of pelvic high-grade serous cancer, by applying a comprehensive and 
powerful method of multiplex immunofluorescent staining followed by high-resolution 
whole-slide imaging, and quantification of cells by an automated image analysis software. 
In this study, we focused on the CD3+ T cell population including its helper, cytotoxic, and 
regulatory T cell subsets. 
Here, we report that STICs have a significantly increased density of T cells compared to 
normal fallopian tube tissue. T cell densities between STIC and paired invasive carcinoma 
within subjects were observed to be more elevated in the associated HGSC than in 
STIC. The gradual increase in lymphocytes between normal epithelium and STIC, and 
between STIC and paired HGSC indicates an immune response that is associated with the 
hypothesized malignant progression from normal epithelium to STIC to invasive HGSC.
Most studies investigating immune responses in (high-grade serous) ovarian cancer have 
focused on invasive primary carcinomas with little attention to the immune response 
associated with its pre-invasive stage located in the fallopian tube. In this study, an 
immune response was observed in the vast majority of STICs, marked by an elevated T cell 
density compared to normal fallopian tubes. In addition, the density of helper, cytotoxic, 
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and regulatory T cells was found to be increased in STIC. Our results are in contrast with 
the study of George et al., which showed similar levels of T cells in STIC, HGSC, and normal 
controls (23). Their small sample size (N = 15) may explain this contradicting finding, since 
we studied a large cohort of 59 patients with STIC. Recently, increased numbers of T cells 
(CD3+, CD4+, CD8+, and TRegs) have been identified in the pre-invasive stage of breast 
cancer (ductal carcinoma in situ, DCIS), supporting our findings (24-26). 
From studies focused on ovarian carcinomas, several effects of tumor-infiltrating T cells 
on the clinical outcome are known. Subsets of CD8+, CD8+ CD103+, and CD103+ PD-1+ 
tumor infiltrating lymphocytes correlate most strongly with favorable patient outcome 
(10-15). On the other hand, relatively high levels of regulatory T cells have a negative effect 
on patient outcome, which is consistent with their proposed immunosuppressive role (10, 
16, 17). Eventually, the balance between immune promoting and immune inhibiting cells 
may determine the effect on patient prognosis. Anti-tumor immunity in advanced-stage 
ovarian cancer has been proposed to be counterbalanced by an immune suppressive 
microenvironment (18, 19). In STIC, a significant influx of both immune activating and 
immune inhibiting T cells was observed, however, the increase of TReg was relatively higher 
than the increase of cytotoxic T cells. These data may cautiously suggest that a significant 
immunosuppressive response exists within the microenvironment of STIC. A strong 
increase of TRegs has also been associated with the progression of normal epithelium into 
DCIS (24). Nevertheless, Morita et al. reported that CD8+ T cells might be involved in the 
healing of DCIS (25). Finally, additional characterization of immune parameters is needed 
to expand our understanding of cancer immunity in pre-invasive HGSC. 
Little is known about the evolution of the immunological response against aberrant 
cells within the microenvironment along the continuum from pre-invasive lesions into 
invasive carcinoma. Our results show that the density of T cells was significantly lower in 
STIC compared to associated invasive carcinoma within patients. It seems likely that the 
immune microenvironment in STIC and paired invasive HGSC may be largely comparable, 
marked by comparable numbers of helper T cells and a relatively comparable increase of 
cytotoxic T cells and TRegs between STIC and paired HGSC. Further characterization of the 
evolving immune microenvironment in malignant epithelial progression is necessary to 
assess whether immune-based therapies are a treatment option for pre-invasive lesions 
of the pelvic HGSC.
The prognostic relevance of T cell localization within the cancer microenvironment, 
i.e. stromal or intra-epithelial, is not entirely clear. The presence of lymphocytes in the 
stromal compartment has been less significantly associated with prolonged survival 
rather than intraepithelial localization (10). On the other hand, it was recently reported 
that stromal CD8+ T cells have a positive effect on the prognosis of ovarian cancer 
patients by abrogating stromal mediated chemo resistance (27). Here, we observed a high 
intraepithelial/stromal T cell ratio in normal fallopian tubes that shifted into a more or less 
equal ratio in STIC, while an additional increase in numbers of stromal T cells was observed 
T CELL INFILTRATION IN SEROUS TUBAL INTRAEPITHELIAL CARCINOMA (STIC)
77
in paired HGSC. In healthy fallopian tubes, there was a relatively low number of T cells that 
was predominantly located in the intraepithelial, rather than in the stromal compartment. 
Furthermore, the subpopulation of TC cells was most abundantly present, while levels of 
Th cells, and especially levels of TRegs, were significantly lower. The substantial population 
of intraepithelial Tc cells in normal fallopian tubes may represent tissue-resident CD8+ 
memory T cells, non-recirculating memory T cells that persist long-term in epithelial 
barrier tissues like the reproductive tract (28, 29). A common feature of tissue-resident 
memory T cells is their expression of CD103 (30, 32, 33). As high levels of intratumoral CD8+ 
CD103+ T cells have been associated with favorable prognosis in ovarian cancer patients, 
tissue-resident memory T cells located in the fallopian tube may be involved in the 
immunological response against STIC and progression into HGSC (11, 12). The influx of T 
cells in the stroma seems to be associated with malignant epithelial progression into STIC 
and HGSC. The stromal localization of T cells might reflect tumor-specific properties that 
hinder T cells from infiltrating tumor tissue. In melanoma, a low intratumoral/peritumoral 
T cell ratio is associated with worse patient outcome (30). However, the exact mechanisms 
of stromal T cell localization in ovarian cancer remain to be elucidated. 
The presence of multifocal STIC in the fallopian tube is not uncommon, but little is known 
about this phenomenon. Multifocal (unilateral) STICs might originally belong to a single 
largely outstretched STIC lesion (i.e. before sectioning and embedding), however, subtle 
differences between the multifocal lesions regarding their potency for further progression 
may exist. The density of infiltrating T cells in paired multifocal lesions was generally found 
to be in a similar range, only in a few cases substantial differences were seen. In addition, 
a relatively high inter-patient variability of infiltrating T cell density was observed when 
compared to the intrinsic patient-related variability (even when STIC was bilaterally 
located), as also noticed in DCIS (24). 
Currently, there is no data about the immune response in STIC without the presence of 
associated invasive carcinoma, and the risk for development of pelvic HGSC afterwards. 
It is proposed that epithelial cells shed from STIC, have direct access to the peritoneal 
cavity and may disseminate and give rise to invasive disease (31). The risk for development 
of pelvic HGSC after STIC is largely unknown, yet reported to be at least 4.5% (32). 
Although the number of patients diagnosed with STIC only are small and results should 
be interpreted with caution, increased numbers of infiltrating T cells were identified, 
including the patient who developed invasive HGSC two years after diagnosis of STIC. 
The distribution of T cell subsets within the immune infiltrate was largely comparable 
to STIC with associated HGSC, although marginally significant increased numbers of Th 
cells were observed in STIC only. Necessarily, these data should be validated in a larger 
study cohort.   
Chemotherapeutics including platinum-based agents are considered to have an effect 
on the immune microenvironment in carcinomas. In this respect, both negative and 
positive regulations on the immune response have been described (33-35). We observed no 
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difference in the T cell density in STIC cases that were treated with chemotherapy, neither 
any difference in the distribution of T cell subsets. Still, from these data we cannot exclude 
an effect on the immune response as the intrinsic patient-related effect was not studied.
The results presented here give first insights into the immune microenvironment in 
ovarian cancer precursor lesions. Future analyses should investigate the T cell infiltration 
in STICs in more detail. Not only the presence of T cells, but also cell ratios might give 
important information on the immune response. For example, the ratio of CD8+ cytotoxic 
T cells and regulatory T cells could indicate if STICs progress into HGSC or whether they 
are cleared. As already mentioned, since TRegs suppress the activity of CD8+ cytotoxic T 
cells, lower ratios of CD8+/TRegs correspond to worse patient outcome in ovarian cancer 
(10, 16, 17). Since this suppression is mediated via cell contact-dependent mechanisms 
and via the secretion of cytokines, these two cell types need to be in close proximity (36). 
By using the Vectra imaging system for data analysis, the location of each cell is known. 
Therefore, the distance between CD8+ T cells and regulatory T cells can be calculated to 
investigate whether immunosuppression could occur. Furthermore, clustering analyses 
could determine if STIC lesions from different patients share the same infiltrate or if STIC 
and HGSC from the same patient are more similar. Finally, the infiltrate in HGSC could be 
correlated to survival. However, performing these analyses was beyond the scope of this 
paper and are subject to future research. 
In conclusion, we demonstrate increased levels of T cells in the microenvironment of STIC, 
the putative precursor lesion of invasive high-grade serous ovarian cancer. Our findings 
may serve as a starting point in our understanding of cancer immunity in STIC. 
Material and methods
Case selection
This study was approved by the Regional Committee for Medical Research Ethics and 
performed according to the Code for Proper Secondary Use of Human Tissue (Dutch 
Federation of Biomedical Scientific Societies, www.federa.org). By using the nationwide 
network and registry of histopathology and cytopathology (PALGA) as the primary 
source, STICs and associated HGSCs were collected from the Radboud university medical 
center, the Netherlands Cancer Institute, the Canisius-Wilhelmina hospital, and the 
Elisabeth-TweeSteden hospital in the Netherlands (range 1997-2016) (37). After reviewing 
pathology reports, 114 relevant cases were selected for histological analysis. As a control 
group, fallopian tubes from patients with a BRCA mutation (N = 5) and from patients with a 
benign gynecologic abnormality (N = 5) were included.
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Identification of STICs
For the identification of STIC, sections were independently assessed by two experienced 
gynecological pathologists (JB and KVdV). Lesions were categorized according to the 
algorithm for diagnosis of serous tubal intraepithelial carcinoma based on morphology, 
p53 and Ki-67 immunoreactivity (38, 39). In case of no consensus, sections were 
reevaluated to reach consensus. One or more STICs were identified in 59 cases, Cohen’s 
kappa coefficient for inter-observer reliability of the characterization of the tubal lesions 
(i.e. STIC or no STIC) was determined to be 0.81. In 40 cases (67.8%), fallopian tubes were 
sectioned and embedded in total (e.g. SEE-FIM protocol) (40).  
Immunohistochemistry
Paraffin-embedded sections (4 µm) were deparaffinized in xylene and hydrated in graded 
ethanol. Heat-induced antigen retrieval was performed in 10 mM citrate buffer (pH 6.0, 
ScyTek Laboratories, 15 min). Subsequently, peroxidase activity was blocked with 3% 
hydrogen peroxide in phosphate buffered saline (PBS). Sections were then incubated 
overnight at 4°C with mouse anti-human p53 tumor suppressor protein (1:400, clone 
DO7, ImmunoLogic) or monoclonal mouse anti-human Ki-67 antigen (1:100, clone MIB-1, 
Dako) diluted in normal antibody diluent (ImmunoLogic). Next, sections were incubated 
with poly-HRP-anti-mouse/rabbit/rat-IgG (ImmunoLogic, 60 min) and bound antibodies 
were visualized with 3,3-diaminobenzidine (ImmunoLogic). Sections were counterstained 
with hematoxylin, dehydrated, and mounted with Quick-D mounting medium (Klinipath).
Immunoreactivity of p53 and Ki-67 were scored for the intensity (weak, moderate, or 
intense) and proportion (range 0-100%) of positive cells. The expression pattern of p53 
was classified as mutated (diffuse moderate to strong nuclear staining of >75% of epithelial 
cells or a completely negative nuclear staining), or as wild type (39). The Ki-67 proliferation 
index was determined as low when nuclear expression was observed as <10% or high when 
expression was ≥10%.
Multiplex immunohistochemistry
Paraffin-embedded tissue was cut into 4 µm sections, deparaffinized in xylene and 
hydrated in ethanol. Afterwards, antigen retrieval was performed in 10 mM citrate (pH 
6.0, ScyTek Laboratories, 15 min). Sections were blocked with 1% (w/v) bovine serum 
albumin (BSA, fraction V, Sigma-Aldrich) in Tris-buffered saline 0.05% (v/v) Tween 20 
(TBST) for 10 minutes. Samples were stained by Opal TSA Plus multiplex tissue staining 
kits (PerkinElmer) according to the manufacturer’s protocol. All slides were stained by 
the following panel of antibodies (antibodies were added in order as mentioned): anti-
CD8 (1:1600, clone C8/144B, cat M7103, Dako) labeled with Opal 570, anti-CD3 (1:400, 
clone sp7, cat RM-9107, Thermo Scientific) labeled with Opal 520, anti-Foxp3 (1:300, 
clone 236A/E7, cat 14-4777, eBioscience Affymetrix) labeled with Opal 540. To identify 
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epithelial cells, all sections were stained with anti CK8.18 (1:100, clone cam5.2, cat 
563613, BD) labeled with Opal 650. Poly-HRP-anti-mouse/rabbit/rat-IgG (ImmunoLogic) 
was used as secondary antibody. Finally, slides were counterstained with DAPI and 
mounted in Fluoromount-G (Southern Biotechnology Associates, Inc). 
Multispectral scanning was performed using the Vectra slide scanner (version 2.0.7; 
PerkinElmer). Multispectral images were unmixed using spectral libraries build from 
images of single stained tissues for each reagent and unstained tissue using inForm 
(version 2.1.1; PerkinElmer). A selection of 30 to 40 representative original multispectral 
images of ovarian carcinomas and controls were used to train inForm for quantitative 
image analysis; segmentation of epithelial (tumor) cell/stromal tissue based on Opal 650, 
cell segmentation based on DAPI and membrane stain signals, and finally phenotyping of 
different cell types). After optimizing the analysis software, phenotyping and epithelial/
stromal segmentation were performed and depicted in a computer-generated overview. 
The automated quantification and segmentation were manually checked and were found 
to be adequately performed.
All settings applied to the training images were saved within an algorithm and used for 
batch analysis. Vectra Review (Version 2.0.8, PerkinElmer Inc.) was used to select the areas 
for analysis; epithelial cells and underlying stroma of STIC, HGSC, and normal fallopian 
tube as control. Additionally, STICs were precisely marked by applying regions of interest 
using ImageJ 1.48v (National Institutes of Health, USA).
Statistics
Logarithmic transformation was applied in order to achieve normal distribution of T cell 
density in the subgroups. In case of multifocal STIC, all STIC regions were added up and 
T cell densities of the total area were calculated and used in statistical analysis. T-tests 
were performed to evaluate the difference in mean T-cell density between subgroups. 
Paired t-tests were used to compare the mean difference in T cell density between STIC 
and invasive carcinoma within patients. All tests were two-sided and p-values < 0.05 were 
considered significant. T cell densities that are presented in graphics comprise the non-
logarithmic transformed values. Statistical analyses were performed using Graphpad 
Prism version 5.03 (Graphpad software, La Jolla, CA, USA). 
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Supplementary Data
table s1  Density of T cells in STIC and paired HGSC (N = 52).
CD3+ T cells per mm2 Percentage
STIC HGSC Difference 
Pat 1 444 540 21
Pat 2 269 241 -11
Pat 4 202 490 142
Pat 5 1808 504 -72
Pat 6 418 124 -70
Pat 7 185 744 303
Pat 8 277 828 199
Pat 9 525 n.a. n.a.
Pat 10 233 249 7
Pat 11 454 40 -91
Pat 12 210 251 20
Pat 13 406 783 93
Pat 14 219 332 52
Pat 15 24 184 655
Pat 16 40 185 358
Pat 17 316 198 -37
Pat 18 975 422 -57
Pat 19 1518 1260 -17
Pat 20 339 271 -20
Pat 21 1468 2220 51
Pat 22 830 864 4
Pat 23 405 167 -59
Pat 24 476 53 -89
Pat 25 267 2314 767
Pat 27 110 953 764
Pat 28 97 250 158
Pat 30 98 86 -12
Pat 31 230 1238 438
Pat 32 804 2070 158
Pat 33 884 5616 535
Pat 34 746 677 -9
Pat 35 240 701 192
Pat 36 86 62 -28
Pat 37 315 949 201
Pat 38 150 128 -15
Pat 39 594 356 -40
Pat 40 84 141 67
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Pat 41 168 903 438
Pat 42 209 844 304
Pat 43 67 194 187
Pat 45 141 192 36
Pat 46 56 86 53
Pat 47 138 255 84
Pat 48 290 302 4
Pat 49 847 332 -61
Pat 50 287 82 -71
Pat 51 299 402 35
Pat 52 176 318 81
Pat 56 142 381 167
Pat 57 288 465 62
Pat 58 433 907 109
Pat 59 390 202 -48
Mean 395 634 116 (95% CI: 57-176)
P-value 0.035
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Abstract
Lipid metabolism is altered in several cancer settings, leading to different ratios of 
intermediates. Ovarian cancer is the most lethal gynecological malignancy. Cancer cells 
disperse in the abdominal space and ascites occurs. T cells obtained from ascites are unable 
to proliferate after an antigenic stimulus. The proliferation of ascites-derived T cells can 
be restored after culturing the cells for ten days in normal culture medium. No pathway 
aberrancies were detected. The acellular fraction of ascites can inhibit the proliferation of 
autologous as well as allogeneic peripheral blood lymphocytes, indicating the presence 
of soluble factors that interfere with T cell functionality. Therefore, we analyzed 109 lipid 
mediators and found differentially regulated lipids in suppressive ascitic fluid compared to 
normal abdominal fluid. Our study indicates the presence of lipid intermediates in ascites 
of ovarian cancer patients, which coincidences with T cell dysfunctionality. Since the 
immune system in the abdominal cavity is compromised, this may explain the high seeding 
efficiency of disseminated tumor cells. Further research is needed to fully understand the 
correlation between the various lipids and T cell proliferation, which could lead to new 
treatment options. 
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Introduction
Worldwide, more than 239,000 women per year are diagnosed with ovarian cancer and 
152,000 succumb annually (1, 2). Due to aspecific symptoms, the majority of the patients 
present in an advanced stage, having extensive tumor burden and often accumulation 
of fluid, called ascites, in the peritoneal cavity. Ascitic fluid contains lymphocytes, 
mesothelial cells, macrophages, tumor cells and, in the case of rapid fluid development, 
a high proportion of red blood cells. The ratio of the different cells can vary between 
patients, but lymphocytes are generally the biggest cell population (3). T cell immunity 
in the tumor microenvironment has a profound impact on ovarian cancer outcome and 
plays a significant role in controlling recurrence (4, 5). Several studies demonstrated that 
high levels of C D8+ T cells positively correlate with patient survival in high-grade serous 
ovarian cancer (6-8). However, tumor cells can escape destruction by the immune system 
in several ways. Ovarian cancer cells can recruit and induce the expansion of regulatory 
T cells (TRegs), which are able to inhibit the anti-tumor response of effector CD8+ T cells, 
either by secretion of interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) or 
via a cell-cell contact-dependent mechanism. Accumulation of TRegs at the tumor site is 
associated with reduced survival of ovarian cancer patients, as are high CD4/CD8 ratios. 
Furthermore, CD8+ effector T cells are inhibited by tumor macrophages expressing B7-H4 
(9, 10). Recent studies also investigated the effect of the presence of immune cells in ascites 
and confirmed the results from solid ovarian cancer (11). 
Over the past 30 years, the standard treatment for ovarian cancer has remained cyto-
reductive surgery in combination with platinum- and taxane-based chemotherapy 
(carboplatin and paclitaxel)(12, 13). About 70% of the patients respond to the first-line 
therapy, although most patients will get recurrent disease within two years (14, 15). 
Therefore, new treatment options are necessary. Enforcing the immune response through 
immunotherapy could benefit ovarian cancer patients. However, ascites provides a 
growth-promoting environment for tumor cells by down-regulation of the anti-tumor 
immune response. Understanding the immunosuppressive mechanisms in ovarian 
cancer is essential for effective enhancement of the immune system. To determine the 
functionality of immune cells in the peritoneal cavity of ovarian cancer patients, we 
measured the proliferation and cytokine secretion of ascites-derived T cells. In this 
paper, we demonstrate that ascites can transiently suppress local T cell proliferation in 
the peritoneal cavity, weakening the role of the immune system. This suppression seems 
to be mediated by a deregulated lipid metabolism in malignant ascites. Lipid mediators 
are known to modulate the immune response in cancer (16-18). Low oxygen in the tumor 
microenvironment limits the aerobic glycolysis and thus proliferation of T cells but this 
is overcome by switching to fatty acid oxidation (19). In several cancers, lipooxygenases 
(LOX) are modified which lead to either pro-tumorigenic or anti-tumorigenic functions 
(20). Interfering with lipid metabolism might open new ways to help the immune system 
to eradicate tumor cells.
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Results
Ascites-derived T cells proliferate poorly upon αCD3/28 stimulation
A functional cellular immune response is crucial for the eradication of tumor cells. One of 
the key processes of cellular immunity is antigen specific T cell proliferation. Therefore, 
lymphocytes from cryopreserved ascites-derived mononuclear cells (MNCs) were sorted 
using a lymphocyte gate and stimulated with different concentrations of αCD3/28 beads. 
The proliferative capacity was measured after three days (Figure 1A). 
 
figure 1  Decreased proliferation, but normal cytokine secretion of ascites-derived T cells.
Proliferation and cytokine secretion was measured after stimulating 5 × 104 cells with increasing 
concentrations of αCD3/28 beads for three days. (A) Proliferation of control PBLs (mean of n = 8), 
sorted lymphocytes (n = 7) and sorted CD4+CD25− T cells (n = 5) from ascites-derived MNCs. (B) 
Proliferation of patient-derived PBMCs. Data are given as mean of cpm 3H-thymidine incorporation 
of triplicate cultures ± SEM. (C) IFN-γ and (D) IL-2 production of ascites-derived lymphocytes (n 
= 4) and control PBLs (n = 3). Supernatants of triplicate cultures were pooled and tested by an 11-
plex for cytokine production. Statistical analysis using one-way ANOVA with Bonferroni post-test 
(* p < 0.05, ** p < 0.01 or *** p < 0.001).
 
 
Peripheral blood lymphocytes (PBLs) from healthy individuals had higher proliferation 
rates when stimulated with increasing concentrations of αCD3/28 beads. In contrast, the 
majority of ascites-derived T cells hardly proliferated upon αCD3/28 stimulation. Only two 
patients (P73 and P98) showed a dose-response curve when stimulated with increasing 
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concentration of beads, but proliferation was low compared to PBLs from healthy 
individuals. Altogether, proliferation of ascites-derived cells was significantly lower when 
stimulated with 10,000 or 40,000 beads/well compared to PBLs from control individuals 
(mean difference 50,737 cpm and 63,549 cpm, p < 0.05 and p < 0.01 respectively). The 
decreased proliferation of ascites-derived T cells was not mediated by the presence of 
TRegs, as there was no significant difference in the proliferation of sorted CD4+CD25- T cells 
lacking TRegs and sorted lymphocytes from ascites that contain TRegs.
To rule out a systemic T cell defect, the proliferative capacity of patient peripheral blood 
mononuclear cells (PBMCs) was tested (Figure 1B). Patient PBMCs showed enhanced 
proliferation when stimulated with increasing concentrations of αCD3/28 beads. 
Furthermore, the proliferation of patient PBLs did not differ significantly from control 
PBLs (mean difference 31,726 cpm, p > 0.05).
Lack of cytokine production could be the cause of T cell proliferation insufficiency. 
Therefore, the cytokine secretion was measured after three days of αCD3/28 bead 
stimulation. Using an 11-plex Flowcytomix Multiplex assay, samples from four patients 
and three controls were analyzed for the secretion of interferon γ (IFN-γ), interleukin-2 
(IL-2), IL-4, IL-5, IL-6, IL-10, tumor necrosis factor α (TNF-α), and tumor necrosis factor β 
(TNF-β).
Ascites-derived T cells from all tested patients showed an increase in IFN-γ and IL-2 
production when stimulated with increasing concentrations of αCD3/28 beads (Figure 
1C,D). Moreover, there was no significant difference in the IFN-γ and IL-2 production of 
ascites-derived cells and control PBLs. All other cytokines were produced at low levels 
(data not shown).
Ascites-derived CD4+CD25- T cells are unresponsive to IL-2
A possible explanation for the hampered proliferation of ascites-derived lymphocytes is T 
cell anergy. T cells can become functionally inactivated or anergic after antigen encounter, 
meaning that they do not react to re-stimulation. To test this hypothesis, CD4+CD25- 
ascites-derived T cells were stimulated for three days with αCD3/28 beads in combination 
with IL-2 and/or IL-12. IL-2 is known for its ability to overcome the non-proliferative 
status of anergic T cells. IL-2 and IL-12 synergize (21) and are able to reverse T cell anergy 
in mycobacterial disease (22). Subsequently, proliferation as well as IFN-γ secretion was 
measured (Figure 2). 
Stimulation with αCD3/28 resulted in proliferation of control cells (Figure 2A). The 
proliferation was enhanced when cells were treated with αCD3/28 in combination with 
IL-2 and/or IL-12. In contrast, ascites-derived cells barely proliferated in response to 
αCD3/28 beads. Stimulation with αCD3/28 in combination with IL-2 and/or IL-12 was 
not able to overcome the unresponsiveness of patient-derived cells. Similar effects were 
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observed for IFN-γ secretion (Figure 2B). Control cells produced low amounts of IFN-γ 
when stimulated with αCD3/28 beads only. Addition of IL-2 resulted in an increase of 
IFN-γ secretion, which was even stronger for stimulation with αCD3/28 beads together 
with IL-12. There was a synergistic effect on IFN-γ secretion when cells were stimulated 
in the presence of IL-2 and IL-12. This synergistic effect was absent in patient samples. 
Ascites-derived cells did not increase IFN-γ when stimulated in the presence of IL-2. 
Cytokine secretion was only enhanced in response to IL-12. This indicates that ascites-
derived T cells are unresponsive to IL-2.
 
figure 2  Hypoproliferation of ascites-derived T cells cannot be overcome by IL-2 or IL-12. (A) 
Proliferation; and (B) IFN-γ secretion of control (n = 3) and ascites-derived CD4+CD25− T cells (P61, 
P68, P73) after three days of stimulation. Cells were cultured with αCD3/28 (2,500 beads/well), 
IL-2 (25 or 125 U/mL), and IL-12 (1,000 pg/mL), or a combination of the different stimuli. Values 
are means ± SD.
 
Ascites-derived CD4+CD25- T cells have a normal expression of IL-2R and 
its downstream signaling components
We hypothesized that the unresponsiveness to IL-2 could be caused by aberrant expression 
of the high affinity IL-2 receptor (IL-2R). Therefore, expression of the three IL-2R subunits 
CD25, CD122, and CD132 was measured on stimulated ascites-derived CD4+CD25− T cells 
(23). All three components were expressed on both, control PBLs and on ascites-derived T 
cells (Figure 3A). In each patient, there was a fraction of cells that highly expressed CD25, 
and this level was comparable to control PBLs. 
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figure 3  Normal expression and phosphorylation of the IL-2 receptor and its downstream 
signaling components. PBLs of healthy individuals or sorted ascites-derived CD4+CD25− T cells 
(5 × 105 cells/well) were stimulated with 20,000 αCD3/28 beads/well for three days. Subsequently, 
samples were stained for flow cytometry analysis. (A) Cells were stained for isotype control, CD25, 
CD122, and CD132. Plots are representative for three controls and three patients. (B) Control (n = 
3) and ascites-derived T cells (n = 3) were stained for JAK3, STAT5, phospho-STAT5, phosphor-AKT 
and phosphor-ERK. One representative example is shown.
 
Since the high affinity IL-2R was normally expressed, we reasoned that the cause of IL-2 
unresponsiveness could be located downstream in the IL-2 signaling pathway. IL-2 binding 
to its receptor results in Janus kinase 3 (JAK3) phosphorylation. Next, three different 
signaling pathways can be activated, via signaling of signal transducer and activator of 
transcription 5 (STAT5), phosphoinositide 3-kinase (PI3K) or through mitogen-activated 
protein kinase (MAPK). Therefore, total JAK3 and STAT5 was measured, as well as 
phosphorylation of STAT5, the serine/threonine kinase AKT and the MAP kinase ERK1/2 
(Figure 3B). Previous studies showed a reduced expression of JAK3 as a mechanism for 
IL-2 non-responsiveness (24). Ascites-derived lymphocytes from ovarian cancer patients 
normally expressed JAK3 and STAT5. Next, the STAT5 phosphorylation was evaluated 
by intracellular flow cytometry. Freshly isolated ascites-derived MNCs and PBMCs from 
the same patient were stained for CD4, incubated with or without 100 U/mL IL-2 for one 
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hour, and subsequently stained for phospho-STAT5. IL-2 stimulated samples had a higher 
percentage of phospho-STAT5 positive CD4 cells compared to medium-treated controls. 
The size of CD4+ and phospho-STAT5 positive population differed greatly among patients, 
ranging from 19-63% in the ascites-derived cells to 26-50% in the corresponding PBLs. 
To analyze the phosphorylation of ERK1/2 and AKT, ascites-derived lymphocytes were 
stimulated with αCD3/28 for 4 days. Control PBLs and ascites-derived lymphocytes were 
highly positive for CD25 and had comparable levels of phosphorylated AKT and ERK1/2.
Acellular fraction of ascites inhibits proliferation of control PBLs
The tumor microenvironment can strongly influence T cell activation. As we observed a 
severely decreased proliferative capacity in ascites-derived T cells, we wondered if ascites 
could induce the same effect in control PBLs. Lymphocytes obtained from healthy donors 
were stimulated with αCD3/28 beads in the presence of the acellular fraction of ascites 
and proliferation was measured after three days. Some variability in the inhibition of 
proliferation was observed. However, the proliferative capacity of PBLs was markedly 
decreased in the vast majority of tested donors (Figure 4). 
figure 4  Ascites inhibits proliferation of PBLs from healthy donors. (A) 5 × 104 control PBLs 
were stimulated with 2,500 beads/well in the presence of 20% ascites fluid from ovarian cancer 
patients. Data are given as mean of cpm 3H-thymidine incorporation of triplicate cultures ± SEM. 
(B) Summary of PBLs stimulated with αCD3/28 (n = 4) and PBLs stimulated in the presence of 
ascites (n = 14). Values are given as mean ± SD. Statistical analysis using unpaired student’s t-test 
with Welch’s correction (* p < 0.05, ** p < 0.01 or *** p < 0.001).
 
Suppression of ascites-serived T cells is reversible
As IL-2 signaling was not (or only minimally) affected in ascites-derived T cells, we 
hypothesized that there could be a more general proliferation defect. We therefore 
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decided to analyze the expression of cyclin D and cyclin E, two proteins required for 
the transition from G1- to S-phase. Lymphocytes isolated from ascites of ovarian cancer 
patients were unable to upregulate cyclin E upon stimulation (Figure 5). 
 
figure 5  Cyclin D and E expression in control and ascites-derived lymphocytes. Control PBLs or 
sorted ascites-derived lymphocytes (5 × 105 cells) were stimulated with 20,000 αCD3/28 beads/
well. After 48 h, cells were stained for CD4, cyclin D and cyclin E. Plots are representative for three 
individual controls and four patients.
To determine whether the proliferative capacity of ascites-derived T cells can be restored, 
sorted lymphocytes were stimulated with αCD3/28 beads for three days. Subsequently, 
a fraction of those cells was cultured for 10 days in the presence of IL-2 and IL-7. After 
10 days, the cells were washed and re-stimulated for three days with αCD3/28 in the 
presence or absence of IL-2, IL-12, or a combination of both cytokines.
Ascites-derived lymphocytes barely proliferated in response to the first stimulation with 
αCD3/28 beads, alone or in combination with IL-2 and IL-12 (Figure 6A). Additionally, 
IFN-γ secretion was also low across all treatment conditions (Figure 6B). However, when 
cells of the same patient were re-stimulated after 10 days of culturing in the absence of 
ascites, proliferation and cytokine secretion was markedly increased and comparable to 
control PBLs from healthy donors. Together, this indicates that the proliferation halt of 
ascites-derived T cells is reversible. 
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figure 6  IL-2 and IL-12 responsiveness of ascites-derived CD4+CD25- can be restored. In total, 
5 × 105 sorted CD4+CD25- ascites-derived T cells of P71 were stimulated directly with 5,000 
αCD3/28 beads/well for three days in the presence or absence of 25 or 125 U/mL IL-2, 1,000 pg/
mL IL-12 or a combination of both and subsequently cultured for 10 days in normal medium before 
being re-stimulated. (A) Proliferation was measured before (Day 3) and after culture (Day 10). Data 
are given as mean of cpm 3HTdR incorporation of triplicate cultures ± SEM. (B) Triplicate cultures 
were pooled and tested in three different dilutions in an IFN-γ ELISA. The data are representative 
for three tested patients. (C) Ascites-derived MNCs were sorted using a lymphocyte gate. 
Subsequently, ascites-derived lymphocytes and PBLs from healthy donors were labeled with CFSE, 
plated at a concentration of 5 × 105 cells and stimulated with 20,000 αCD3/28 beads. After three 
days, the cells were stained for CD4 and CD25 and measured with FACS (upper panel). A part 
of the stimulated cells was kept in culture for ten days and restimulated with αCD3/28 beads, 
stained for CD4 and CD25 and subsequently measured with FACS (lower panel).
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table 1  Concentration of lipid intermediates in abdominal fluid of controls and ascites of 
ovarian cancer patients.
Sample (ng/mL) Mean SD Mean SD Ratio
Controls (n = 5) Patients (n = 5) Patients/controls
5-HETE 85.26 81.8 289.69 58.2 3.4
EPA 101 16.4 169.51 81 1.7
4-HDoHE 38.66 40 120.22 20.8 3.1
13-HODE 24.34 6.1 109.87 64.4 4.5
9-HODE 6.07 3.6 74.4 46.3 12.3
9-HETE 2.75 2.4 65.47 35.3 23.8
13-KODE 1.34 0.8 45.9 29 34.3
5-HEPE 10.34 12.4 45.61 15 4.4
11-HETE 2.3 1.5 38.75 18.1 16.9
12-HETE 6.4 5.8 35.95 16.1 5.6
8-HETE 1.99 1.5 32.24 17.9 16.2
9-KODE 0.76 0.5 30.94 26.6 40.5
6-trans-LTB4 1.56 1.8 29.5 13.2 18.9
8-HDoHE 1.41 1.2 25.36 12 17.9
11-HDoHE 1.46 1.1 25.08 12.9 17.2
5,15-DiHETE 2.47 2.6 23.63 10 9.6
17-HDoHE 10.3 5 22.67 8.1 2.2
PGD2 0.85 0.7 20.57 8.1 24.3
PGD1 0.45 0.4 17.27 9.5 38.5
5-HETrE 3.05 3.4 16.5 7.2 5.4
8,15-DiHETE 0.26 0.2 16.31 8.5 63.8
15-HETE 10.05 4.8 15.14 4.5 1.5
15-KETE 0.92 0.6 12.28 7.3 13.3
5,6-DiHETE 0.58 0.7 10.54 4.7 18.2
14-HDoHE 2.14 0.8 7.83 2.5 3.7
9-HEPE 0.31 0.3 7.19 3.8 23.1
15-HETrE 1.2 0.4 6.65 2.3 5.6
5-KETE 0.57 0.8 5.8 2.7 10.2
12-HEPE 0.53 0.2 5.09 2.7 9.5
12-KETE 0.16 0.2 4.98 3 30.8
13-HOTrE 3.04 1.1 4.86 4.2 1.6
11-HEPE 0.25 0.2 4.79 2.6 19.4
10,17-DiHDoHE 0.06 0.1 4.15 2 65.1
5-iPF2a-VI 0.25 0.2 3.1 1.4 12.6
8-HEPE 0.23 0.2 3.09 1.8 13.7
8-HETrE 0.26 0.2 2.72 1 10.5
PGE1 0.19 0.1 2.46 1.1 13.1
9,10,13-TriHOME 0.38 0.2 2.07 1.1 5.5
9,12,13-TriHOME 0.48 0.3 1.87 0.9 3.9
18-HEPE 0.15 0.1 1.86 0.8 12.1
LXB4 0.08 0.1 1.83 0.9 22.5
15-HEPE 0.68 0.4 1.82 0.7 2.7
9-HOTrE 0.36 0.2 1.62 1.3 4.5
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12,13-DiHOME 4.57 1 1.53 0.9 0.3
13-HOTrE(gamma) 0.41 0.1 1.37 0.4 3.3
EKODE 0.85 0.2 1.36 0.8 1.6
11-HEDE 0.29 0.1 1.36 0.8 4.7
9,10-DiHOME 7.01 2.2 1.35 0.7 0.2
20-COOH-LTB4 0 0 1.16 0.8 -
6-keto-PGF1a 12.78 10.9 1.13 0.6 0.1
8(9)-EpETrE 0.05 0.1 1.1 0.4 20
17(18)-EpETE 0.18 0.2 1.05 0.3 5.7
15-HEDE 0.1 0 0.82 0.4 8.1
12-HHTrE 3.29 4.7 0.78 0.5 0.2
8-isoPGE2 0.21 0.1 0.76 0.1 3.7
LTB4 0.06 0 0.67 0.4 11.8
17,18-DiHETE 1.01 0.2 0.67 0.2 0.7
14,15-DiHETrE 0.39 0 0.65 0.1 1.7
PGE2 1.07 1.2 0.64 0.3 0.6
19-HETE 0.6 0.2 0.64 0 1.1
20-HETE 0.28 0.1 0.63 0.1 2.3
11,12-DiHETrE 0.31 0.1 0.51 0 1.6
14,15-DiHETE 0.23 0 0.5 0.2 2.1
7-Maresin-1 0 0 0.49 0.3 -
12(13)-EpOME 0.47 0.1 0.48 0.2 1
19,20-DiHDPA 0.3 0 0.39 0.1 1.3
5,6-DiHETrE 0.18 0 0.31 0.1 1.8
7,17-hydroxy-DPA 0.03 0 0.28 0.1 9.3
11-keto-TXB2 0.03 0 0.27 0.1 10.2
9(10)-EpOME 0.22 0.1 0.26 0.1 1.2
LTE4 0.12 0.1 0.2 0.1 1.7
iPF2a-IV 0 0 0.2 0.1 48.3
PGB2 0.34 0.4 0.17 0.1 0.5
8,9-DiHETrE 0.11 0 0.17 0 1.5
11B-PGF2a 0.29 0.4 0.11 0 0.4
8-iso-PGF2a 0.04 0 0.07 0 2
15-KEDE 0.01 0 0.07 0 5.5
12(13)EpODE 0.02 0 0.05 0 2.5
15-deoxy-delta-12,14-PGJ2 0.01 0 0 0 0
LTB3 0 0 0 0 -
PGD3 0 0 0 0 -
delta-12-PGJ2 0 0 0 0 -
17-RvD1 0 0 0 0 -
11(12)-EpETrE 0 0 0 0 -
PGF2a 6.22 8.1 0 0 -
PGE3 0 0 0 0 -
PGJ2 0 0 0 0 -
RvD1 0 0 0 0 -
RvD2 0 0 0 0 -
14(15)-EpETE 0 0 0 0 -
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Ascites-derived lymphocytes and PBLs from healthy individuals were furthermore labeled 
with CFSE and subsequently stimulated with αCD3/28 beads. After three days, a small 
fraction of the samples was stained for CD4 and CD25 and the proliferative capacity was 
analyzed by flow cytometry. The remaining cells were kept in culture without ascites. After 
10 days, the CFSE positive cells that did not divide were sorted and re-stimulated with 
αCD3/28 beads for three days, stained for CD4 and CD25 and analyzed by flow cytometry 
to determine if the proliferative capacity of those cells was restored. Indeed, the initially 
non-proliferative cells showed proliferation after re-stimulation with αCD3/28 (Figure 6C).
Altered lipid metabolites in suppressive ascites
Our results point towards a suppressive compound within ascites. Lipid metabolism is 
deregulated in many cancers and known to affect the immune system in various ways. 
Therefore, normal abdominal fluid and suppressive ascites fluid were screened for 109 
lipid mediators using LC-MS/MS (Table 1). 
Ascites from five patients with maximal suppressive ascites and abdominal fluid from five 
control individuals was analyzed. We expected only a few lipid mediators to be different. 
Instead, 82 metabolites were differentially expressed in ascites compared to healthy 
abdominal fluid controls. The results were consistent across controls and patients. The 
values for each lipid metabolite were averaged and the ratio of the concentration in ascites 
and normal abdominal fluid was calculated.
Several of the lipid metabolites are able to activate peroxisome proliferator-activated 
receptors (PPAR), which can modulate the activity of immune cells (25). PPAR can be 
activated by 9-HODE, a lipid metabolite that was increased in suppressive ascites. We 
tested purified 9-HODE isomers in a T cell activation assay and indeed 9(R)HODE was able 
to partially inhibit proliferation, while 9(S)HODE and 13-OxODE did not have an effect on 
proliferation (Figure 7). 
14(15)-EpETrE 0 0 0 0 -
16(17)-EpDPE 0 0 0 0 -
19(20)-EpDPE 0 0 0 0 -
5(6)-EpETrE 0 0 0 0 -
9-KOTrE 0 0 0 0 -
20-OH-LTB4 0 0 0 0 -
LXA4 0 0 0 0 -
LXA5 0 0 0 0 -
tetranor-PGDM 0 0 0 0 -
13,14-dihydro-15-ke-
to-PGE2
0.01 0 0 0 -
8-iso-PGF3a 0 0 0 0 -
11-keto-TXB3 0 0 0 0 -
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figure 7  Synthetic lipid-metabolites partially inhibit T cell proliferation. In total, 50,000 
control PBLs from healthy donors were stimulated with αCD3/28 for three days in the presence 
of 9(R)HODE, 9(S)HODE or 13-OxODE. Only 9(R)HODE decreased the proliferation of control 
PBLs. Data given as mean of cpm 3HTdR incorporation of triplicate cultures ± SEM. Statistical 
analysis was performed using one-way ANOVA with Bonferroni post-test (* p < 0.05, ** p < 0.01 
or *** p < 0.001).
Discussion
Epithelial ovarian cancer is a devastating disease. Most patients are diagnosed at an 
advanced stage and present with a massive tumor burden. The immune system plays 
an important role in cancer development. Ovarian cancer metastases are generally 
found within the peritoneal cavity and barely elsewhere in the body (26, 27). CD8+ T cell 
infiltrates in primary ovarian cancer and ovarian cancer-associated ascites are correlated 
to improved prognosis and survival (8). Despite their presence, complete tumor regression 
is not observed, pointing towards suppression of a full-blown immune response (19, 
28). Our findings demonstrate that ascites is able to locally and transiently inhibit T cell 
proliferation within the peritoneal cavity, creating a T cell deficiency. In contrast, cytokine 
secretion of ascites-derived T cells was not affected. The fact that ascites fluid decreases 
the proliferative capacity of control PBLs points towards a soluble factor present in ascites 
that interferes with T cell proliferation. Addition of exogenous IL-2 and IL-12 did not 
increase proliferation of ascites-derived T cells. Since patient-derived cells produced more 
IFN-γ when stimulated with IL-12, we reasoned that IL-2 unresponsiveness might be the 
cause for the observed hypoproliferation. Several studies described defects in different 
components of the IL-2R signaling pathway, resulting in decreased T cell proliferation, 
such as the absence of CD25 expression (29), impaired STAT1 and STAT5 activation (30) or 
soluble products released from renal cell carcinoma that suppress JAK3 (24). Interestingly, 
we could not detect any differences in the expression of IL-2 receptor subunits or the 
activation of downstream components of the IL-2R signaling pathway in ascites-derived T 
cells. The next members of the pathway, JAK3 and STAT5, were expressed at normal levels. 
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Furthermore, phosphorylation of STAT5, AKT, and ERK1/2 was detected after stimulation 
with IL-2 or other stimuli like αCD3/28 beads. We did observe lower levels of cyclin E in 
ascites-derived lymphocytes, a protein important for transition from G1 to S-phase (31). 
This suggests that lymphocytes isolated from ascites of ovarian cancer patients were 
halted in G0/G1.
Since ascites also inhibited proliferation of normal T cells we analyzed the lipid composition 
of ascites and normal abdominal fluid. Cancer cells are known to have a deregulated 
lipid metabolism (32), which could modulate the T cell response. Comparison of normal 
abdominal fluid and ascites from ovarian cancer patients showed that the concentration 
of several lipid metabolites varied between the two groups. Moreover, these differences 
were consistent for five high-grade serous ovarian cancer patients and five controls. Since 
T cells that were isolated from normal abdominal fluid of healthy individuals proliferated 
normally when kept in standard culture medium, T cell anergy must be either induced by 
compounds that are only present in suppressive ascites or by metabolites that are highly 
elevated in suppressive ascites or by lacking intermediates that are present in normal belly 
fluid. 
Lipid metabolites are bound by peroxisome proliferator-activated receptors (PPARs). 
The PPARs are the spider in the web that regulates various cell functions depending on 
the environment and stimulus. Their function is determined by a co-repressor and co-
activator bound to PPAR (33). In T cells, PPAR can bind to nuclear factor of activated T 
cells (NFAT), thereby inhibiting cell proliferation and IL-2 secretion (25, 34). In our studies, 
we did not observe lower IL-2 quantities, indicating that NFAT does not bind to activated 
PPAR. However, another pathway could be the interaction of PPAR with factors, like 
STAT3 or receptor-induced NF-κB, that induce p21WAF/Cip. P21WAF/Cip in turn modulates 
p27, resulting in suppression of cyclin E (35). This could explain the reduced levels of 
cyclin E that we observed in ascites-derived T cells and thus the lack of proliferation (36). 
The lipid metabolite with the highest concentration in suppressive ascites was 5-HETE. 
However, 5-HETE itself is not able to activate PPAR (37). It must first be converted to OXO 
derivatives (25). Since 5-HETE does not activate PPAR, we tested if 9-HODE, another 
compound that is present in high concentrations in suppressive ascites, is able to inhibit 
cell proliferation. Culturing cells with 9(R)HODE was able to decrease the proliferation 
of control PBLs. The monocytic cell line U937 is halted in G1 when stimulated in the 
presence of 9-HODE, most likely via activation of PPARγ (38). Furthermore, it has been 
shown that 9-HODE activates G2A, a G protein-coupled receptor, in pro-B and T cells, 
resulting in accumulation of cells in G2 (39, 40). This indicates that 9-HODE, which is 
present in large amounts in suppressive ascites, might be able to interfere with T cell 
proliferation. However, since the inhibition was only partial, several lipids may synergize 
to block proliferation of ascites-derived T cells. Another candidate could be PGD2, which 
is low in controls and more than 24 times higher in patient ascitic fluid. PGD2 is converted 
to 15-deoxy-delta-12,14-PGJ2, a covalent activator of PPAR (41). 15-deoxy-delta-12,14-
PGJ2 is not found in suppressive ascites while it is present in minute amounts in normal 
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belly fluid. Thus far, we cannot decide, which metabolites act in concert with 9-HODE to 
inhibit T cell proliferation. PPARs are involved in a myriad of other pathways to adapt to 
changes in the microenvironment. Hopefully, “selective PPAR modulators” (SPPARγ M) 
can be used to unravel the metabolite(s) (42).
To summarize, we demonstrate that ascites-derived CD4+CD25− T cells are impaired in 
proliferation upon αCD3/28 stimulation. In contrast, cytokine production is not affected. 
Our data suggest that this could be due to lipid metabolites present in suppressive ascites 
that cause a proliferation halt of ascites-derived lymphocytes in G0/G1. Unraveling the 
mechanisms responsible for the hypoproliferation of ascites-derived T cells remains 
crucial and should be subject of further investigation, as this may suggest possible 
treatment options.
Material and methods
Patient material
Ascites from stage III or IV epithelial ovarian cancer patients was obtained either during 
debulking surgery or via ascites drainage. Only material of patients that did not receive 
chemotherapy prior to sample collection was used in this study. The majority of patients 
were diagnosed with high-grade serous ovarian cancer, expect for patient 61 and 73 who 
had mucinous and clear cell ovarian cancer, respectively. The guidelines for collection 
of human material of the Radboudumc were followed. Approval from the Medical 
Ethics Review Committee was not required. Ascites is considered as waste material and 
the Medical Research Involving Human Subjects Act (WMO) does not apply. Patients 
were not asked for informed consent and no identifying patient information was used. 
Ovarian cancer patients donated blood after informed consent, which was taken shortly 
after surgery. Blood cells from controls were obtained from buffy coats from anonymous 
healthy donors of the blood bank after informed consent. Experiments were approved and 
carried out in accordance with the guidelines and regulations of the Radboudumc.
Antibodies
The following antibodies were used in this study: CD4-APC (300514, Beckman Coulter, 
Brea, USA), CD4-FITC (A07750, Beckman Coulter), CD25-PE (555432, BD Biosciences, 
San Jose, USA), CD122-PE (IM1978, Beckman Coulter), CD132-APC (338608, BioLegend, 
San Diego, USA), cyclin D (2936P, Cell Signaling, Danvers, USA), cyclin E (551159, Cell 
Signaling, Danvers, USA), JAK3 (ab45141, Abcam, Cambridge, UK), STAT5 (9363P, Cell 
Signaling, Danvers, USA), pSTAT5 (9314S, Cell Signaling, Danvers, USA), pAKT (4075S, Cell 
Signaling, Danvers, USA), and pERK1/2 (4284S, Cell Signaling).
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Cell isolation and activation
Ascites was filtered over a 100 µm Cell Strainer (BD Biosciences, San Jose, USA) and 
centrifuged for 15 minutes at 1400 rpm. Thereafter, ascites cells were centrifuged over a 
density gradient. MNCs at the interphase were collected, washed with PBS supplemented 
with 1% bovine serum albumin, frozen, and stored in liquid nitrogen. Ascites MNCs were 
thawed, stained for CD4 and CD25, and CD4+CD25− T cells sorted with an Epics Altra 
Cell Sorter (Beckman Coulter, Brea, USA). The purity was always above 95%. In addition, 
lymphocytes were sorted by setting a lymphocyte gate on the FSC-SSC scatter plot. As a 
control, either PBMCs from the same patient or PBLs from healthy controls were taken 
along. PBMCs were obtained by density-gradient centrifugation. To obtain PBLs, PBMCs 
were plated and monocytes were allowed to adhere to the plastic. After one hour of 
incubation at 37 °C, the non-adherent PBLs were collected. Cells were plated in a 96 well 
U bottom plate at a concentration of 5 × 104 cells/well in medium (IMDM, Invitrogen, 
Thermo Fisher Scientific, Waltham, USA) supplemented with 10% human serum (HS), 
and stimulated with human T-activator CD3/CD28 Dynabeads® (11131D, Gibco, Thermo 
Fisher Scientific, Waltham, USA) in the presence or absence of 25, 100 or 125 U/mL IL-2 
(Proleukin®, Novartis, Arnhem, the Netherlands), 1000 pg/mL IL-12 (219-IL-005, R&D 
systems, Minneapolis, USA), 25 µg/mL 9(R)-HODE (38405.S4, Bio Connect, Huissen, the 
Netherlands), 25 µg/mL 9(S)-HODE (38410.S1, Bio Connect, Huissen, the Netherlands) or 
25 µg/mL 13-OxODE (38620.S3, Bio Connect, Huissen, the Netherlands) when indicated. 
Supernatant was collected after three days of incubation prior to the addition of 1 µCi/
well of 3H-thymidine. After an additional 16 hours of incubation at 37 °C, 3H-thymidine 
incorporation in DNA was measured using a β-counter and expressed as counts per 
minute (cpm).
Cytokine measurement
IFN-γ production was measured using an IFN-γ ELISA. As coating antibody, αIFN-γ clone 
2G1 (M700a, Thermo Scientific, Waltham, USA) was used, and as detection antibody, 
biotin labeled αIFN-γclone B133.5 (M701b, Thermo Scientific, Waltham, USA). As IFN-γ 
standard, recombinant human αIFN-γ (RIFNG100, Thermo Scientific, Waltham, USA) was 
used. The assay was performed according standard ELISA procedures. To enable multiple 
cytokine detection in culture supernatants, the human Th1/Th2 11 plex Flowcytomix 
Multiplex (BMS810FFRTU, Bender MedSystems, eBioscience, San Diego, USA) was used 
according to the protocol of the manufacture.
Flow Cytometric analysis
Cells were first incubated for 30 minutes with cell surface markers (CD4, CD25). 
Afterwards, cells were fixed for 10 minutes at 37 °C using 2% paraformaldehyde, and 
permeabilized by incubating the cells in 90% methanol for 30 minutes on ice. Subsequently, 
the cells were stained with anti-JAK3, anti-STAT5, anti-phospho-STAT5, anti-phospho-Akt, 
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anti-phospho-ERK1/2, anti-cyclin D, or anti-cyclin E. As secondary antibody, goat-anti-
rabbit IgG Alexa 647 (A21245, Invitrogen, Thermo Fisher Scientific, Waltham, USA) or 
goat-anti-mouse IgG Alexa 488 (A11029, Invitrogen, Thermo Fisher Scientific, Waltham, 
USA) was used. For the detection of phospho-STAT5, cells were stimulated with medium 
or 100 U/mL IL-2 for one hour at 37 °C prior to fixation. Cells were measured on a CyAnTM 
ADP Analyzer equipped with a 488, 561, and 630 nm laser (Beckman Coulter, Brea, USA), 
and analyzed with Summit 4.3.
Lipid mediator analysis of abdominal fluid
Abdominal fluid from five high-grade serous ovarian cancer patients and five control 
individuals was centrifuged to remove cells and debris. The supernatant was collected and 
stored at -80 °C until further analysis. Samples were prepared by thawing abdominal fluids 
and mixing 900 µL with 10 µL of internal standard solution and 900 µL of extraction buffer 
(citric acid: Na2HPO4, pH = 5.6). Solid phase extractions were done using an Extrahera 
liquid handling system (Biotage, Uppsala, Sweden) and Evolute Express ABN SPE 
cartridges (cartridge capacity: 60 mg, 3 mL sample volume, Biotage, Uppsala, Sweden). 
After conditioning (2.5 mL of methanol) and equilibration (2.5 mL of H2O) samples were 
loaded on the cartridges and washed with 2 mL of H2O/methanol (90:10). Lipid mediators 
were eluted in 2.5 mL methanol. As trap solution 30% glycerol in methanol (30 µL) was 
added to each eluate and methanol was evaporated under a nitrogen gas stream using a 
TurboVap LV evaporation system (Biotage, Uppsala, Sweden). Extracts were reconstituted 
in 70 µL methanol/water (6:1, v/v) and filtered by centrifugation for 2 minutes at 12,000 
g using 0.1 µm polyvinylidenfluorid membrane spin filters (Merck Millipore Cooperation, 
Billerica, MA, USA). Quantitative analysis of lipid mediators was done using a liquid 
chromatography-mass spectrometry (LC-MS/MS) method previously described (43).
Statistics
GraphPad Prism software version 5 was used for statistical analysis. Error bars represent 
mean ± SD or SED, as indicated in the figure legends. Comparison of three or more groups 
was done on Log(Y) transformed data. One-way ANOVA with Bonferroni (significance 
level p = 0.05) post test were used to compare three or more groups with equal variances 
(determined by Bartlett’s test for equal variances). In the case of unequal variances, data 
were log-transformed. If variances were still different, non-parametric Kruskal-Wallis test 
with Dunns (significance level p = 0.05) post test was used. For the comparison of two 
groups, unpaired, two-tailed Student’s t-test was used. Differences were considered to be 
significant when * p < 0.05, ** p < 0.01 or *** p < 0.001.
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Abstract 
Ascites is a prominent feature of ovarian cancer and could serve as liquid biopsy to 
assess the immune status of patients. Tumor-infiltrating T lymphocytes are correlated 
with improved survival in ovarian cancer. To investigate whether immune cells in ascites 
are associated with patient outcome, we analyzed the amount of dendritic cell (DC) and 
T cell subsets in ascites from ovarian cancer patients diagnosed with high-grade serous 
cancer (HGSC). Ascites was collected from 62 HGSC patients prior to chemotherapy. 
Clinicopathological, histological and follow-up data from patients were collected. Ascites-
derived immune cells were isolated using density-gradient centrifugation. The presence 
of myeloid DCs (BDCA-1+, BDCA-3+, CD16+), pDCs (CD123+BDCA-2+) and T cells (CD4+, 
CD8+) was analyzed using flowcytometry. Complete cytoreduction, response to primary 
treatment and chemosensitivity were associated with improved patient outcome. In 
contrast, immune cells in ascites did not significantly correlate with patient survival. 
However, we observed a trend towards improved outcome for patients having low 
percentages of CD4+ T cells. Furthermore, we assessed the expression of co-stimulatory 
and co-inhibitory molecules on T cells and non-immune cells in 10 ascites samples. PD-1 
was expressed by 30% of ascites-derived T cells and PD-L1 by 50% of non-immune cells. 
However, the percentage of DC and T cell subsets in ascites was not directly correlated to 
the survival of HGSC patients.  
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Introduction
The majority of patients with epithelial ovarian cancer is diagnosed with advanced stage 
high-grade serous cancer (HGSC), with a poor 5-year overall survival rate of just 25% (1, 2). 
Standard treatment consists of cytoreductive surgery and platinum-based chemotherapy 
(3). Despite good initial response rates, about 70% of the patients relapse within 18 
months (3-5). Unfortunately, over the last 30 years no significant improvement in survival 
is seen and ,therefore, new treatment options are needed (6).
Ovarian cancer is an immunogenic disease and the tumor microenvironment is infiltrated 
by various immune cells that influence tumor progression and metastasis. The best 
studied immune cell type in solid tumors are T cells. CD8+ cytotoxic T cells kill tumor cells 
when they recognize an antigen that is presented by MHC class I. In ovarian cancer, tumor-
infiltrating CD3+ and, more precisely, CD8+ T cells are associated with improved overall 
survival in advanced stage HGSC, as are high CD8/CD4 ratios (7-9). 
In addition to T cells, DCs have been identified to infiltrate tumor tissue (10). DCs sample 
antigens and display them in an MHC-dependent context to T cells in the lymph node 
in order to initiate a potent anti-tumor T cell response. In blood, two main DC subsets 
exist that can be divided into myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). Based 
on the expression of surface markers, mDCs can be further subdivided into BDCA-1+ and 
BDCA-3+ mDCs (11). There is much debate about the existence of a third, CD16 expressing 
mDC subset (12-14). Each DC subset has its own characteristics and function. Hence, the 
DCs present in the tumor microenvironment determine the nature of the generated T cell 
response (15). Tumor infiltrating DCs have been identified in many cancer types (16), but 
their correlation with patient outcome is unclear. 
The tumor-suppressive microenvironment in ovarian cancer inhibits the function of 
effector T cells. Tumor cells down-regulate MHC molecules to escape detection by 
T cells (17). These tumor cells should be recognized and eliminated by natural killer 
(NK) cells (18). However, in ovarian cancer, NK cells are enriched for the less cytotoxic 
CD56brightCD16- phenotype (19). In general, the link between infiltration of NK cells 
and patient survival is not yet clear. Furthermore, tumor cells attract and expand 
immunosuppressive cells, such as M2 macrophages and regulatory T cells (TRegs) (20). 
Depending on their activation, macrophages can acquire a M1 (classical activation) or 
M2 (alternative activation) phenotype. Whereas M1 macrophages exert anti-tumorigenic 
functions, M2 macrophages promote tumor progression (21). Therefore, a high M1/M2 
ratio is associated with improved patient survival in ovarian cancer. In contrast, a higher 
density of M2 macrophages correlated with worse outcome (22). TRegs inhibit the function 
of CD8+ T cells via cell-cell contact dependent mechanisms and by secreting inhibitory 
cytokines, such as IL-10, thereby limiting their tumor killing capacity (23). Tumor-
infiltrating TRegs are associated with worse patient outcome (24). The immunosuppressive 
tumor microenvironment also promotes the accumulation of immature DCs, which can 
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induce tolerance and expand the TRegs pool (25). Thus, boosting the pre-existing anti-tumor 
immune response by immunotherapy to overcome the immunosuppressive mechanisms 
should be a promising treatment strategy for ovarian cancer patients. 
Immune infiltration into tumor tissue at baseline is an important predictor for patient’s 
response to immunotherapy (26, 27). Acquisition of tumor material can only be achieved by 
invasive procedures. A prominent feature of advanced stage HGSC is fluid accumulation 
(ascites) within the peritoneal cavity. Ascites contains immune cells, such as macrophages, 
monocytes, granulocytes, and lymphocytes and could be seen as a reflection of the tumor 
microenvironment. The fluid can be obtained by drainage, which is an easier and safer 
procedure. Therefore, ascites could serve as liquid biopsy to assess the immune status of 
ovarian cancer patients (28, 29). However, so far it remains unclear whether immune cells in 
ascites can be correlated to clinical patient outcome. To investigate whether the different 
DC subsets correlate to T cell subsets, and whether these immune cells can be linked to 
patient survival and clinical characteristics, we analyzed the ascites of 62 HGSC patients.
Results
Patient characteristics
Ascites from 62 ovarian cancer patients was collected prior to any chemotherapy 
treatment via ascites drainage or during primary surgery (Table 1). All patients were 
diagnosed with HGSC. Out of 62 patients, 52 were diagnosed with FIGO stage III and 10 
with stage IV disease. The median age at diagnosis was 64 years (range 42-80 years). One 
patient was treated with chemotherapy only and one patient underwent cytoreductive 
surgery only. 21 patients underwent a primary debulking, followed by six courses of 
adjuvant chemotherapy. The remaining 39 patients received three courses of neo-
adjuvant chemotherapy, followed by interval debulking and another three courses of 
adjuvant chemotherapy. Complete or optimal (≤1 cm residual tumor foci) cytoreduction 
was achieved in 26 and 28 patients, respectively, whereas 7 patients had a suboptimal 
(>1 cm residual tumor foci) debulking. The majority of patients received combination 
chemotherapy, consisting of taxol and platinum (cisplatin, carboplatin), and six patients 
received carboplatin monotherapy. A good response to primary treatment was observed 
in 38 patients. Median PFS and OS was 7 months (range 0-95) and 21 months (range 1-99), 
respectively. 
mDCs, pDCs and T cells are present in ascites
DC and T cell subsets in ascites were analyzed using flowcytometry. Due to limited cell 
numbers in some samples, mDCs were measured in 56 samples and pDCs and T cells in 62 
ascites samples. 
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table 1  Clinicopathological characteristics of high-grade serous ovarian cancer patients
 
BDCA-1+, BDCA-3+ and CD16+ mDCs were analyzed in the CD45+CD14- cell population 
(Table 2, Figure 1A). pDCs were identified by co-expression of CD123 and BDCA-2 (Figure 
1B). BDCA-1+ and BDCA-3+ mDCs were detected in 91% (51/56) and 96% (54/56) of ascites 
samples, respectively. CD16+ mDCs and pDCs were present in 100% (56/56 and 62/62) of 
patient samples. The median percentage of the different DC subsets in ascites was 1.8% 
for BDCA-1+ mDCs (range 0.0-21.2%), 0.9% for BDCA-3+ mDCs (range 0.0-4.9%), 2.8% for 
CD16+ mDCs (range 0.4-21.4%), and 2.1% for pDCs (range 0.1-8.8%) (Figure 1D). T cells 
were detected in 100% (62/62) of ascites samples. The median percentage of T cell subsets 
in the CD3+ cell population was 45.5% for CD4+ T cells (range 2.0-78.0%), containing T 
helper cells and TRegs, and 33.0% for CD8+ cytotoxic T cells (range 1.0-65.0%) (Figure 1C, 
E). The correlation between DC and T cell subsets was investigated by calculating the 
Pearson correlation coefficient. There was no correlation between BDCA-1+, BDCA-3+, and 
CD16+ mDCs and the different T cell subsets. In contrast, percentages of pDCs positively 
correlated with higher percentages of CD4+ T cells (r=0.348, p=0.048). 
N (62) %
Median age (range) 64 (42-80)
FIGO stage
III 52 84
IV 10 16
Surgery
Primary cytoreduction 22 35
Secondary cytoreduction 39 63
No cytoreduction 1 2
Outcome surgery
Complete 26 42
Optimal (≤1cm) 28 46
Suboptimal (>1cm) 7 12
Chemotherapy
Taxol/Platinum 56 90
Non-taxol 5 8
No chemotherapy 1 2
Response to primary treatment
Responder 38 63
Non-responder 22 37
FIGO: Fédération Internationale de Gynécologie Obstétrique
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table 2  Markers used for the identification of mDCs, pDCs and T cells by flowcytometry.
figure 1  T cell and DC subsets in ascites. DC en T cells subsets were measured in ascites of 62 
high-grade serous ovarian cancer patients using flowcytometry. (A) Gating strategy for myeloid 
dendritic cells. Lymphocytes were excluded based on FSC/SSC. BDCA-1+, BDCA-3+ and CD16+ 
mDCs were gated in the CD45+CD14- cell population. (B) pDCs were identified based on co-
expression of BDCA-2 and CD123. (C) T cell gating strategy. CD4+ and CD8+ T cells were gated in 
the CD3+ lymphocyte population. (D) Percentage of DC subsets in ascites. (E) Percentage of T cells 
in ascites. Red line indicates mean.
Cell type Markers Function
BDCA-1+ mDCs CD45+CD14-BDCA-1+ Directing polarization of CD4+ T helper cells to Th1, 
Th2 or Th17 phenotype 
BDCA-3+ mDCs CD45+CD14-BDCA-3+ Polarization of CD4+ T helper cells to Th1 phenotype; 
Cross-presentation of antigens to CD8+ T cells
CD16+ mDCs CD45+CD14-CD16+ Antibody-dependent cellular cytotoxicity
pDCs CD123+BDCA-2+ Secretion of type I interferons; induction of T regu-
latory cells
CD4+ T cells CD3+CD4+ CD4+ T helper cells aid to initiate a proper immune 
response; CD4+ T regulatory cells dampen the 
immune response
CD8+ T cells CD3+CD8+ Cytotoxic T cells; kill infected or cancerous cells
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figure 2  Kaplan-Meier curves for progression-free survival of HGSC patients. (A) Progression-
free survival curves for clinical characteristics. (B) Progression-free survival for patients stratified 
as having low or high percentages of immune cells in ascites. Cut-off values based on median. 
BDCA-1: 1.8%; BDCA-3: 0.9%; CD16: 2.8%; pDC: 2.1%; CD4: 45.5%; CD8: 33.0%; (C) Progression-
free survival for patients stratified as having low or high CD4/CD8 ratios. Cut-off at 1.3, based on 
population median. P values for significant differences are given. P values <0.05 were considered 
significant.
 
PFS and OS are independent of the percentage of DC and T cell subsets in 
ascites
We did not find a significant difference in the percentage of DC and T cell subsets 
between complete vs. incomplete cytoreduction, responders vs. non-responders, and 
chemosensitive vs. chemoresistant tumors (Table S1). Clinical characteristics significantly 
correlated with patient outcome. Patients with complete cytoreduction, a good response 
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to primary treatment and chemo sensitive primary tumors had improved PFS (Figure 2A) 
and OS (Figure 3A, Table S2). Furthermore, based on the median, patients were stratified 
as having low or high percentages of immune cells. There was no significant difference in 
PFS (Figure 2B, C) and OS (Figure 3B, C) for patients with low or high percentages of DC 
and T cell subsets in ascites, although we observed a trend towards improved PFS and OS 
for patients having low percentages of CD4+ T cells in ascites.  
 
figure 3  Kaplan-Meier curves for overall survival of HGSC patients. (A) Overall survival 
curves for clinical characteristics. (B) Overall survival for patients stratified as having low or high 
percentages of immune cells in ascites. Cut-off values based on median. BDCA-1: 1.8%; BDCA-3: 
0.9%; CD16: 2.8%; pDC: 2.1%; CD4: 45.5%; CD8: 33.0%; (C) Overall survival for patients stratified 
as having low or high CD4/CD8 ratios. Cut-off at 1.3, based on population median. P values for 
significant differences are given. P values < 0.05 were considered significant.
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Trend towards improved PFS and OS for patients with high percentages 
CD16+ mDCs and low percentages of CD4+ T cells
Even though the percentage of DC and T cell subsets did not significantly correlate 
with patient outcome, long PFS and OS were more likely to occur in patients with a low 
percentage of CD4+ T cells and a high percentage of CD16+ mDCs (Table S3). For patients 
with a low percentage of CD4+ T cells, the PFS rate at 18 months was 30.0% and the OS 
rate at 60 months was 17.0%, in contrast to 13.0% and 7.0%, respectively, for patients with 
a high percentage of CD4+ T cells. Furthermore, 26.0% of patients with a high percentage 
of CD16+ mDCs were free of recurrence after 18 months and 19.0% alive at 60 months, 
whereas the probability of PFS and OS for patients with a low percentage of CD16+ mDCs 
was 19.0% and 7.0%, respectively.
 
 
figure 4  Expression of MHC, co-stimulatory and co-inhibitory molecules on CD3+ T cells and 
non-immune cells in ascites. Flow cytometry gating of immune checkpoint and MHC on (A) 
CD3+ positive cells and (C) CD45- cells. Grey line represents control; black line represents CD3+ 
T cells or CD45- cells. (B) CD3+ T cells and (D) CD45- cells positive for co-stimulatory, co-inhibitory, 
and MHC molecules. Red lines indicate mean.
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Ascites-derived T cells are positive for the inhibitory checkpoint PD-1
Since the percentage of CD4+ and CD8+ T cells was not directly correlated to clinical 
characteristics of HGSC patients, we investigated the activation status of ascites-derived 
T cells. The expression of immune checkpoint markers was investigated in 10 ascites 
samples, being 6 responders and 4 non-responders, of which enough cells were available 
for further analysis. Checkpoint marker expression was analyzed on CD3+ T cells (Figure 
4A, B) and on the CD45- cell population (Figure 4C, D). 
The co-stimulatory molecule CD28 was detected on 81.6% of T cells, whereas CD40L and 
ICOS were expressed on a minority of cells, 4.8% and 8.1%, respectively. About 21.4% of 
the T cells were positive for the activation marker HLA-DR. The co-inhibitory molecule 
CTLA-4 was barely present on T cells. In contrast, the mean of PD-1 expressing cells was 
30.7%, ranging from 14-51.5% in the ascites samples. 
We also analyzed the expression of the corresponding ligands and receptors on the CD45- 
cell population in ascites. The co-stimulatory molecule CD28 competes with the co-
inhibitory molecule CTLA-4 for binding to CD80 and CD86. About 32.0% of non-immune 
cells expressed the co-stimulatory molecule CD80, whereas CD86 is only expressed by 
5.4%. The ligand for the ICOS receptor, ICOS-L, was present on 3.8% of non-immune 
cells. CD40, which binds to CD40L, was detected on 22.4.0% and HLA-ABC, important for 
antigen presentation to CD8+ T cells, was detected on 44.1% of CD45- cells. On average, 
48.8% of non-immune cells were positive for the ligand for the co-inhibitory molecule PD-
1, PD-L1, ranging from 9.1-72.3%.
Discussion
The aim of this study was to investigate whether the main DC and T cell subsets in ascites 
are correlated to clinical characteristics or patient outcome. We detected DCs and T cells 
in a majority of ascites samples. However, survival of ovarian cancer patients was largely 
independent of the amount of these cells in ascites. 
DC subsets were analyzed in the CD45+CD14- cell population. The rationale to study DCs 
is that each subset has its own characteristics and functions. Whereas BDCA-1+ mDCs 
direct the polarization of CD4+ T helper cells, BDCA-3+ DCs are potent at cross-presenting 
antigens to CD8+ T cells and, therefore, have an important role in inducing T cell responses 
against tumor cells (11). There is much debate about whether CD16+ mDCs are actual DCs 
or non-classical monocytes. Nevertheless, these cells are potent in antibody-dependent 
cellular cytotoxicity and induce T cell proliferation and we observed a trend towards 
improved survival in patients with high percentages of CD16+ mDCs (13). However, we did 
not find a correlation between mDC subsets and CD4+ or CD8+ T cells. pDCs have a strong 
pro-inflammatory function by secreting type I IFNs in response to viral infections (11). On 
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the other hand, they produce indoleamine 2,3-dioxygenase (IDO) and induce TRegs, thereby, 
dampening the immune system (11, 23). We found a positive correlation between pDCs 
and CD4+ T cells in ascites of HGSC patients. We additionally observed a trend towards 
improved PFS and OS in patients with low percentages of CD4+ T cells. Patients with a 
high percentage of CD4+ T cells had worse clinical outcome, pointing towards a regulatory 
phenotype of these cells. However, there was no significant link between the percentage 
of DC and T cell subsets in ascites and survival of HGSC patients. In contrast, clinical 
characteristics, such as complete cytoreduction, good response to primary treatment and 
chemosensitivity correlated to improved patient outcome.
Ascites is an immunosuppressive milieu, which could explain why immune cells in 
ascites are not correlated to patient outcome. We, as well as others, showed that ascites 
interferes with T cell function. This inhibition is mediated by various factors, such as lipids, 
chemokines, and by the presence of regulatory immune cells in ascites fluid (30-33). For 
example, Landskron et al. characterized the T cell population in ascites and peripheral 
blood of ovarian cancer patients. They demonstrated that activated cytokine-secreting 
TRegs were enriched in ascites (34). Furthermore, ascites contains high levels of IL-10, which 
can stimulate the expansion of the TReg population and inhibits CD8+ T cell function (35). 
Additionally, ascites affects the polarization of macrophages. IL-6 and IL-10 in ascites 
promote the differentiation of macrophages into the immunosuppressive M2 phenotype, 
which stimulates tumor cell proliferation and suppresses the effector functions of 
cytotoxic T cells (36, 37). We also detected that 30% of the T cells in ovarian cancer ascites 
were positive for PD-1. The ligand PD-L1 is present on 50% of the CD45- population, which 
contains tumor cells. The PD-1/PD-L1 axis could be a mechanism that interferes with the 
cytotoxic activity of CD8+ T cells in ascites. However, it remains to be elucidated whether 
PD-1 expression is a marker for exhaustion or activation. Next to T cells, ascites fluid may 
also inhibit the function of DCs. Recently, ascites fluid was shown to interfere with the 
activation of in vitro generated monocytes-derived DCs. Ascites reduced the expression 
of the co-stimulatory molecule CD86 and decreased the T cell stimulatory capacity (38). 
Hence, ovarian cancer ascites may effectively limit the anti-tumor immune response and, 
therefore, ascites-derived immune cells might not correlate to patient outcome. In the 
future, it might be important to assess the activation status of DC and T cell subsets in 
ovarian cancer ascites. 
So far, only a few research groups have investigated the effect of immune cells in ascites 
on the outcome of ovarian cancer patients. These studies found contradicting results and 
are partly in contrast to our own findings. For example, Giuntoli et al. showed that the 
ratio of CD4/CD8 T cells in ovarian cancer ascites is correlated to patient outcome. They 
demonstrated that patients with low CD4/8 ratios had improved survival (39), a finding 
we could not confirm. In contrast, Lieber et al. found no correlation of CD4+ or CD8+ T 
cells with patient outcome, but identified memory T cells to confer survival advantage in 
HGSC patients (40). Although not statistically significant, we observed a trend towards 
improved outcome of patients with low percentages of CD4+ T cells. The group of Bamias 
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et al. found that CD3+CD56+ cells in ascites were associated with platinum resistance (41), 
whereas we did not observe a correlation of DC or T cell subsets with platinum resistance. 
Hoogstad-van Evert et al. detected no association of CD3+ with patient outcome, but 
found NK cells in ovarian cancer associated to be correlated with improved survival (42). 
These studies used a limited number of samples or were composed of a heterogeneous 
patient population, including different epithelial ovarian cancer subtypes and material 
from before and after therapy. In this study, we tested the ascites of a well-defined group 
of patients, all being chemotherapy naïve and with diagnosed advanced-stage HGSC. 
In summary, we showed that DC and T cell subsets in ascites, in contrast to tumor 
infiltrating T cells, did not correlate with clinical characteristics or survival of HGSC 
patients. Future research needs to directly compare the immune infiltration in ascites 
and primary tumor tissue to draw conclusions on the immune environment in these two 
compartments. Furthermore, research on ascites would benefit from lager patient cohorts, 
as this would allow for more advanced statistical analysis. This requires the systematic 
biobanking of ascites, which is currently not done. Finally, homogenous patient cohorts 
are crucial to reliably correlate immune cells in ascites with patient outcome. This study 
serves as starting point for future research investigating the immune infiltrate in ovarian 
cancer ascites. 
Material and methods
Patient material
Ascites was collected from stage III or IV high-grade serous ovarian cancer patients before 
start of the treatment. The study pr otocol was approved by the regional ethics committee 
(“Commissie mensgebonden onderzoek”). Guidelines and regulations of the Radboudumc 
for collection of human material were followed. The outcome of the cytoreductive surgery 
was defined as complete (no macroscopically visible residual tumor), optimal (residual 
tumor foci ≤1 cm) or suboptimal (residual tumor foci >1 cm). Staging was based on the 
International Federation of Gynecology and Obstetrics (FIGO) staging system. Data on 
adjuvant treatment, CA-125 serum levels, recurrence and last date of follow-up were 
collected. A good response to primary treatment was defined by a normalized serum CA-
125 level, a normal physical examination and, if performed, a CT scan without evidence of 
recurrence. Patients with recurrence within 6 months after completion of chemotherapy 
were classified as having chemoresistant tumors. Progression-free survival (PFS) was 
defined as period of time (months) between last course of chemotherapy and recurrence. 
Overall survival (OS) was defined as the period of time (months) between the last course 
of chemotherapy and death or date of last follow-up. 
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Isolation of immune cells from ascites
Immune cells were isolated as described elsewhere (43). In brief, ascites was filtered over a 
100 μm cell strainer (352360, Corning, Falcon®) and centrifuged for 15 min at 1500 rpm 
and 4°C. The cell pellet was resuspended in phosphate buffered saline (PBS). Mononuclear 
cells were isolated using gradient centrifugation with LymphoprepTM (1114544, Axis-
Shield). Isolated immune cells were cryopreserved in a dimethyl sulfoxide (DMSO, 
06800001, WAK-Chemie)-containing medium.
Flow cytometry
Ascites-derived mononuclear cells were blocked for 10 min with 50 µl PBA/2% FcR 
blocking reagent (130-090-532, Miltenyi). Subsequently, cells were incubated for 30 
min with directly conjugated antibodies. The cells were washed with PBA and analyzed. 
Different panels were used for immune cell phenotyping. T cells were identified using 
antibodies against CD3, CD4, and CD8. mDCs were identified using antibodies against 
CD45, CD14, CD16, CD19, BDCA-1 (CD1c) and BDCA-3 (CD141). For pDCs, antibodies 
against CD123 and BDCA-2 (CD303) were used. Immune checkpoint expression was 
analyzed on CD3+ T cells and CD45- cells.
Antibodies
The following antibodies were used: CD3-FITC (1:25, 555339, BD Pharmingen), CD3-
BV510 (1:25, 563083, BD), CD4-APC-Cy7 (1:20, 300518, BioLegend), CD8-PerCP (1:20, 
345774, BD), CD14-APC-Cy7 (1:20, 557831, BD Pharmingen), CD16-PE-Cy7 (1:200, 
335823, BD), CD19-PerCP (1:2.5, 345778, BD), CD40-PE (1:10, IM19360U, Beckman), 
CD40-L-PE (1:10, IM2216U, Beckman), CD45-V450 (1:50, 560367, BD), CD45-FITC (1:10, 
130-080-202, Miltenyi Biotec), CD80-PE-Cy7 (1:50, 561135, BD), CD86-PE (1:10, 555658, 
BD) CD123-FITC (1:10, 130-090-897, Miltenyi Biotec), BDCA-1-PE (1:10, 130-090-508, 
Miltenyi Biotec), BDCA-2-APC (1:10, 130-090-905, Miltenyi Biotec), BDCA-3-APC (1:10, 
130-090-907, Miltenyi Biotec), CTLA-4-PE (1:5, 555853, BD), HLA-DR-BV510 (1:25, 
563083, BD), ICOS-PerCP-Cy5.5 (1:10, 562833, BD), ICOS-L-PerCP (1:5, FAB165C, R&D 
Systems), PD-1-PerCP-Cy5.5 (1:10, 561273, BD), PD-L1-PE-Cy7 (1:10, 558017, BD).
Statistical analysis
Comparisons between DC and T cell subsets were made using Pearson’s r test on Log-
transformed data. The Mann-Whitney U test was used for comparisons between 
clinicopathological characteristics and DC and T cell subset percentages. Correlations 
between immune cell populations and clinical characteristics were done using univariate 
Cox regression analysis. Correlations between immune cell populations and survival 
were analyzed using Cox regression and Kaplan-Meier survival curves (log-rank test). 
All p-values were considered significant when p<0.05. SPSS 22.0 software was used for 
statistical analyses.
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Supplementary material
supplementary table s1  Comparison of the percentage DC and T cell subsets with clinico-
pathological characteristics.
BDCA-1 BDCA-3 CD16 pDCs CD4 CD8 CD4/CD8
Cytoreduction
Complete
Not complete
1.2
2.2
0.9
0.7
3.2
2.1
2.1
2.1
42.0
53.0
36.0
28.5
1.2
1.6
CaA-125 after treatment
Normal
Elevated
1.5
2.9
0.9
0.9
3.6
4.0
2.3
2.5
43.0
53.5
35.5
28.0
1.2
1.9
Response to chemo
Chemosensitive
Chemoresistant
1.7
2.5
0.9
0.9
2.2
4.4
2.5
2.0
43.0
46.5
32.0
33.5
1.4
1.3
Response to treatment
Responder
Non-responder
1.5
2.1
0.9
0.7
2.8
2.6
2.4
2.0
44.0
52.8
35.5
30.0
1.2
1.8
 Comparison using Mann-Whitney U analysis.
supplementary table s2  Univariate Cox regression analysis on progression-free and overall 
survival.
HR: hazard ratio; CI: confidence interval; mDC: myeloid dendritic cell; pDC: plasmacytoid dendritic cell.
 Progression- free survival                 Overall survival
Variables n HR 95% CI p value HR 95% CI p value
C
lin
ic
al
 c
ha
ra
ct
er
is
ti
cs
Complete cytoreduction
   Complete 26 1 1
   Not complete 35 1.70 0.98-2.96 0.061 1.76 0.93-3.14 0.053
Response to chemotherapy
Chemo sensitive 33 1 1
Chemo resistant 28 3.56 2.98-10.32 0.002 4.80 2.60-8.84 <0.001
Response to treatment
   Responder 38 1 1
   Non-responder 22 2.76 1.56-4.90 0.001 2.16 1.19-3.93 0.011
D
C
 s
ub
se
ts
BDCA-1+ mDC 
   Low (< 1.7) 28 1 1
   High (≥ 1.7) 28 1.27 0.72-2.22 0.411 1.33 0.73-2.41 0.349
BDCA-3+ mDC 
   Low (< 0.9) 28 1 1
   High (≥ 0.9) 28 1.21 0.69-2.11 0.498 0.96 0.54-1.70 0.885
CD16+ mDC 
   Low (< 2.8) 28 1 1
   High (≥ 2.8) 28 0.87 0.50-1.53 0.644 0.68 0.38-1.21 0.190
pDC 
   Low (< 2.1) 31 1 1
   High (≥ 2.1) 31 1.09 0.65-1.85 0.737 0.76 0.44-1.31 0.318
T 
ce
ll 
su
bs
et
s
CD4+ T cell
   Low (< 45.5) 31 1 1
   High (≥ 45.5) 31 1.83 1.07-3.11 0.182 1.66 0.96-2.88 0.189
CD8+ T cell 
   Low (< 33) 30 1 1
   High (≥ 33) 32 0.72 0.42-1.21 0.215 0.78 0.45-1.34 0.369
CD4/CD8 T cell ratio
   Low (< 1.3) 31 1 1
   High (≥ 1.3) 31 1.43 0.85-2.41 0.183 1.34 0.78-2.30 0.294
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supplementary table s3  PFS and OS rate (%) for patients with a low or high percentage of DC 
and T cell subsets. 
   
PFS: Progression-free survival; OS: Overall survival. 
BDCA-1 BDCA-3 CD16 pDCs CD4 CD8
Low High Low High Low High Low High Low High Low High
PFS
≥ 12 months 30 33 33 30 26 37 23 31 40 23 23 37
≥ 18 months 22 22 22 19 19 26 17 24 30 13 17 23
≥ 24 months 22 15 19 15 11 26 17 17 30 7 10 23
OS 
≥ 48 months 26 15 15 26 11 30 20 17 23 13 13 23
≥ 60 months 26 0 11 15 7 19 10 14 17 7 7 17
≥ 72 months 19 0 11 7 7 11 10 7 13 3 3 13
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Abstract
Despite advances in therapy, ovarian cancer remains the most lethal gynecological 
malignancy and prognosis has not substantially improved over the past 3 decades. 
Immunotherapy is a promising new treatment option. However, the immunosuppressive 
cancer microenvironment must be overcome for immunotherapy to be successful. Here, 
we present a unique case of spontaneous regression of ovarian carcinoma after septic 
peritonitis. A 79-year-old woman was diagnosed with stage IIIc ovarian cancer. The 
omental cake biopsy was complicated by sepsis. Although the patient recovered, her 
physical condition did not allow further treatment for her ovarian cancer. After 6 months, 
spontaneous regression of the tumor was observed during surgery. Analysis of the immune 
infiltrate in the tissues showed a shift from a pro-tumorigenic to an anti-tumorigenic 
immune response after sepsis. Strong activation of the immune system during sepsis 
overruled the immunosuppressive tumor microenvironment and allowed for a potent 
anti-tumor immune response. More understanding of immunological responses in cases 
with cancer and septic peritonitis might be crucial to identify potential new targets for 
immunotherapy. 
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Introduction
Ovarian cancer is the most lethal gynecological malignancy. Standard of care for epithelial 
ovarian cancer patients includes surgical resection and chemotherapy with non-specific 
cytotoxic drugs. Despite advances in treatment strategies, such as more aggressive 
surgery, combination chemotherapy, intraperitoneal chemotherapy, hyperthermia and 
targeted molecular therapy, the 5-year survival rate and quality of life of ovarian cancer 
patients has not substantially improved over the past 30 years. Therefore, new therapeutic 
approaches are needed. Immunotherapy and immune modulation are promising 
treatment options. However, the immunosuppressive ovarian cancer microenvironment 
must be overcome for successful immunotherapy (1, 2).
We hereby present a unique case of spontaneous regression of a histologically confirmed 
FIGO stage IIIC serous papillary ovarian carcinoma after a septic peritonitis. The rare 
phenomenon of spontaneous regression and recovery of cancer after sepsis has been 
described in several cancer types over the past centuries, including embryonal and breast 
cancer, renal adenocarcinoma, neuroblastoma, melanoma, and sarcoma or carcinoma 
of the urinary bladder, but not in ovarian cancer (3). The mechanisms for spontaneous 
regression of cancer are not clear but the remissions are often associated with concurrent 
bacterial, fungal, viral or protozoan infections. The most commonly reported symptom 
wherein spontaneous regression is registered is an acute febrile state that is evoked by 
either natural or induced acute infection (4).
Septic peritonitis includes inflammation of the peritoneum that can be caused by 
microorganisms. It is a life-threatening condition that requires hospitalization, 
resuscitation and close monitoring to prevent systemic spread, which might lead to 
organ failure. The strong activation of the immune response within the peritoneal 
cavity during sepsis involves both the innate and adaptive immune system. The host 
inflammatory response consequent to initial exposure to pathogens is often followed 
by anti-inflammatory forces and these responses are immunologically highly complex 
and not completely understood (5-7). Information on septic peritonitis and spontaneous 
regression of ovarian cancer is even more scarce. More understanding of immunological 
responses in cases with cancer and septic peritonitis might be crucial to identify potential 
new targets for immunotherapy in the future.
Case
A 79-year-old woman with an increasingly distended abdomen, fatigue and dyspnoea was 
referred to a secondary clinic in the Netherlands. During primary workup with CT-scan, an 
enlarged ovary and extensive ascites with omental cake were demonstrated. In addition, 
the serum marker CA-125 was elevated (808 kU/L). Based on histopathological results 
of an omental biopsy and prior aspiration of ascites, the diagnosis of stage IIIC epithelial 
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ovarian cancer was established. Unfortunately, the biopsy was complicated by a septic 
peritonitis with fever up to 39.8°C for which she was admitted to the intensive care unit and 
was treated accordingly. Differential diagnosis involved intra-abdominal contamination or 
bowel puncture/injury during the biopsy procedure. Although the patient recovered, her 
physical condition afterwards did not allow a surgical debulking procedure or neoadjuvant 
chemotherapy. She was discharged from the hospital with palliative comfort care. 
Six months later, she was referred to our hospital for a second opinion as she was in a 
good physical and mental condition. During physical examination she did not show signs 
of lymphadenopathy, ascites or an abdominal mass. The serum marker CA-125 was normal 
(10 E/mL). An additional CT-scan demonstrated no pulmonary or pleural abnormalities 
and no signs of lymphadenopathy. Both the left ovary (42 × 24mm) and the right ovary (23 
× 11mm) were slightly enlarged. There were no signs of free fluid, ascites, omental cake, 
peritonitis carcinomatosis, or other abnormalities.
An uncomplicated laparoscopic bilateral salpingooophorectomy was performed including 
peritoneal biopsies and a partial omentectomy along with free fluid collection from the 
pouch of Douglas. Intraoperative findings showed an enlarged left ovary, without further 
residual tumor deposits intra-abdominally. In concordance with the prior omental biopsy, 
a high-grade serous carcinoma was noted within the left ovary. There were no tumor 
deposits detected in the right ovary, the omentum or in any of the other biopsies. After 
counseling, the patient opted for expectant management and did not receive adjuvant 
systemic chemotherapy. To date, 42 months after diagnosis, she shows no signs of 
recurrent or progressive disease with a serum CA-125 at 11.0 E/mL.
We conclude that this patient represents a very rare case, and the only case described 
in literature, of spontaneous regression of a histologically confirmed stage IIIC ovarian 
carcinoma after a septic peritonitis. Since we were interested in the immunological 
mechanisms at play in our patient, we set out to study this further.
Results
Multiplex immunohistochemistry was used to visualize the tumor-infiltrating 
lymphocytes (CD3, CD8, Foxp3) (8) and macrophages (CD68, CD163) (9) and to quantify 
the infiltrating immune cells in the omental cake biopsy taken before sepsis and in the 
carcinoma resected 6 month after sepsis. Untreated primary tumors from stage III and 
IV high-grade serous ovarian cancer patients that did not suffer from sepsis were used as 
a control. Sections were stained using an automated imaging system and the cell ratios 
were calculated. The biopsy (before sepsis) was highly infiltrated by effector CD8+ T cells, 
as well as Foxp3+ regulatory T cells (TRegs) (Figures 1A,bB). In contrast, the number of 
infiltrating TRegs was decreased in the carcinoma (after sepsis). Overall, there was a shift 
in the CD8/TReg ratio (Figure 1C), which was accompanied by a decrease in the Foxp3 
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staining intensity (Figure 1D). Before the sepsis, the ratio was comparable to the mean 
of the control tumors. After the sepsis, the CD8/TReg ratio increased, indicating that the 
carcinoma contained relatively more effector CD8+ T cells compared to TRegs. The biopsy 
and carcinoma were also stained for macrophage markers. Macrophages can acquire a 
M1 (CD68+CD163−) or M2 (CD68−/+CD163+) phenotype, having anti- or pro-tumorigenic 
effects, respectively (10). Whereas the biopsy contained high numbers of M1 and M2 
macrophages, the presence of M2 macrophages was markedly decreased after sepsis in 
the carcinoma (Figures 1A, B). Before sepsis the M1/M2 ratio was at the lower end of the 
spectrum of control tumors, whereas after the sepsis it was higher than the ratio of control 
tumors (Figure 1C). The staining intensity for CD163+ M2 macrophages was decreased 
after the sepsis (Figure 1D). These results point toward a decrease of immunosuppressive 
cells in the tumor microenvironment after sepsis. 
figure 1  Multiplex IHC on tissue before and after sepsis. (A) Images showing T cell infiltration 
and macrophage infiltration in tissue before (omentum biopsy) and after (tumor resection) sepsis. 
CKAE1/AE3 was used to visualize tumor cells. Effector T cells were characterized as CD3+CD8+, 
TRegs as CD3+Foxp3+, M1 macrophages as CD68+, and M2 macrophages as CD163+. (B) CD8+ T cells, 
TRegs, M1 and M2 macrophages per mm2. Immune cells were quantified in control tissue, and in 
tissue obtained before and after sepsis. (C) CD8 effector T cell/TReg ratio and M1/M2 ratio before 
and after sepsis. (D) Average staining intensity of immune cell markers before and after sepsis. 
Unstained tissue was used as control. Untreated primary tumor from stage III and IV ovarian 
cancer patient were used as control (n = 16). Red line indicates mean.
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Discussion
More than 60-80% of ovarian cancer patients are diagnosed at an advanced stage due 
to the lack of symptoms and adequate screening methods. The 5-year survival rates 
in stage III and IV ovarian cancer are ~35 and ~15%, respectively. Ovarian cancer is an 
intra-peritoneal disease, which tends not to metastasize outside the peritoneal cavity. 
Current treatment for advanced disease consists of cytoreductive surgery combined with 
chemotherapy. Despite the good initial response to primary therapy around 70–85% of 
the patients with advanced stage of disease develop recurrence and eventually die.
Research has shown that the immune system plays an important role in ovarian cancer 
progression and is able to influence clinical outcome. Activation of the immune system 
requires presentation of antigen by antigen-presenting cells (APCs) to T cells. The 
cytotoxic effects are driven by a combination of T-lymphocyte activity, antibody-dependent 
mechanisms, and natural killer (NK) cell activation. Most tumors are in some way recognized 
by the immune system as tumor infiltrating lymphocytes (TILs) have been observed within 
and around the tumor tissue in a variety of different cancers. In ovarian cancer, a high 
number of TILs in the tumor are associated with a favorable clinical outcome (1).
However, ovarian cancer can escape the immune system via various mechanisms: 1) 
evasion of immune recognition; 2) secretion of immune suppressive factors; and 3) 
recruitment of immune suppressive cells (1, 11). TRegs and M2 macrophages in the ovarian 
cancer microenvironment are able to inhibit the anti-tumor response of cytotoxic T cells, 
either by secretion of immunosuppressive cytokines like IL-10 and TGF-β or via a cell-cell 
contact-dependent mechanism. Accumulation of TRegs at the tumor site is associated with 
reduced survival of ovarian cancer patients (1, 11). Immunotherapy needs to overcome the 
immunosuppressive tumor microenvironment to evoke an effective anti-tumor immune 
response.
Different immunotherapeutic strategies can be used to boost the anti-tumor immune 
response, including vaccination with tumor-specific dendritic cells, adoptive T cell therapy 
and immune checkpoint blockade (12-15). Several clinical trials are currently investigating 
the safety and feasibility of these approaches in ovarian cancer. Two phase 1 studies 
showed that DC vaccination (using whole-tumor lysate) alone or in combination with 
bevacizumab or cyclophosphamide was safe, well tolerable and effective in eliciting 
a broad anti-tumor immune response in patients with recurrent ovarian, fallopian tube 
or peritoneal cancer (16, 17). Immunotherapy using ex vivo expanded tumor-infiltrating 
lymphocytes or genetically engineered T cells also demonstrated feasibility and safety in 
platinum-resistant or recurrent ovarian cancer with manageable toxicities (18-20).
The inhibition of immune checkpoints has shown great success in the treatment of 
melanoma patients and, therefore, data on ovarian cancer are eagerly awaited. Antibodies 
against CTLA-4 (ipilumumab), PD-1 (nivolumab, pembrolizumab), and PD-L1 (avelumab, 
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durvalumab) are currently tested in clinical trials and seem to be well tolerated by ovarian 
cancer patients (21, 22). For example, a phase II study for nivolumab in patients with 
platinum-resistant ovarian cancer showed partial response and stable disease in 20 and 
25% of the patients, respectively. Their overall disease control rate in 20 patients was 45% 
with grade 3 or 4 treatment-related adverse events occurring in eight (40%) patients (23). 
Others showed that pembrolizumab and avelumab in phase 1 clinical trials were very well 
tolerated, with an acceptable safety profile and with durable antitumor activity in patients 
with advanced ovarian, fallopian tube or peritoneal cancer. Regarding treatmentrelated 
adverse events after treatment with pembrolizumab, 73.1% of the patients had grade 
1–2 adverse events with only one grade 3 adverse event (22). For avelumab, grade 3 or 
4 treatment-related adverse events occurred in 10.2% (25–27) (24-26). Currently there are 
two other phase 2 clinical trials underway to determine the safety, feasibility and efficacy 
of durvalumab (anti-PD-L1) and ipilimumab (anti-CTLA-4) in first-line neo-adjuvant 
setting for ovarian cancer (combined with chemotherapy), or as monotherapy in recurrent 
platinum sensitive ovarian cancer, respectively. These results are expected in 2019 and 
2021.
Although these data might seem promising, many of the clinical trials are ongoing and 
progress in the development of these highly specific immunotherapeutic approaches to 
ovarian cancer treatment is slow and a crucial clinical break-through is still missing.
Sepsis induces a hyperactive immune system in response to invading pathogens (27). 
Immune cells are activated by the recognition of pathogen-associated molecular patterns 
(PAMPs) that are present on microorganisms (28). This group of various pathogens, which 
among others include lipopolysaccharides (LPS), a component of bacterial cell walls, 
interact with Toll-like receptors (TLRs) on various immune cells (T lymphocytes, DCs 
and neutrophils). Binding of the TLRs by PAMPs induces activation of dendritic cells and 
cytotoxic T cells, leading to a highly improved pro-inflammatory response that is able to 
clear the invading pathogens. Sepsis not only stimulates the adaptive immune response 
but it also activates innate immune cells, such as granulocytes and macrophages. We 
detected a shift in the CD8+ effector T cells/TReg ratio and M1/M2 ratio when comparing the 
immune cell infiltrate before and after sepsis. These results indicate that sepsis is able to 
overrule the immunosuppressive tumor microenvironment, inducin g a long-lasting anti-
tumor immune response that is still detectable 6 months after the sepsis. Non-specific 
activation (e.g., natural or induced acute infection) of the innate immune system may 
critically support the initiation of a functional specific immune response against cancer.
The hyperactive immune response is accompanied by fever. A febrile state enhances 
the cytokine secretion of immune cells with an increase in proinflammatory cytokines. 
Furthermore, cancer cells aremore fragile and vulnerable to heat with apoptosis taking 
place at lower temperatures compared to normal cells. Necrotic or heat-stressed cancer 
cells can function as antigens or PAMPs and thereby generate an immune-stimulating 
environment (29). Recently, in patients with metastatic melanoma treated with 
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immunotherapy, fever of 39.5°C or above was an independent factor for improved survival 
and objective tumor response (30).
The use of bacteria, fungi, or components thereof might be a promising path for non-
specific immunotherapy against tumors and might be a helpful adjuvant for specific 
immunotherapy. The choice of pathogen or PAMP is essential in this scenario. For example, 
activation of TLR-4 by LPS or its derivates drives macrophage polarization toward an M1 
pro-inflammatory phenotype (31). Hence, TLR-4 agonists could be used to target tumor-
associated macrophages that counteract anti-tumor immunity. However, since in vitro 
studies have shown that TLR-4 on ovarian cancer cells promotes cell proliferation and 
survival, more research is needed to investigate the use of TLR- 4 agonists (32, 33). The 
severity of the hyperactive immune response is amongst others determined by pathogen-
load and virulence factor. If the activation of the immune system is too strong, organ 
failure and death may occur. On the other hand, if activation of the immune system is not 
strong enough, the immunosuppressive tumor microenvironment may not be overcome 
(34, 35). In addition to modern antigen-specific antibody- and vaccine-based immunologic 
cancer therapies, non-specific immunotherapies might serve as an ideal tool. More insight 
in the interaction between ovarian cancer and the immune system is needed to develop 
effective anti-tumor immunotherapy. We believe that non-specific activation of a broad 
immune response could tilt the balance from an immune suppressive to an immune active 
environment. This could have an impact on ovarian cancer treatment. Can we boost the 
immune system using bacterial or fungal components to evoke a potent and long-lasting 
anti-tumor immune response?
Material and methods
Institutional and ethical approval
This study was carried out in accordance with the recommendation of the “Code of 
conduct for responsible use of human tissue”, established by the Federa (Federation of 
Dutch Medical Scientific Societies). The study was officially deemed exempt from medical 
ethical approval. A signed consent form was obtained from the patient described in this 
case report. Anonymous rest material was used as control tissue. The experiments were 
carried out in accordance with the guidelines and regulations of the Radboudumc. Criteria 
for ovarian cancer regression were based on clinical data, such as normalization of CA-125 
serum levels, normal physical examination, no abnormalities on imaging (ultrasoun/CT/
MRI) and tumor-free biopsies evaluated by a pathologist.
Multiplex immunohistochemistry
Multiplex immunohistochemistry was performed using sequential staining cycles as 
described elsewhere (36). In brief, tissue sections of 4 µm were cut form FFPE tissue. 
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Sections were deparaffinized in xylene, rehydrated and washed in tap water. Sections were 
stained with a T cell panel and macrophage panel. T cell panel: CD3 (RM-9107, Thermo 
Fisher), CD8 (M7103, Dako), Foxp3 (14-4777, eBioscience Affymetrix). Macrophage panel: 
CD68 (M087601, Dako), CD163 (CD163-L-CE, Leica). Both panels contained CKAE1/AE3 
(ab86734, Abcam) to visualize tumor cells. Heat mediated antigen retrieval was performed 
in citrate. Protein block was performed with TBS-Tween containing 1 % BSA. Primary 
antibodies were incubated for 1 hour at room temperature. Sections were incubated 
with BrightVision poly-HRP-anti-MS/Rb/Rt IgG (DPVO999HRP, ImmunoLogic) for 30 
min, followed by visualization with the Opal color IHC kit (NEL801001KT), PerkinElmer). 
A second antigen retrieval step with citrate or Tris-EDTA was performed to remove the 
antibody-TSA complex and to continue with the next staining cycle. Tissue sections were 
counterstained with DAPI and mounted in Fluoromount-G (0100-01; SouthernBiotech).
Imaging and analysis
Tissue slides were imaged with the PerkinElmer Vectra system (Vectra 3.0.3, Perkin 
Elmer). InForm software (Version 2.2.1, PerkinElmer) was used for image analysis. Spectral 
libraries were built from single stains and used to unmix multispectral images. 
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The immune environment in ovarian cancer
High-grade serous ovarian cancer (HGSC) and its surrounding microenvironment are 
infiltrated by a variety of immune cells. These cells form an interactive network that 
influences tumor progression and metastasis by exerting anti-tumorigenic or pro-
tumorigenic functions (1, 2). 
The presence of tumor-infiltrating CD8+ T cells is associated with improved survival of 
HGSC patients (3). CD8+ T cells possess cytotoxic activity and kill tumor cells when they 
recognize an antigen presented by MHC class I molecules (4). However, ovarian cancer 
creates an immunosuppressive microenvironment that interferes with the function 
of CD8+ T cells (Figure 1). For example, tumor cells attract regulatory T cells (TRegs) by 
secretion of CCL22 or mediate the expansion of the existing pool of TRegs (5). TRegs inhibit 
the cytotoxic function of CD8+ T cells via contact-dependent mechanisms and secretion of 
suppressive cytokines, such as IL-10 (6, 7). Hence, high numbers tumor-infiltrating Foxp3+ 
TRegs and a high CD4/CD8 ratio are correlated with worse patient outcome in ovarian 
cancer (3, 5). 
figure 1  Immunosuppressive tumor microenvironment in ovarian cancer. Tumor-specific CD8+ 
T cells kill cancer cells when they recognize an antigen presented by MHC class I. However, ovarian 
cancer cells secrete cytokines that attract and induce immunosuppressive cells, thereby inhibiting 
the function of CD8+ cytotoxic T cells. The chemoattractant CCL22 recruits regulatory T cells 
(TRegs) to the tumor, which block the function of CD8+ T cells via contact-dependent mechanisms 
and secretion of immunosuppressive cytokines, such as IL-10. DCs downregulate MHC and co-
stimulatory molecules in response to IL-10 and TGF-β. Dysfunctional DCs stimulate the expansion 
of the TReg pool. Secretion of IL-6 and IL-10 by ovarian cancer cells converts macrophages to tumor-
associated macrophages (TAMs). TAMs are immunosuppressive and upregulate the surface 
molecule B7-H4 in the presence of IL-10. The immune checkpoint molecule B7-H4 negatively 
regulates CD8+ T cell activation and proliferation. 
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Furthermore, tumor-associated macrophages (TAMs) in the tumor-microenvironment 
interfere with T cell function. Macrophages can be divided into classically activated 
M1 macrophages and alternatively activated M2 macrophages, having anti- or pro-
tumorigenic functions, respectively (8). TAMs in ovarian cancer resemble M2 macrophages 
and upregulate the immune checkpoint molecule B7-H4 in response to IL-10. B7-H4 
negatively regulates the activation and proliferation of CD8+ T cells (9, 10). A high density of 
CD163+ M2 macrophages and a higher ratio of M2/M1 macrophages are associated with 
poor prognosis in ovarian cancer patients (11). 
Ovarian cancer is also infiltrated by dendritic cells (DCs), which are the best antigen-
presenting cells in our body and able to induce a potent T cell response. However, their 
activation and maturation in the tumor microenvironment is inhibited. Tumor cells 
and TRegs secrete IL-10 and TGF-β, resulting in dysfunctional or tolerogenic DCs. Tumor-
associated DCs have a decreased expression of MHC and co-stimulatory molecules, 
upregulate PD-L1 and secrete immunosuppressive cytokines. Dysfunctional DCs inhibit 
the function of CD8+ effector cells and mediate the expansion of TRegs, thereby contributing 
to an immunosuppressive microenvironment (12-14).
The above-mentioned studies indicate that ovarian cancer is an immunogenic tumor 
and that boosting the pre-existing anti-tumor immune response could be a potential 
therapeutic approach. Currently, the standard treatment for ovarian cancer consists 
of cytoreductive surgery and chemotherapy. Even though most patients respond well 
to first line treatment, about 70% get disease relapse within 18 months (15-17). Recent 
advances in treatment, such as (hyperthermic) intraperitoneal chemotherapy, were able 
to increase overall survival rates, but did not improve cure (18-20). A strong anti-tumor 
immune response could provide long-term control of tumor cells. However, effective 
immunotherapy needs to overcome the immunosuppressive mechanisms in the tumor 
microenvironment. Therefore, understanding of the interaction of immune cells and 
cancer cells is needed. In this thesis, the role of the immune system in ovarian cancer 
development and progression has been investigated. 
The immune response in ovarian cancer precursor lesions
Due to an asymptomatic early stage, most ovarian cancer patients are diagnosed in stage 
III or IV (21). Therefore, little is known about the early steps of HGSC development. Over 
the last decade, our knowledge on the origin of HGSC has greatly advanced. Precursor 
lesions of pelvic HGSC have been identified in the fimbriated end of the fallopian tube, 
progressing from p53-signatures to STILs and STICs, which develop into cancer (22). 
However, whereas p53-signatures are commonly found in healthy women with and 
without BRCA mutation, STICs are only occasionally detected in healthy non-mutation 
carriers, but often present in patients with HGSC (23-25). This raises the question whether 
the steps of tumor development are the same in women with and without BRCA mutation. 
Recent exome-wide sequence and structure analysis of ovarian cancer precursor lesions 
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and HGSC in five patients without a genetic predisposition showed that p53-signatures 
indeed progress to STICs, which gives rise to HGSC. The genetic alternations present in 
p53-signatures were also identified in STICs and HGSC. STICs carried de novo mutations 
that were not present in p53-signatures, and HGSC contained mutations that could not 
be identified in STICs. This strengthens the hypothesis of malignant transformation of the 
fallopian tube epithelium (26). Nevertheless, more research is needed to confirm the data 
described above. 
figure 2  Development of high-grade serous ovarian cancer is accompanied by T cell infiltration. 
High-grade serous cancer (HGSC) develops in the fimbriated end of the fallopian tube. (A) The 
malignant transformation of the fallopian tube epithelium starts with a mutation in TP53, called 
p53-signature, that have a morphological normal appearance. Over time, p53-signatures acquire 
more mutations and progress into serous tubal intraepithelial lesions (STILs), showing first signs 
of cellular atypia. STILs develop into serous tubal intraepithelial carcinoma (STICs). STICs have 
evident cellular atypia but do not invade the basal membrane. STICs develop into HGSC, which 
spreads throughout the peritoneal cavity. (B) The malignant transformation is accompanied by a 
gradual increase in T cell infiltration. Whereas T cells are absent in p53-signatures and STILs, they 
are present in 50% of STICs and in almost all HGSC to variable extend.
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Most research has focused on the role of the immune system in HGSC and information 
on the immune response in precursor lesions is scarce. It was shown that about 50% 
of the STICs are infiltrated by immune cells, whereas no infiltrate was detected in p53-
signatures and STILs (27). Since T cells play an important role in HGSC, we used multiplex 
immunohistochemistry, followed by automated whole-slide image analysis to investigate 
the T cell infiltrate in ovarian cancer precursor lesions. This allowed us to analyze T helper 
cells, cytotoxic T cells, and TRegs. We detected an increase in the T cell density from normal 
fallopian tubes to STIC and HGSC (Figure 2). This increase was most pronounced in the 
TReg population, with HGSC having a significantly higher TReg density than normal fallopian 
tubes and STICs. This indicates that there is a gradual increase in immunosuppressive 
cells in the microenvironment during the malignant transformation from STIC to HGSC. 
We furthermore observed a change in location of the infiltrating immune cells. In 
normal fallopian tubes, most T cells were located in the epithelium, whereas there was 
no difference between the stromal and epithelial compartment in STICs. In contrast, 
in HGSC, the majority of T cells was identified in the stromal compartment. Changes 
in the stroma and extracellular matrix may capture cytokines and signaling molecules 
that inhibit cells from invading the tumor tissue, thereby preventing T cells from killing 
ovarian cancer cells (28). 
Although our results shed some light on the immune response in ovarian cancer 
precursor lesions, further analyses are needed to obtain a more detailed understanding 
of the immune response in STIC and HGSC. Comparing the T cell infiltrates in STICs from 
different patients and multifocal STICs from the same patients, and comparing T cell 
infiltration in STIC and paired HGSC, could give important insights in the dynamic changes 
of the anti-tumor immune response. Clustering analysis could provide answers to these 
questions, showing whether infiltrate of individuals or infiltrates of STIC and HGSC are 
more similar. Additionally, the distance between immune cells could be calculated. For 
example, not only the presence of TRegs, but also their distance to CD8+ cytotoxic T cells 
might be an important factor in the tumor microenvironment. If TRegs and CD8+ T cells are 
in close proximity this may hint at TReg-mediated suppression of effector T cells.  
Performing these analyses requires refinement of the data processing pipeline. So far, cell 
segmentation and cell phenotyping were performed using inForm, but we encountered 
several problems. First, while inForm adequately discriminates between stromal and 
tumor regions, the segmentation of individual cells is error-prone. Therefore, cells are 
hypo- or hypersegmentend, falsifying cell numbers. Second, phenotyping of cells requires 
training of an algorithm to recognize the different subsets. Since InForm only recognizes 
the cell types that it is trained for, the user decides on thresholds for positive cells. Rare 
cell types can be easily missed and training an algorithm to detect these populations is 
hard, as examples are scarce. Hence, this can result in biased analyses. 
To circumvent these problems, readjustment of the analysis pipeline is highly 
recommended. A possible alternative to cell phenotyping with inForm is data analysis of 
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pseudo-FACS plots. Since the location of each cell is known, the images can be converted 
to FACS plots, allowing analysis with FlowJo. We assumed that looking at the entire 
cell population would make it easier to define negative and positive cell populations. 
However, due to the erroneous cell segmentation, discrimination of cell populations is 
difficult. Therefore, improving cell segmentation is crucial to improve data analysis. 
The open source program CellProfiler (http://cellprofiler.org/) could be an alternative 
to cell segmentation with inForm (29). CellProfiler provides more options to adjust cell 
segmentation and can be fine-tuned to get the best results for the tissue to be analyzed. 
Additionally, the phenotypes present in STICs could be determined using t-distributed 
stochastic neighbor embedding (t-SNE). T-SNE analysis is a machine learning algorithm 
to visualize clusters based on their similarity. This is an unbiased approach to identify the 
cell types present in tissues and could indicate which phenotypes are most interesting for 
further analysis (30). 
So far, our study shows that the immune system is already involved in the early steps of 
HGSC development and may serve as starting point for understanding the immunological 
changes during malignant transformation. Improving the image analysis pipeline is 
crucial to further analyze the immune response in precursor lesions and required for the 
correlation of immune infiltration with clinical aspects. Additionally, investigating the 
presence of other immune cells, such as NK cells and macrophages, and analyzing the 
properties of precursor lesions, including mutational changes, may help to determine 
which precursor lesions give rise to HGSC.
Lipid mediators in ascites dampen the anti-tumor immune response and 
promote metastasis
Progression of HGSC is often accompanied by malignant ascites. The accumulation of fluid 
within the peritoneal cavity is the result of increased vascular permeability, obstructed 
lymphatics, and secretions from tumor cells, immune cells and stromal cells. Therefore, 
ascites contains chemokines, cytokines and other soluble factors that can modulate tumor 
growth, as well as the anti-tumor immune response (31, 32). 
Lipids are major constituents of cellular membranes, an important source of energy, and 
can directly act as intracellular signaling molecules. Therefore they can regulate cellular 
processes, such as cell proliferation, differentiation and migration (33). We detected 
a different lipid metabolite profile in malignant ascites compared to normal abdominal 
fluid. The upregulated lipid mediators in ovarian cancer ascites could promote the 
intraperitoneal dissemination of cancer cells by interfering with anti-tumor immunity (34). 
The top upregulated lipid metabolites were derivates from linoleic acid and arachidonic acid. 
Lipoxygenases (LOX) and cyclooxygenases (COX) mediated the formation of lipid mediators. 
Alternatively, they can be produced via non-enzymatic hydrolysis. Linoleic acid and α-linoleic 
acid are essential n-3 polyunsaturated fatty acids that can only be obtained from the diet. 
CHAPTER 8 
152
Linoleic acid is converted to octadecanoids (HPODE, HODE, OxoODE), whereas α-linoleic 
acid is transformed into eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and 
decasopentanoic acid (DPA). EPA generates hydroxyeicosapentaenoic acids (HPEPE, HEPE) 
and DHA is transformed into docosanoids (HDHA, resolvins, neuroprotectins, maresins). 
LOX enzymes mediate the conversion of arachidonic acid to hydroxyeicosatetraenoic acids 
(HETE, HPETE, OxoETE), whereas COX enzymes generate eicosanoids (33, 35). 
We have observed that the lipid metabolite 9-HODE in ascites fluid inhibited the 
proliferation of lymphocytes. Since ascites contains a variety of lipid mediators, it may 
also affect other immune cells and tumor cells. For example, incorporation of 5-HETE 
into the membrane of neutrophils enhances secretion of IL-8, while inhibiting formation 
of neutrophil extracellular traps (NET) (36). Furthermore, lipid mediators can act as 
direct signaling molecules. 5-HETE promotes proliferation of prostate cancer cells and 
12-HETE stimulates secretion of VEGF to promote neovascularization in the tumor 
microenvironment (37-39). The lipid mediators 9-HODE, 13-HODE and 15-HETE can 
directly activate the nuclear receptor PPARγ (40). Activation of PPARγ influences the 
function of various immune cells, including DCs, T cells and neutrophils (41). For example, 
PPARγ activation is involved in DC maturation and migration by regulation of CCR7 
(42). Furthermore, the eicosanoids prostaglandin E2 (PGE2) and LTB4 promote tumor 
progression by immunosuppression and induction of angiogenesis (43, 44). However, we 
did not find elevated concentration of these lipid mediators in malignant ascites. 
So far, the complex signaling network of lipid mediators in HGSC is not yet understood. 
Many of the underlying mechanisms by which fatty acids and lipid mediators influence 
cancer progression and anti-tumor immunity remain to be elucidated. Nevertheless, the 
data described above indicate that lipid metabolism plays an important role in HGSC 
progression.
Survival of ovarian cancer patients is independent of the immune cells 
present in ascites
The amount of tumor-infiltrating immune cells before the start of treatment seems to be 
an important predictor for the success of immunotherapy (45). In ovarian cancer, ascites 
could serve as liquid biopsy and replace the need for tumor tissue to determine the 
immune status of patients. From a clinical point of view that would be a great benefit since 
collecting ascites is less invasive.
Ascites has been considered to be a reflection of the immune response in the tumor 
microenvironment. However, our data suggest that this might not be entirely true. For 
HGSC it is known that higher numbers of tumor-infiltrating CD8+ T cells are associated 
with improved patient survival, as is a low CD4/CD8 T cell ratio (46-48). We could not 
confirm these findings in ascites from 62 HGSC patients. There was no significant 
correlation between DC and T cell subsets and survival of HGSC patients, although we 
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observed a trend towards improved patient outcome in patients with a low percentage 
of CD4+ T cells. Several groups have investigated the immune infiltrate in ascites, but 
found contradicting results. The group of Lieber et al. found a correlation between 
memory T cells and improved survival, but not for CD4+ or CD8+ T cells (49). Bamias et 
al. identified CD3+CD56+ cells to be associated with platinum resistance. There was no 
correlation between other immune cells and patient characteristics or survival (50). It is 
questionable whether these results are true or caused by the small sample size and mixed 
ovarian cancer subtypes. Nevertheless, the data from our study indicate that ascites has a 
different immune environment compared to primary tumor tissue. Further research needs 
to explore whether this is also true for other immune cells, such as macrophages or NK cells. 
Several reasons could account for the discrepancy between primary HGSC tissue and 
ascites. HGSC development is a slow process that spans a period of about 7 years (26). This 
means that immune cells have lots of time to be recruited to the tumor microenvironment. 
In contrast, there might be much difference in the time it takes for malignant ascites to 
accumulate. Rapidly produced ascites may rather contain immune cells that are washed 
off from the periphery of the tumor, whereas ascites that is formed slowly may actively 
recruit immune cells. However, little is known about the actual time frame that is needed 
for ascites to accumulate in the abdomen. Another reason for the difference might be the 
origin of immune cells. Ascites fluid can contain immune cells from the tumor, from blood, 
or from both. Since it is not possible to discriminate between tumor-associated and blood-
derived immune cells, interpretation about what the presence of immune cells in ascites 
mean is difficult. Further, as described above, we and others have shown that ascites is 
an immunosuppressive environment. The mere presence of immune cells might not be 
sufficient to predict treatment outcome or survival. Instead, investigation of the activation 
status of DCs and T cells could give important additional information on the functional 
orientation of immune cells. 
In the future, research on ascites fluid would benefit from larger patient cohorts, as 
this would allow for better statistical analysis. While ascites is routinely removed for 
diagnostic purposes and to alleviate associated symptoms, it is barely stored in biobanks. 
Furthermore, results obtained from ascites fluid should be interpreted with caution, as 
these results may not be extrapolated to primary tumor tissue. To conclude, ascites fluid 
is not per se a reflection of the tumor and its microenvironment, but is worth researching 
since it plays an important role in abdominal spread of disease.
Implications for immunotherapy 
The immune system is involved in the formation of ovarian cancer precursor lesions, as 
well as in HGSC progression. This stresses the possibility to use immunotherapy as a new 
treatment modality. 
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Clinical trials for ovarian cancer are often performed with patients suffering from epithelial 
cancer. However, epithelial ovarian cancer can be subdivided into clear cell cancer, 
mucinous cancer, endometrioid cancer, low-grade cancer and high-grade serous cancer. 
These subtypes differ in morphology, the cellular origin and the mutations that drive 
tumorigenesis, which can result into different treatment responses. Clinical trials should 
stratify patients with different subtypes of epithelial ovarian cancer (51). Additionally, 
HGSC seems to have several phenotypes, being mesenchymal, immune, differentiated, 
and proliferative (52, 53). Each of these phenotypes may require a different therapeutic 
approach. Stratification of the patients could add valuable information about which 
figure 3  Treatment strategy for ovarian cancer. (A) Multiplex immunohistochemistry could be a 
suitable technique to investigate the immune infiltrate in cancer biopsies. The density of infiltrating 
immune cells, their location and functional orientation could be used to establish an immunoscore. 
This information could help to identify patients that would most likely benefit from immunotherapy 
and may aid to choose the best immunotherapeutic approach. (B) Surgery and chemotherapy are 
the standard treatment for ovarian cancer patients and effectively reduce tumor size. However, 
not all cancer cells are removed by chemotherapy or surgery, which can result in disease relapse. 
(C) Immunotherapy could be used to eradicate remaining tumor cells in the peritoneal cavity. If 
checkpoint molecules are expressed, their signaling could be inhibited by the use of monoclonal 
antibodies. For example, blocking of CTLA-4 and PD-1 on T cells could result in prolonged T cell 
activation. Furthermore, PD-L1 could be inhibited, which is expressed on cancer cells and immune 
cells. If large amounts of tumor-infiltrating T cells are present, they could be isolated and ex vivo 
expanded to re-inject tumor-specific T cells. Alternatively, vaccination approaches could be used. 
Tumor-specific antigens, tumor cell lysate, DNA or microorganisms can be directly injected into the 
patient to generate an anti-tumor immune response in vivo. Furthermore, isolated DCs can be ex-vivo 
loaded with tumor- or CSC-specific antigens. An advantage of the vaccination strategy is that it can 
induce immune memory, resulting in long-lasting protection. 
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treatment options are most suitable for the different subtypes. Since some subtypes are 
rare, collaboration of research teams is essential.
Another important aspect is the establishment of an immunoscore for ovarian cancer. 
Research on colon cancer has shown that an immunoscore can provide a reliable estimate 
of the risk of recurrence (54). The immunoscore is based on the type of infiltrating immune 
cells, their density and location (55). So far, there is no consensus on how to classify immune 
infiltrates in ovarian cancer. Since we and others showed that ovarian cancer ascites has 
a different immunologic response, primary tumor tissue should be used to determine the 
immunoscore. 
The immunoscore in colon cancer is calculated by image analysis of standard immuno-
histochemistry stainings (56). Multiplex fluorescent immunohistochemistry on primary 
HGSC could be a new and suitable method to quantify tumor-infiltrating immune cells. 
As shown in chapter 3, this method is a powerful tool for automated, high-resolution, 
whole-slide imaging of paraffin-embedded tissue. Since it allows the visualization of up 
to six markers at the same time, infiltration of multiple immune cells or their functional 
orientation can be investigated. This may provide valuable information on the immune 
response in ovarian cancer and may help to identify patients that will most likely benefit 
from immunotherapy.
The choice of immunotherapy and target
Ovarian cancer patients respond well to first line treatment, consisting of cytoreductive 
surgery and chemotherapy that effectively reduce tumor size. However, many patients 
suffer from disease recurrence, indicating that not all tumor cells were removed. 
Immunotherapy uses the body’s own immune system to fight cancer and could help to 
eradicate cancer cells that were missed by first line therapy. Different treatment strategies 
are applied to elicit a potent anti-tumor immune response, including antibodies, adoptive 
cell therapy, and cancer vaccines (Figure 3). 
Inhibition of checkpoint molecules is the most recent example for the use of monoclonal 
antibodies in cancer treatment. Immune checkpoint molecules control the proliferation 
and activation of immune cells and are a natural feedback-mechanism to dampen an 
immune response. Signaling via CTLA-4 and PD-1 downregulates T cell activity, which 
inhibits anti-tumor immunity in cancer patients. Inhibition of CTLA-4 and PD-1 by 
monoclonal antibodies results in prolonged activation of tumor-reactive T cells and 
improved eradication of cancer cells (57, 58). Ipilimumab (anti-CTLA-4) and nivolumab 
(anti-PD-1) are two checkpoint inhibitors that are used for the treatment of melanoma 
patients (59-61). Several clinical trials are currently investigating the efficacy of immune 
checkpoint blockade in ovarian cancer (62). 
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Adoptive cell therapy either uses natural T cells that possess tumor reactivity or natural 
T cells that are modified to express tumor-specific chimeric antigen receptors (CARs) 
or tumor-specific T cell receptors. Isolated TILs are expanded ex vivo to generate a large 
amount of cells that can be re-infused into the patient with the aim to effectively recognize 
and kill cancer cells (63). This approach is labor-intensive and may not generate a sufficient 
number of cells. 
Cancer vaccines can be composed of specific tumor antigens, whole tumor lysate, or 
tumor DNA that are directly injected into the patients to boost the immune system. 
These vaccines aim to generate a specific anti-tumor immune response (64). In contrast, 
injections of microorganisms or components thereof induce a broad host reaction. The 
most prominent example is Bacillus Calmette-Guerin (BCG) treatment in bladder cancer. 
Attenuated BCG is infused into the bladder, leading to a potent anti-tumor immune 
response. To date, BCG is more effective than any other treatment tested (65, 66). The 
spontaneous regression of ovarian cancer after septic peritonitis raises the question 
whether the aspecific activation of a systemic immune response is a possible treatment 
option in ovarian cancer. Spontaneous regression of cancer is often associated with acute 
infections and has been observed in many cancer types (67). The recognition of danger-
associated molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs) leads to activation of the innate and adaptive immune system and induces the 
secretion of a variety of cytokines (68). However, sepsis is a life-threatening condition that 
requires hospitalization and close monitoring. The infection and the resulting immune 
response need to be strong enough to overrule the immunosuppressive mechanisms 
in the tumor microenvironment, but should not be too strong in order to prevent organ 
failure (69-71). Although research on the use of microorganisms as cancer treatment is 
studied by several groups, more research is needed to unravel the mechanisms that lead to 
a shift from pro-tumor to an anti-tumor immune response during sepsis. 
Another vaccination approach is the use of DC-based vaccines. DC vaccination uses 
DCs isolated from cancer patients, which are ex vivo maturated and loaded with tumor 
antigens before being re-infused into the patient (72, 73). Targeting cancer stem cells 
(CSCs), which are inherently resistant to classical anti-cancer treatment and the source 
for recurrent disease, by DC vaccination could improve the survival of cancer patients (74). 
We believe that DC vaccination against NANOG, a protein required for CSC maintenance, 
is a potential new treatment option for HGSC patients (75). However, little is known on 
the immunobiological properties of CSCs and research is complicated by a heterogeneous 
expression of so called CSC specific cell surface markers (76). Future studies should focus on 
the intracellular proteins NANOG and OCT-4, which are essential for CSCs, to investigate 
expression of immune checkpoint molecules and potential antigens. Additionally, in vitro 
experiments should investigate the interaction of T cells and CSCs to study the feasibility 
of DC vaccination against CSCs.  
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Conclusion
Immune cells are present in ovarian cancer precursor lesions, in primary tumor tissue 
and ascites. They form a complex interaction network that exerts pro-tumorigenic and 
anti-tumorigenic functions. Therefore, the immune cells play an important role in ovarian 
cancer development and progression. Since ovarian cancer is an immunogenic tumor, 
immunotherapy could be a potential treatment option. Several clinical trials are ongoing 
that investigate the effect of different treatment strategies, such as DC vaccination and 
adoptive T cell transfer. The unique case report of spontaneous regression of ovarian 
cancer has shown that the immune system is able to eradicate ovarian cancer when 
activated in the right way. An important factor for the success of immunotherapy is the 
choice of the best target. A major challenge in ovarian cancer is that patients experience 
disease recurrence within a short time. Targeting CSCs, which are resistant to standard 
treatment and are the source of recurrence, could improve survival of HGSC patients. In 
the future, researchers should investigate the interaction of immune cells and CSCs, for 
example by using organoids. Furthermore, it will be critical to select patients that will most 
likely benefit from immunotherapy, which requires the establishment of an immunoscore. 
Treating the right patient at the right time with the right approach might be the key for 
successful immunotherapy in ovarian cancer. 
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Summary 
 
The majority of epithelial ovarian cancer patients is diagnosed with advanced-stage high-
grade serous cancer (HGSC), with a poor 5-year overall survival rate of 25%. Standard 
treatment consists of cytoreductive surgery and (neo-)adjuvant chemotherapy. Recent 
advances in treatment, such as (hyperthermal) intraperitoneal chemotherapy, increased 
overall survival of ovarian cancer patients, but the majority gets disease recurrence and 
succumbs to the disease.
Over the last decade, immunotherapies, such as DC vaccination and immune checkpoint 
blockade, have emerged as promising treatment option for many cancer types. 
Immunotherapy stimulates the body’s immune system to initiate a potent anti-tumor 
immune response. CD8+ cytotoxic T cells are important players in anti-tumor immunity, as 
they recognize and kill cancer cells. Many immunotherapeutic strategies aim at activating 
CD8+ T cells. However, there are different mechanisms by which tumor cells can evade 
immune recognition. Effective immunotherapy requires a detailed understanding of the 
interaction between the immune system and cancer to overcome the immunosuppressive 
mechanisms that the cancer exploits to escape immune-mediated killing. This thesis 
investigates the role of the immune system in HGSC development and progression.
Although ovarian cancer has for a long time not been recognized as immunogenic tumor, 
we now know that tumor-infiltrating immune cells are associated with improved patient 
survival. For example, high numbers of intratumoral CD8+ T cells correlate with improved 
patient outcome, whereas the presence of T regulatory cells is linked to decreased survival 
in ovarian cancer patients. These findings suggest that ovarian cancer is vulnerable to 
immunological attack and that boosting the body’s anti-tumor immune response could be 
a potential new treatment option. Chapter 2 reviews current knowledge on the immune 
microenvironment in ovarian cancer and summarizes cellular immunotherapeutic 
strategies. 
A novel DC vaccination strategy is proposed in chapter 3. Here, we propose to use DC 
vaccination against the cancer stem cell protein NANOG to eradicate ovarian cancer 
stem cells (CSCs). NANOG+ cells are resistant to chemotherapy and responsible for 
ovarian cancer relapse. Hence, patient survival could be improved by elimination of 
CSCs. DC vaccination could induce T cell memory against NANOG, thereby eradicating 
newly formed CSCs that emerge by interconversion of mature cancer cells. We show that 
NANOG+ cells express MHC class I and that predicted NANOG peptides are able bind 
to HLA-A. DC vaccination against NANOG could be applied after primary treatment to 
eliminate remaining CSCs and prevent disease recurrence. 
Since most research focused on primary ovarian cancer, understanding of the early steps 
of HGSC development is limited. With the identification of BRCA1 and 2 as risk genes for 
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ovarian cancer and prophylactic salpingo-oophorectomy to prevent cancer development, 
precursor lesions of pelvic HGSC have been identified in the fallopian tube. While it is 
known that the immune system is important in established HGSC, information on immune 
infiltration in precursor lesions, called serous tubal intraepithelial carcinoma (STIC), is 
missing. However, this knowledge could be of great importance for the development of 
new prevention strategies. In chapter 4, we analyzed the T cell infiltration in STICs using 
automated, high-resolution, whole-slide multiplex immunohistochemistry. We observed 
an increased density of T cells from normal fallopian tubes to STIC and HGSC. This increase 
was most pronounced in the regulatory T cell population, with HGSC having significantly 
more regulatory T cells than normal fallopian tubes and STICs. This indicates that there is 
a gradual increase in immunosuppressive cells during ovarian cancer development. The 
malignant transformation was furthermore accompanied by a shift in the localization 
of T cells. Whereas most T cells in normal fallopian tubes were located in the epithelial 
compartment, they were equally spread between stroma and epithelium in STICs. In full 
blown HGSC, the majority of T cells were found in the stromal compartment. This may 
suggest that T cells are retained at the tumor border and prevented from killing tumor 
cells. Our results demonstrate that the immune system is already involved during the early 
steps of ovarian cancer development and could serve as starting point to understand the 
immune response in precursor lesions.  
Progression of HGSC is often accompanied by accumulation of fluid within the 
peritoneal cavity, called ascites. Disseminated tumor cells are transported in ascites fluid 
throughout the abdomen, making it easy to form metastases at distant sites. A reason 
for the high seeding efficiency of ovarian cancer cells within the peritoneal cavity could 
be a dysfunctional immune response. The functionality of ascites-derived T cells was 
investigated in chapter 5. Here, we demonstrated that ascites-derived T cells have a 
decreased proliferative capacity compared to peripheral blood lymphocytes (PBLs) 
from healthy donors. The defect in T cell proliferation was transient and confined to the 
peritoneal cavity. Furthermore, ascites fluid was able to inhibit the proliferation of control 
PBLs, indicating that soluble factors within the ascites supress T cell proliferation. Analysis 
of ascites fluid using liquid chromatography-mass spectrometry (LC-MS/MS) indicated 
that lipid metabolism is deregulated in malignant ascites. One of the top candidates, 
9-HODE, was able to interfere with proliferation of control PBLs. This proof-of-principle 
data set indicates that lipid metabolites in ascites fluid locally suppress T cell activation in 
the peritoneal cavity, thereby interfering with the anti-tumor immune response.
T cell infiltration in primary ovarian cancer is associated with improved survival and 
infiltration at baseline seems to be predictable for response to immunotherapy. In 
contrast to tumor tissue, ascites is a relatively easily accessible body fluid to analyze the 
immune status of HGSC patients. In chapter 6, we investigated whether DC and T cell 
subsets in ascites fluid can be used to predict outcome of HGSC patients. mDCs (BDCA-1+, 
BDCA-3+, CD16+), pDCs, and T cells (CD4+, CD8+) were present in the majority of ascites 
samples. The percentage of pDCs correlated with an increased percentage of CD4+ T cells. 
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No correlation between the other DC and T cell subsets was found. As expected, clinical 
characteristics, such as complete cytoreduction, good response to primary treatment, and 
chemosensitivity, correlated with improved patient survival. Although not significant, we 
observed a trend towards improved survival in patients with a low percentage of CD4+ 
T cells, which could be interpreted as a low influx of regulatory T cells. Furthermore, 
there was a higher chance of long PFS (18 months) and OS (60 months) in patients with 
a low percentage of CD4+ T cells or a high percentage of CD16+ mDCs. Nevertheless, the 
presence of DC and T cell subsets in ascites was neither correlated to clinical characteristics 
nor could it predict patient survival. This indicates that the immune response in ascites is 
not necessarily a reflection of the immune response in primary HGSC tissue. 
Chapter 7 describes the unique case of spontaneous regression of ovarian cancer after 
septic peritonitis. A 79-year old woman was diagnosed with stage IIIc high-grade serous 
ovarian cancer. The tumor biopsy was complicated by intra-abdominal contamination or 
bowel puncture, resulting in septic peritonitis. The patient recovered from the sepsis but 
her physical condition did not allow for any further treatment. She was discharged from 
the hospital and received palliative care. After 6 months she was still in a good physical 
and mental condition. Examination showed that the patient was almost completely tumor-
free, except for some residual disease in the left ovary. Since sepsis is a strong activator of 
the immune system, T cell and macrophage infiltration were investigated using multiplex 
immunohistochemistry. When comparing the tumor biopsy taken before sepsis and the 
tumor resection collected 6 months after the sepsis, a shift from a pro-tumor to an anti-
tumor immune response was detected. The resection contained more CD8+ cytotoxic 
T cells and M1 macrophages and less regulatory T cells and M2 macrophages than the 
former biopsy. We concluded that this patient represents a rare case of spontaneous 
regression of ovarian cancer after septic peritonitis. The strong activation of the immune 
system during sepsis may have overruled the immunosuppressive mechanism of ovarian 
cancer, demonstrating the power of the immune system.
Chapter 8 summarizes the findings of this thesis and places them into context of current 
knowledge on the role of the immune system in ovarian cancer. 
168
Samenvatting  
 
De meerderheid van de ovariumcarcinoompatiënten wordt gediagnosticeerd in een ver-
gevorderd stadium van het hooggradig sereus carcinoom en heeft een 5-jaarsoverleving 
van slechts 25%. De standaardbehandeling bestaat uit een operatie in combinatie met 
chemotherapie. Verbeteringen in behandelmethoden, zoals (hypotherme) intraperitoneale 
chemotherapie, verhogen de overlevingskans van ovariumcarcinoompatiënten. Hoewel 
patiënten vaak goed op de initiële behandeling reageren, keert de kanker in de meeste 
gevallen binnen 18 maanden terug en overlijden de meeste vrouwen aan deze ziekte. 
In de afgelopen jaren heeft immuuntherapie zich als een veelbelovende behandelings-
methode gepresenteerd. Immuuntherapie stimuleert het lichaamseigen immuunsysteem 
om een krachtige immunologische respons op te wekken tegen de kanker. CD8+ 
cytotoxische T cellen, die tumorcellen kunnen herkennen en aanvallen, spelen hierbij een 
belangrijke rol. Veel vormen van immuuntherapie proberen om deze reden CD8+ T cellen 
te activeren. Echter beschikt de tumor over diverse immuunsuppressieve mechanismen 
die de herkenning door het immuunsysteem voorkomen. Effectieve immuuntherapie zou 
deze mechanismen mogelijk kunnen overwinnen. Gedetailleerde kennis over de interactie 
tussen het immuunsysteem en het ovariumcarcinoom is hiervoor van essentieel belang. 
Dit proefschrift onderzoekt de rol van het immuunsysteem bij de ontwikkeling en de 
progressie van het ovariumcarcinoom.
Het ovariumcarcinoom werd lange tijd niet beschouwd als een immunologische 
tumor. Tegenwoordig is bekend dat de aanwezigheid van CD8+ T cellen in de tumor een 
belangrijke voorspeller is voor een langere overleving. Deze bevindingen suggereren dat 
het ovariumcarcinoom kwetsbaar is voor een immunologische aanval en dat de stimulatie 
van het lichaamseigen immuunsysteem een potentiële nieuwe behandelingsmethode kan 
zijn. In hoofdstuk 2 wordt de huidige kennis over de rol van verschillende immuuncellen 
in het ovariumcarcinoom samengevat en worden de verschillende immunotherapieën 
beschreven. 
Een nieuw dendritische cel (DC) vaccin wordt voorgesteld in hoofdstuk 3. Hier stellen 
wij voor om DC vaccinatie tegen het kankerstamcel eiwit NANOG te gebruiken met 
als doel de kankerstamcellen op te ruimen. NANOG+ kankerstamcellen zijn resistent 
tegen chemotherapie en zijn de oorsprong voor kankerrecidieven. Door het uitroeien 
van kankerstamcellen zou de overleving van ovariumcarcinoom patiënten dus verlengd 
kunnen worden. DC vaccinatie kan resulteren in immunologisch geheugen. Hierdoor 
kunnen nieuwgevormde kankerstamcellen, die door de dedifferentiatie van rijpe 
kankercellen ontstaan, worden herkend en vervolgens worden opgeruimd. Wij laten 
zien dat NANOG+ kankerstamcellen in ascites MHC klasse I moleculen tot expressie 
brengen en dat voorspelde NANOG peptiden aan HLA-A kunnen binden, twee belangrijke 
voorwaarden voor DC vaccinatie. Door DC vaccinatie tegen kankerstamcellen te geven 
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na de primaire behandeling van ovariumcarcinoom patiënten, zouden achterblijvende 
kankerstamcellen uitgeroeid kunnen worden, waardoor een recidief voorkomen kan 
worden. 
Het hooggradig sereus ovariumcarcinoom wordt meestal pas in een laat stadium 
ontdekt, waardoor kennis over de initiële stappen van de kankerontwikkeling ontbreekt. 
Door het identificeren van BRCA1 en -2 als risicogenen voor het ovariumcarcinoom 
en de profylactische salpingo-oophorectomy om het ontstaan van eierstokkanker te 
voorkomen, werden voorloper laesies in de eileiders ontdekt. Hoewel bekend is dat het 
immuunsysteem een belangrijke rol bij de progressie van het ovariumcarcinoom speelt, 
is de interactie tussen de voorloper laesies en immuuncellen nauwelijks onderzocht. In 
hoofdstuk 4 wordt de infiltratie van T cellen in dergelijke voorloper laesies, het sereus 
tubair intraepitheliaal carcinoom (STIC), bekeken. Hiervoor hebben wij gebruik gemaakt 
van een geautomatiseerd microscoop systeem, waarmee het mogelijk is om van de hele 
coupe hoge resolutie afbeeldingen van multiplex fluorescente kleuring te maken. Er 
was een graduele toename van T cellen tijdens de maligne transformatie van normaal 
eileiderweefsel, naar STIC, naar tumor. Vooral de regulatoire T cellen waren verhoogd 
in STIC en tumor vergeleken met normale eileiders. Maar ook de lokalisatie van T cellen 
was veranderd. Terwijl de T cellen in normale eileiders voornamelijk in het epitheliale 
compartiment zaten, waren de T cellen in te tumor vooral in het stromale compartiment 
te vinden. Dit onderzoek laat zien dat het immuunsysteem al bij het ontstaan van het 
ovariumcarcinoom betrokken is en dient als uitgangspunt voor het betere begrijpen van 
de immunologische response.
Een groot deel van de patiënten met het hooggradig sereus ovariumcarcinoom heeft 
ascites. Kankercellen die losraken van de primaire tumor komen terecht in de ascites, 
waardoor de cellen door de gehele buikholte transporteerd worden en metastases kunnen 
vormen. Een niet-functionerend immuunsystem in de buikholte zou de hoge mate aan 
metastases kunnen verklaren. In hoofdstuk 5 laten wij zien dat T cellen uit ascites in vele 
gevallen niet meer konden prolifereren na aspecifieke stimulatie. Dit effect was tijdelijk 
en beperkt tot de buikholte. Verder was supernatant afkomstig van ascites in staat om de 
proliferatie van controle cellen te onderdrukken. Dit suggereert dat oplosbare factoren in 
de ascites de proliferatie van T cellen remmen. Met behulp van liquid chromatography-
mass spectrometry (LC-MS/MS) werden 103 lipiden metabolieten in ascites en normaal 
abdominaal vocht gemeten. Een van de topkandidaten, 9-HODE, was inderdaad in staat 
om de proliferatie van T cellen te onderdrukken. Dit suggereert dat lipiden metabolieten 
de activatie van T cellen kunnen remmen en op die manier de immunologische respons 
tegen kanker in de buikholte tegenwerken. 
De aanwezigheid van T cellen in het ovariumcarcinoom is voorspellend voor een verhoogde 
kans op langere overleving. De mate van infiltratie bij begin van de therapie lijkt te 
voorspellen hoe goed patiënten op immuuntherapie reageren. In tegenstelling tot tumor 
weefsel, is ascites een relatief makkelijk te verkrijgen materiaal om de immuunstatus van 
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patiënten te bepalen. Het is echter niet bekend of ook de immuuncellen in ascites van 
prognostische waarde zijn voor de overleving. In hoofdstuk 6 hebben wij onderzocht of 
de aanwezigheid van DCs and T cellen in ascites van patiënten met het hooggradig sereus 
ovariumcarcinoom invloed heeft op de progressievrije en algehele overleving. Myeloide 
DCs (BDCA-1+, BDCA-3+, CD16+), plasmacytoide DCs en T cellen (CD4+, CD8+) werden in 
het merendeel van ascites samples gedetecteerd. Er was een positieve correlatie tussen 
plasmacytoide DCs en CD4+ T cellen, terwijl er geen samenhang tussen de andere DC 
en T cel subsets te vinden was. Zoals verwacht waren de klinische gegevens van invloed 
op de overleving. Patiënten met een complete debulking, een goede response op de 
primaire behandeling en sensitiviteit voor chemotherapie correleerden met een betere 
progressievrije en algehele overleving. Hoewel het verschil niet significant was, zagen wij 
dat patiënten met een lage hoeveelheid CD4+ T cellen in ascites een betere progressievrije 
overleving hadden. Verder was de kans op lange progressievrije (18 maanden) en 
algehele (60 maanden) overleving groter voor patiënten met een lage hoeveelheid CD4+ 
T cellen of een hoge hoeveelheid CD16+ myeloide DCs. Echter waren de hoeveelheden 
van DC en T cel subsets in ascites niet gecorreleerd aan de klinische patiëntengegevens 
en niet voorspellend voor de overleving van ovariumcarcinoompatiënten. De 
immuunsamenstelling in ascites lijkt geen weerspiegeling van de tumor te zijn. Hieruit 
blijkt dat ascites niet het goede materiaal is om de immuunstatus van patiënten te bepalen.
Een unieke patiëntcasus wordt beschreven in hoofdstuk 7. Een 79-jarige vrouw werd 
gediagnosticeerd met stadium IIIc van het hooggradig sereus ovariumcarcinoom. De 
afname van een tumorbiopt werd gecompliceerd door een intra-abdominale contaminatie 
of beschadiging van de darm, wat tot sepsis van de buikholte leidde. De patiënt herstelde 
van de sepsis, maar door haar slechte fysieke conditie was een verdere behandeling niet 
mogelijk. Ze werd ontslagen uit het ziekenhuis en ontving palliatieve zorg. Na 6 maanden 
was de patiënt nog steeds in goede conditie. Onderzoek liet zien dat de patiënt bijna 
volledig tumorvrij was, behalve wat resterende kankercellen in het linker ovarium. Omdat 
de sepsis een sterke activatie van het immuunsysteem tot gevolg heeft, werd de infiltratie 
van T cellen en macrofagen onderzocht met behulp van multiplex fluorescente kleuringen. 
Wij hebben het infiltraat in het biopt vergeleken met het infiltraat in de tumorresectie die 
6 maanden later werd verricht. In de resectie waren meer CD8+ cytotoxische T cellen en 
M1 macrofagen en minder TRegs en M2 macrofagen aanwezig. Dit wijst op het ontstaan 
van een goede anti-tumor immuunrespons. Wij concluderen dat deze patiënt een unieke 
casus representeert van een spontane regressie van het ovariumcarcinoom na een septic 
peritonitis. De sterke activatie van het immuunsysteem tijdens de sepsis zou tot de 
overwinning van de immuunsuppressieve mechanismen kunnen hebben geleid. Dit laat de 
kracht van immuunsysteem zien als het op de juiste manier geactiveerd wordt. 
In hoofdstuk 8 zijn de resultaten van het onderzoek, zoals beschreven in dit proefschrift, 
samengevat en bediscussieerd.   
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Einführung
Das Ovarialkarzinom ist die tödlichste gynäkologische Erkrankung bei Frauen. Von 
den 7520 Patientinnen, die in Deutschland jedes Jahr mit einem Ovarialkarzinom 
diagnostiziert werden, überleben gerade einmal 25% länger als fünf Jahre. Ein Grund für 
die hohe Sterblichkeitsrate ist, dass es keine verlässlichen Früherkennungsmöglichkeiten 
gibt und Frauen in der Anfangsphase keine Symptome haben. Das Ovarialkarzinom wird 
daher oft erst in einem späten Stadium (FIGO Stadium III und IV) entdeckt, wenn der 
Krebs sich bereits im Bauchraum ausgebreitet hat. 
Operation und Chemotherapie gehören zu den allgemeinen Behandlungsverfahren beim 
Ovarialkarzinom. Neue Therapiemöglichkeiten wie die hypertherme intraperitoneale 
Chemotherapie (HIPEC) verbessern die Prognose der Patientinnen deutlich. Da das 
Ovarialkarzinom sich vor allem im Bauchraum ausbreitet, wird bei der HIPEC-Behandlung 
die Bauchhöhle nach der Operation mit einer erwärmten Chemotherapie-Lösung 
gespült. Ziel ist es, Metastasen, die mit bloßem Auge nicht zu erkennen waren und 
chirurgisch nicht entfernt wurden, durch die Chemotherapie-Lösung abzutöten. Obwohl 
Ovarialkarzinompatientinnen in der Regel gut auf die primäre Therapie ansprechen, 
erleiden die Meisten innerhalb von 18 Monaten einen Rückfall und erliegen letztendlich der 
Krankheit. Neue Erkenntnisse über die Entstehung des Ovarialkarzinoms und innovative 
Therapiemöglichkeiten sind daher zwingen notwendig, um die Überlebenschancen zu 
verbessern.
Ein derzeit viel erforschter Therapieansatz bei verschiedenen Krebsarten ist die 
Immuntherapie. Das Immunsystem bildet ein komplexes Netzwerk aus Zellen und 
Signalmolekülen, welches unseren Körper von Bakterien und Viren, aber auch vor der 
Entstehung von Krebs beschützt. Krebszellen besitzen jedoch eine Vielzahl von Möglichkeit 
um sich für das Immunsystem unsichtbar zu machen oder dieses gar lahmzulegen. Die 
Immuntherapie hat das Ziel, die Immunantwort gegen den Tumor zu reaktivieren. So soll 
das körpereigene Immunsystem zur Bekämpfung von Krebs genutzt werden.
Das Ovarialkarzinom wurde lange Zeit nicht als immunogener Tumor eingestuft. 
Heutzutage wissen wir jedoch, dass das Immunsystem eine wichtige Rolle bei dessen 
Entstehung und Ausbreitung spielt. Bereits im Vorläuferstadium des Ovarialkarzinoms, 
welches in den Eileitern entdeckt wurde, konnte eine Ansammlung von Immunzellen 
nachgewiesen werden. Allerdings ist bisher wenig über dessen Bedeutung bekannt. 
Der überwiegende Teil der Forschung befasst sich mit den eindringenden Immunzellen, 
dem Immuninfiltrat, im primären Tumorgewebe. Studien konnten nachweisen, dass 
das Immunsystem Auswirkungen auf die Prognose von Krebspatienten hat. Besonders 
viele Studien haben sich auf T-Zellen fokussiert, die Polizisten unseres Immunsystems, 
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welche von den dendritischen Zellen gesteuert werden. Dendritische Zellen sind die 
Wächter des Immunsystems. Sie patrouillieren in unserem Körper und halten Ausschau 
nach krankhaften Zellen, welche andere Moleküle auf der Zelloberfläche präsentieren als 
normale Zellen. Dendritische Zellen nehmen Antigene, kleine Stücke dieser Moleküle auf 
und präsentieren sie an CD8+ T-Zellen. Anschließend kontrollieren die CD8+ T-Zellen, auch 
zytotoxische T-Zellen genannt, jede Körperzelle auf Anwesenheit der Antigene und töten 
entsprechende Zellen ab. Voraussetzung ist, dass das Antigen auf der Zelle durch MHC-
Klasse-I-Moleküle präsentiert wird, da es ansonsten nicht von den T-Zellen erkannt wird. 
Ovarialkarzinompatientinnen, deren Tumore eine hohe Anzahl von CD8+ T-Zellen 
aufweisen, leben deutlich länger als Patientinnen mit einer geringen Anzahl von CD8+ 
T-Zellen im Tumorgewebe. Neben CD8+ T-Zellen gibt es noch CD4+ T-Helferzellen und 
Foxp3+ regulatorische T-Zellen. Im Gegensatz zu CD8+ T-Zellen wirkt sich die Anwesenheit 
von Foxp3+ regulatorischen T-Zellen negativ auf die Überlebenschance aus. Regulatorische 
T-Zellen sind in der Lage die zytotoxische Wirkung der CD8+ T-Zellen unterdrücken und 
verhindern somit die Vernichtung von Krebszellen. Ähnliches gilt für die verschiedenen 
Arten von Makrophagen. M1-Makrophagen werden auch Fresszellen genannt und 
„fressen“ infizierte Zellen oder Krebszellen. Eine hohe Anzahl von M1-Makrophagen im 
Tumorgewebe erhöht daher die Überlebenschance von Ovarialkarzinompatientinnen. 
M2-Makrophage unterdrücken die Wirkung des Immunsystem und sind daher mit 
schlechteren Überlebenschancen assoziiert.
Diese Erkenntnisse zeigen, dass die Reaktivierung das körpereigene Immunsystems ein 
vielversprechender Ansatz für die Behandlung von Ovarialkarzinompatientinnen ist. Der 
derzeitige Kenntnisstand wird in Kapitel 2 zusammengefasst.
Zielsetzung der Arbeit
Um effektive Immuntherapien entwickeln zu können, müssen wir verstehen, welche Rolle 
das Immunsystem beim Ovarialkarzinom spielt und wie die Krebszellen sich vor dem 
Immunsystem schützen. Ziel dieser Arbeit ist es zum einem, die Rolle des Immunsystem 
bei der Entstehung des Ovarialkarzinoms zu untersuchen. Insbesondere welche Arten von 
T-Zellen anwesend sind und ob dies in Zusammenhang mit klinischen Parametern steht. 
Zum anderen wurde untersucht, wie sich das Immunsystem in Aszites verhält. Aszites 
ist die Ansammlung von Flüssigkeit im Bauchraum und vermutlich maßgeblich an der 
Ausbreitung des Ovarialkarzinoms beteiligt. 
Ergebnisse
Eine Möglichkeit die Rückfallrate der Ovarialkarzinompatientinnen zu senken wäre 
die Immuntherapie gegen Krebsstammzellen. Jeder Tumor besitzt eine geringe Anzahl 
von Krebsstammzellen, die typische Stammzelleigenschaften wie Selbsterneuerung 
und Differenzierungspotential besitzen. Krebsstammzellen sind resistent gegen 
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Standardbehandlungsmethoden wie Chemotherapie und vermutlich für die Rezidivbildung 
verantwortlich. In Kapitel 3 konnten wir nachweisen, dass NANOG+ Krebsstammzellen in 
Aszites von Ovarialkarzinompatientinnen zu finden sind und die nötigen Vorrausetzungen 
erfüllen, um durch das Immunsystem erkannt zu werden. Sie exprimieren MHC-Klasse-I-
Moleküle, welche theoretisch NANOG-Peptide präsentieren können. Immuntherapie 
gegen Krebsstammzellen wäre grundsätzlich möglich und könnte die Prognose von 
Ovarialkarzinompatientinnen deutlich verbessern. 
Der überwiegende Teil der Forschung fokussiert sich auf das primäre Ovarialkarzinom, 
wodurch es nur wenige Informationen über die frühen Entstehungsschritte gibt. Mit der 
Entdeckung von BRCA1 und BRCA2 als Risikogene für die Entstehung von Brust- und 
Eierstockkrebs, hat sich unser Verständnis jedoch grundlegend verändert. Bei gesunden 
und erkrankten Mutationsträgerinnen konnten Vorläuferstadien des Ovarialkarzinoms 
in den Eileitern nachgewiesen werden. Während bekannt ist, dass das Immunsystem 
eine wichtige Rolle im primären Ovarialkarzinom spielt, ist über das Immuninfiltrat 
in Vorläuferstadien bisher wenig bekannt. Das T-Zellinfiltrat in Vorläuferstadien des 
Ovarialkarzinoms wurde in Kapitel 4 mittels automatisierter und hochauflösender 
Fluoreszenz-Multiplex-Immunhistochemie untersucht. Dabei war ein Anstieg des 
T-Zellinfiltrates von normalem Eileitergewebe, zu Vorläuferstadien und zum primären 
Ovarialkarzinomen zu beobachten. Der Anstieg der regulatorischen T-Zellen war 
hierbei am stärksten. Im Vergleich zu normalem Eileitergewebe und Vorläuferstadien, 
hatten primäre Ovarialkarzinome deutlich mehr regulatorische T-Zellen. Das lässt 
auf einen graduellen Anstieg immunsuppressiver Zellen während der Entstehung des 
Ovarialkarzinoms schließen. Auch die Lokalisation der T-Zellen änderte sich während 
der malignen Transformation. In normalem Eileitergewebe befand sich der Großteil 
der T-Zellen im Epithelium, während die T-Zellen in Vorläuferstadien gleichermaßen im 
Stroma und Epithelium zu finden waren. In primären Tumoren, waren die meisten Zellen 
hingegen im Stroma, was vermuten lässt, dass sie nicht in der Lage sind das Tumorgewebe 
zu infiltrieren und die Krebszellen zu vernichten. Diese Ergebnisse zeigen, dass das 
Immunsystem bereits in der frühen Phase der Entstehung des Ovarialkarzinoms involviert 
ist. Unsere Studie dient als Anfang um die Rolle des Immunsystem in Vorläuferstadien zu 
verstehen. 
Metastasen des Ovarialkarzinoms sind hauptsächlich in der Peritonealhöhle und nur 
selten anderswo im Körper zu finden. Die Gründe hierfür sind bislang nicht eindeutig 
erklärt. Es wird jedoch vermutet, dass Aszites maßgeblich dazu beiträgt. Ein unterdrücktes 
Immunsystem in Aszites könnte erklären, warum die Krebszellen sich so effektiv im 
Bauchraum ausbreiten können. In Kapitel 5 wurde die Funktionalität der T-Zellen in Aszites 
von Patientinnen mit Ovarialkarzinom untersucht. Das Zellteilungspotenzial von T-Zellen 
aus Aszites war im Vergleich zu T-Zellen von gesunden Probanden deutlich geringer. 
Die defekte Proliferation war vorrübergehend und auf den Bauchraum beschränkt. 
Des Weiteren war Aszites in der Lage die Proliferation von Kontrollzellen, T-Zellen von 
gesunden Probanden, zu unterdrücken. Die Ergebnisse lassen darauf schließen, dass 
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Aszites Stoffe und Signalmoleküle enthält, welche die Proliferation der T-Zellen inhibiert. 
Die Analyse von normaler peritonealer Flüssigkeit und Aszites hat gezeigt, dass eine 
Vielzahl von Lipidmetaboliten in Aszites deutlich erhöht ist. Einer der Topkandidaten, 
9-HODE, war in der Tat in der Lage die Proliferation von Kontrollzellen zu unterdrücken. 
Dieser Grundsatzbeweis zeigt, dass Lipide in Aszites die Proliferation von T-Zellen 
inhibieren können und auf diese Weise die Immunantwort gegen das Ovarialkarzinom 
unterdrücken. 
In Tumorgewebe wurde nachgewiesen, dass eine hohe Anzahl von CD8+ T-Zellen mit 
einer höheren Überlebenschance von Ovarialkarzinompatientinnen assoziiert ist. 
Außerdem scheint die Stärke des Immuninfiltrates im Tumorgewebe mit dem Erfolg 
der Immuntherapie zusammenzuhängen. Die Entnahme einer Gebewebeprobe ist ein 
invasiver Eingriff und in der Regel kann nur wenig Material entnommen werden, was eine 
Analyse erschwert. Im Gegensatz dazu ist die Abnahme von Aszites einfacher und sicherer. 
Es ist jedoch unklar, ob die Immunzellen in Aszites wie im Tumorgeweben Rückschlüsse 
auf die Prognose zulassen. Die Anwesenheit und der Effekt von dendritischen Zellen und 
T-Zellen in Aszites von 62 Ovarialkarzinompatientinnen wurde in Kapitel 6 analysiert. 
Wie zu erwarten korrelierten klinische Charakteristiken wie vollständige operative 
Zytoreduktion, ein gutes Ansprechen auf die primäre Therapie und die Chemosensitivität 
mit einer besseren Überlebenschance. Die Anzahl von dendritischen Zellen und T-Zellen 
hatte jedoch keinen Einfluss auf die Prognose. Lediglich bei Patientinnen mit einer 
geringeren Anzahl CD4+ T-Helferzellen war ein Trend zu besseren Überlebenschancen zu 
erkennen. Das Immunsystem in Aszites scheint sich also deutlich von dem Immunsystem 
in primärem Tumorgewebe zu unterscheiden und kann daher nicht unbedingt für eine 
Prognose genutzt werden.
Zuletzt haben wir in Kapitel 7 den einzigartigen Fall einer Patientin mit Spontanremission 
des Ovarialkarzinoms untersucht. Als Spontanremission bezeichnet man in der Onkologie 
den Rückgang eines Karzinoms ohne jede Behandlung oder durch Therapie, die nach 
allgemeiner Erfahrung nicht dazu führt. Bei einer 79-Jährigen Patientin wurde ein 
Ovarialkarzinom im fortgeschrittenen Stadium diagnostiziert. Die Tumorbiopsie führte 
vermutlich zu einer intraabdominalen Kontamination, was in einer septischen Peritonitis 
resultierte. Die Patientin wurde auf der Intensivstation behandelt und erholte sich, jedoch 
ließ ihr physischer Zustand keine weitere Behandlung zu. Sie wurde aus dem Krankenhaus 
entlassen und palliativ behandelt. Nach 6 Monaten konsultierte die Frau ihren Arzt, 
da sie noch immer in guter Verfassung war. Untersuchungen zeigten, dass sich das 
Ovarialkarzinom fast vollständig zurückgebildet hatte. Lediglich am linken Eierstock befand 
sich noch ein kleiner Tumor. Da Sepsis zu einer starken Aktivierung des Immunsystems 
führt, wurden die Infiltration von T-Zellen und Makrophagen im Tumorgewebe 
untersucht. Beim Vergleich der Biopsie mit dem Tumorgewebe, welches 6 Monate später 
entfernt wurde, konnte eine Verschiebung von einer tumorunterstützenden zu einer 
tumorabwehrenden Immunreaktion festgestellt werden. Die Biopsie enthielt deutlich 
mehr regulatorische T-Zellen und M2-Makrophagen, während der später entfernte Tumor 
175
SUMMARY | SAMENVATTING | ZUSAMMENFASSUNG
wesentlich mehr CD8+ T-Zellen und M1-Makrophagen besaß. Vermutlich hat die septische 
Peritonitis bei dieser Patientin zu einer Spontanremission des Ovarialkarzinoms geführt. 
Die Sepsis könnte zu einer so starken Aktivierung des Immunsystem geführt haben, 
dass die inhibierenden Mechanismen des Ovarialkarzinoms außer Kraft gesetzt wurden. 
Dieser Fall verdeutlicht die Stärke des Immunsystems und unterstütz die Forschung in 
ihrem Bestreben, Immuntherapien zur Behandlung des Ovarialkarzinoms zu entwickeln. 
Fazit
Entgegen der Erwartungen gibt es beim Ovarialkarzinom deutliche Unterschiede 
zwischen der Immunreaktion in Vorläuferstadien, Aszites und primärem Tumor. 
Nichtsdestotrotz spielt das Immunsystem bei der Entstehung, der Ausbreitung 
und der Genesung eine wichtige Rolle. Die Funktionen des Immunsystem in den 
verschiedenen Phasen zu untersuchen und zu verstehen ist essentiell um effektive 
Therapiemöglichkeiten entwickeln zu können. Der einzigartige Fall der Spontanremission 
nach septischer Peritonitis zeigt, wie wirkungsvoll das Immunsystem sein kann, wenn 
es die suppressiven Mechanismen des Tumors aushebelt. Ein wichtiger Faktor für den 
Erfolg der Immunotherapie ist die Wahl des Ziels. Das Anvisieren von Krebsstammzellen, 
welche resistent gegen Chemotherapie und vermutlich verantwortlich für Rezidive sind, 
könnten die Prognose der Ovarialkarzinompatientinnen deutlich verbessern. Zukünftige 
Studien sollten daher die Interaktion von Krebsstammzellen und dem Immunsystem 
untersuchen. Des Weiteren ist es wichtig jene Patientinnen zu identifizieren, die mit 
großer Wahrscheinlichkeit auf die Immuntherapie ansprechen werden. Der Erfolg könnte 
davon abhängen, dass die richtigen Patientinnen zur richtigen Zeit mit der richtigen 
Immuntherapie behandelt werden.  
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